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The higher percentage of individuals surviving to older ages has exponentially 
increased the prevalence of Alzheimer’s disease (AD) and other dementias. There are 4.6 
million new cases worldwide each year and the estimates suggest that prevalence will 
double every 20 years. Most dementia cases correspond to AD. With 50% of those 85 and 
above expected to develop AD, the global burden of disease has reached pandemic 
proportions. With no effective preventive or disease-modifying treatments yet available, 
the prospect for those threatened or suffering from most types of dementia remains 
somber. Meanwhile, the cost and social impact of these diseases escalates, especially in 
countries with large aging populations such as Spain and Sweden.  
The neurodegenerative processes which lead to dementia span decades and are not 
entirely understood. Even after diagnosis, the course of the disease is extremely variable 
between individuals, with fluctuating and progressively worsening cognition underlying 
varying degrees of functional impairment. Estimates of survival after dementia diagnosis 
range from 3 to 15 years, and individual patient survival remains unpredictable. Previous 
studies suggest that type of dementia, gender, age and cognitive level, among other 
baseline factors, could impact prognosis. Patients and families demand knowledge on 
mortality after dementia diagnosis, which is also critical to public health planning. The 
aim of this thesis is double: first, to contribute to the characterization of patients with 
mild cognitive impairment (MCI) and subjective cognitive complaints (SCI) who might 
represent a pre-dementia stage of Alzheimer’s disease. Second, once a diagnosis of 
dementia is established, we aim to identify those factors which contribute to mortality 
prognosis.  
Study I was based on the clinical patient database collected at the Karolinska 
Memory Clinic, Karolinska University Hospital, Huddinge, Sweden, with data drawn 
retrospectively from clinical records.  
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For this study, 993 patients with a diagnosis of either AD, MCI or SCI were 
selected. Descriptive statistics and comparisons of characteristics between AD, MCI and 
SCI groups are provided. A logistic regression model (based on age, sex and 
cerebrospinal fluid biomarkers) was created to analyze which characteristics in the MCI 
and SCI groups increased their similarity to the AD population within the statistical 
model. First, a model was created that accurately classified AD, MCI and SCI 
individuals. Results from this model were used to assign a probability to each individual 
in the sample of being more or less “AD-like” according to the model. This probability 
was used as an outcome variable to determine which factors increased an SCI subject’s 
probability of being considered “AD-like”.  In this study, SCI subjects were younger, 
with more years of formal education, higher baseline cognition; less generalized global 
and cortical atrophy, and less medial temporal atrophy (MTA) than the MCI or AD 
groups. Within the statistical regression model, markers of cardiovascular risk, confluent 
white matter lesions, MTA and central atrophy were identified as increasing the 
probability of an SCI patient to be classified as “AD-like” by the model. 
Studies II and III are based on SveDem, the Swedish quality dementia registry 
which records incident dementia diagnosis throughout Sweden. SveDem was established 
in 2007 to improve quality and equality of care for dementia patients throughout the 
country. With coverage of more than 95% of all specialized clinics nationwide and more 
than 45 000 individual entries to date, it affords a unique opportunity to explore factors 
influencing survival after dementia diagnosis. 
These two studies employed a sample from SveDem to explore factors associated 
with mortality risk at the time of dementia diagnosis. Study I examined 15 209 patients 
diagnosed in memory clinics and followed prospectively until death or end of follow-up. 
Higher age, male gender, lower baseline cognitive level as defined by the Mini-Mental 
State Examination (MMSE), institutionalization, and higher number of habitual 
medication taken by the patient were associated with higher mortality risk.  AD presented 
lower risk than any other dementia disorder while vascular dementia (VaD) was the 
deadliest in crude analyses. After adjusting for sex, age, number of medication (as a 
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proxy for comorbidity) and MMSE, frontotemporal dementia (FTD) presented with the 
highest risk. Study II examined the relationship between body-mass index (BMI) and 
mortality after dementia diagnosis in 11 398 patients. Higher BMI was associated with 
lower mortality risk, with the highest risk appearing in the category with BMI under 18.5 
kg/m
2
 and the lowest risk in the obese weight category (BMI 30 kg/m
2
 or above). Each 
point increase in BMI was associated with a reduction in mortality risk up to, and 
including BMI 29.9 kg/m
2




In conclusion, AD, MCI and SCI groups have distinct characteristics. Some 
clinical markers, such as atrophy or cardiovascular risk, might help identify SCI subjects 
at higher risk. Once a diagnosis of dementia is established, factors such as higher age, 
male sex, lower MMSE, non-AD dementia, comorbidity, BMI under 29.9 for men and 
under 24.9 for women, and institutionalization are associated with higher mortality risk. 
Key words: Dementia, subjective cognitive impairment, mild cognitive 
impairment, Alzheimer’s disease, frontotemporal dementia, dementia with Lewy bodies, 
Parkinson’s disease with dementia, mixed Alzheimer and vascular dementia, vascular 




En las últimas décadas, el aumento de la esperanza de vida de la población ha 
elevado la prevalencia de la enfermedad de Alzheimer (EA) y de otras demencias de 
forma exponencial. Cada año 4,6 millones de personas debutan con un cuadro de 
demencia y se estima que la prevalencia se duplicará cada 20 años. La mayoría de los 
casos de demencia corresponden a EA. Con estimaciones que indican que alrededor del 
50% de las personas de más de 85 años llegarán a sufrir una EA, la carga global de esta 
enfermedad está alcanzando proporciones pandémicas. Dado que no existen tratamientos 
preventivos o modificadores de la enfermedad para la mayoría de las causas de demencia, 
las perspectivas de la población que padece demencia o está amenazada por esta 
posibilidad siguen siendo sombrías. Entre tanto, el coste y el impacto social de estas 
enfermedades continúan creciendo, especialmente en países con poblaciones envejecidas, 
como Suecia y España.  
En realidad las enfermedades neurodegenerativas que provocan cuadros de 
demencia se instauran de forma insidiosa a lo largo de muchos años, y su evolución no es 
del todo conocida. Incluso después del diagnóstico, el curso clínico es muy heterogéneo 
entre unos individuos y otros, con grados variables de deterioro funcional condicionados 
por el ritmo de progresión de la enfermedad y por posibles fluctuaciones. Las 
estimaciones de supervivencia a partir del diagnóstico de demencia oscilan entre 3 y 15 
años, y la supervivencia de un paciente en concreto resulta impredecible. Los datos de 
algunos estudios sugieren que el tipo de demencia, el sexo, la edad y el nivel cognitivo, 
entre otros factores, podrían afectar a la supervivencia. Tanto los pacientes como sus 
familias demandan información acerca del pronóstico, y esta información es también 
fundamental para una correcta planificación socio-sanitaria. El objetivo de esta tesis es 
doble: en primer lugar, contribuir a la caracterización de los pacientes con deterioro 
cognitivo ligero (DCL) y quejas cognitivas subjetivas (QCS) que podrían estar en un 
estadio pre-demencia de la EA. En segundo lugar, una vez establecido el diagnóstico de 
demencia, identificar aquellos factores que pueden influir en la supervivencia.  
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El estudio I se centra en la base de datos de pacientes atendidos en la Unidad de 
Memoria del Hospital Universitario Karolinska, en Huddinge, Suecia, con datos 
recogidos de las historias clínicas de manera retrospectiva.  
Para este estudio se seleccionaron 993 pacientes con diagnóstico de EA, DCL o 
SCI. Se compararon las características entre los grupos de EA, DCL y QCS, y se creó un 
modelo de regresión logística (basado en edad, sexo y biomarcadores en líquido 
cefalorraquídeo) para analizar qué características de los grupos QCS o MCI aumentaban 
su similitud con la muestra EA dentro del modelo. En primer lugar, se generó un modelo 
que clasificaba correctamente los sujetos en las categorías de EA, DCL o QCS. Los 
resultados de este modelo se emplearon para asignar una probabilidad a cada individuo de 
ser más o menos “similar a EA”. Esta probabilidad se empleó como variable resultado 
para determinar qué factores aumentaban la probabilidad de un sujeto con QCS de ser 
clasificado como “similar a EA” en el modelo. En este estudio, los sujetos con QCS 
fueron más jóvenes, tenían más años de escolaridad, mejor cognición basal, menos atrofia 
global y cortical generalizada, y menos atrofia del lóbulo temporal medial que los sujetos 
con DCL o EA. Dentro del modelo de regresión logística, los marcadores de riesgo 
cardiovascular, las lesiones de sustancia blanca confluentes, la atrofia del lóbulo temporal 
medial y la atrofia central aumentaban la probabilidad de los pacientes con QSC de ser 
clasificados como “similares a EA” por el modelo.  
Los estudios II y III se basan en SveDem, el registro nacional de demencia sueco, 
que recoge diagnósticos incidentales de demencia de todo el país. SveDem se creó en 
2007 para mejorar la calidad y la equidad en el cuidado de los pacientes con demencia en 
Suecia. Con una cobertura de más del 95% de todos los centros especializados en 
memoria a nivel nacional y más de 45 000 pacientes registrados en el momento actual, 
SveDem representa una oportunidad única para analizar los factores que influyen en la 
supervivencia después del diagnóstico de demencia. 
Estos dos estudios emplearon una cohorte de SveDem para analizar qué factores 
se asociaban con un mayor riesgo de mortalidad en el momento del diagnóstico. En el 
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estudio II se incluyeron 15 209 pacientes diagnosticados en centros de memoria 
especializados y seguidos prospectivamente hasta su muerte o el fin del estudio. La edad 
más avanzada, el sexo masculino, el peor nivel cognitivo basal medido por el Mini-
Mental State Exam (MMSE), la institucionalización y el mayor consumo habitual de 
fármacos se asociaron con un riesgo de mortalidad más elevado. La EA presentó mejor 
supervivencia que otras demencias, mientras que la demencia vascular (DV) fue la más 
letal en análisis crudos. Tras ajustar por sexo, edad, número de fármacos y MMSE, la 
demencia frontotemporal (FTD) presentó el riesgo más alto.  
El estudio III analizó la relación entre el índice de masa corporal (IMC) y la 
mortalidad después del diagnóstico de demencia en 11 398 pacientes. Las cifras más altas 
de IMC se asociaron con menor riesgo de mortalidad: el mayor riesgo se evidenció en el 
grupo con IMC inferior a 18.5 kg/m
2
 y el riesgo más bajo en pacientes en el grupo con 
obesidad (IMC 30 kg/m
2
 o superior). Cada punto de incremento en IMC se asoció con 
una reducción del riesgo de mortalidad hasta un IMC de 29,9 en toda la cohorte y en los 
varones, mientras que esta reducción se demostró sólo hasta un IMC de 24,9 en el caso de 
las mujeres.  
En conclusión, la EA, el DCL y las QCS tienen características distintivas. Algunos 
marcadores clínicos, como la atrofia cerebral y los factores de riesgo cardiovascular, 
podrían ayudar a identificar sujetos con QCS con mayor riesgo de sufrir una EA. Una vez 
establecido un diagnóstico de demencia, determinados factores como la edad avanzada, el 
sexo masculino, la menor puntuación en el MMSE, la demencia no-EA, la comorbilidad, 
el IMC menor de 29,9 en varones y menor de 24,9 en mujeres y la institucionalización se 
asocian con mayor mortalidad. 
Palabras clave: Demencia, quejas cognitivas subjetivas, deterioro cognitivo 
ligero, enfermedad de Alzheimer, demencia frontotemporal, demencia por cuerpos de 
Lewy, enfermedad de Parkinson con demencia, demencia de causa mixta Alzheimer y 




Den ökande andelen individer som överlever till hög ålder har orsakat en 
exponentiell ökning i prevalensen av Alzheimers demens (AD) och andra 
demenssjukdomar. Varje år insjuknar 4,6 miljoner personer av demens i världen och 
prevalensen beräknas fördubblas vart 20e år. De flesta demensfallen är AD. Femtio 
procent av personerna över 85 förväntas få AD. Den globala sjukdomsbördan har nått 
epidemiska proportioner. Utan effektiva förebyggande eller sjukdomsmodifierande 
behandlingar är utsikten mörk för dem som drabbas av demens. Samtidigt stiger 
kostnaderna och de sociala konsekvenserna av demenssjukdomarna, särskilt i länder med 
stor åldrande befolkning som Spanien och Sverige. 
Neurodegenerativa processer som leder till demens pågår i årtionden och är inte 
helt klarlagda. Även efter diagnos varierar sjukdomsförloppet mellan individerna. Den 
kognitiva förmågan fluktuerar en del, men över lag försämras kognitionen över tid och  
leder till varierande grader av funktionsnedsättningar. Efter en demensdiagnos förväntas 
man leva mellan 3 och 15 år. Överlevnaden bland patienter med olika demensdiagnoser 
är inte särskilt väl studerat. Några studier har dock visat att typ av demenssjukdom, kön, 
ålder, och kognition påverkar prognosen. Patienter och anhöriga önskar ofta information 
om hur länge man förväntas leva efter en demensdiagnos. Detta är även viktigt för vård- 
och folkhälsoplanering. 
Denna avhandling har två syften: det första är en grundlig beskrivning av patienter 
med subjektiva minnestörningar (SCI) och “mild cognitive impairment” (MCI), den typ 
av lindrig kognitiv störning som vanligen är en preklinisk fas i Alzheimers sjukdom för 
att på så sätt få ökad kunskap om den tidigaste detektbara fasen i Alzheimers sjukdom. 
Det andra syftet är att identifiera vilka faktorer som bidrar till variationer i dödsrisk för 
patienter med olika typer av demenssjukdomar.  
Studie I är baserad på en patientdatabas från Minnesmottagningen vid Geriatriska 
Kliniken, Karolinska Universitetssjukhuset, Sverige. Uppgifterna samlades retrospektivt. 
I studie I ingår 993 patienter med diagnos av AD, lindrig kognitiv störning (MCI) eller 
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subjektiva minnestörningar (SCI). Artikeln innehåller beskrivande statistik och jämförelse 
mellan personer diagnosticerade med AD, MCI och SCI.  En logistisk regressionsmodell 
(baserat på ålder, kön och biomarkörer i cerebrospinalvätska) skapades för att analysera 
vilka egenskaper hos MCI och SCI grupperna som ökade deras likhet med AD gruppen. 
Först skapades en modell som noggrant klassificerade AD, MCI och SCI individer. 
Resultaten från denna modell användes för att tilldela en sannolikhet för varje individ i 
grupperna att vara mer eller mindre “AD-lik” enligt modellen. Beskrivande resultat från 
studien visade att personer med SCI var yngre, hade högre utbildning, bättre kognition, 
mindre generaliserad kortikal och global atrofi, och mindre atrofi i medialtempralloberna 
än de med MCI och AD. Den statistiska regressionsmodellen med “AD-likhet” som 
beroende variabel visade att bland patienter med SCI var kardiovaskulära riskmarkörer, 
vitsubstans-skador, medialtemporallobs-atrofi och central atrofi kopplade till ökande 
“AD-likhet” innom modellen. 
Studier II och III baseras på SveDem, Svenska Demensregistret, där incidenta 
demensdiagnoser i hela Sverige registreras. SveDem etablerades 2007 för att förbättra 
kvaliteten i vården av demenspatienter i hela landet. Med över 95 % av 
specialistenheterna anslutna till registret och fler än 45 000 registrerade individer erbjuder 
SveDem fantastiska möjligheter att utforska vilka faktorer som påverkar bland annat 
överlevnad efter en demensdiagnos. 
Studie II och III använder data från SveDem för att utforska vilka faktorer som 
påverkar dödsrisken efter att en demensdiagnos ställts. I studie II analyserades 15 209 
patienter som diagnostiserades vid specialistenheter och som följdes upp tills de avled 
eller slutet på uppföljningsperioden (i genomsnitt 2,5 år). Högre ålder, manligt kön, sämre 
kognition (definierad med Mini-Mental State Examination –  MMSE), att bo i särskilt 
boende och användning av många läkemedel var kopplat till högre dödsrisk. Personer 
med AD hade lägre dödsrisk än de med andra demenssjukdomar och vaskulär demens 
hade den största risken i ojusterade analyser. I analyser kontrollerade för kön, ålder, antal 
läkemedel och MMSE blev frontallobsdemens den typ av demenssjukdom som hade 
störst dödsrisk. I studie III studerades sambandet mellan body-mass index (BMI) och 
dödlighet efter demensdiagnos bland 11 398 patienter. Högre BMI associerades med lägre 
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dödsrisk: risken var högst bland patienter med BMI under 18.5 kg/m
2
, och lägst bland 
feta individer (BMI ≥30). Varje enhetsökning av BMI associerades med en minskning av 




Sammanfattningsvis hade personer med AD, MCI och SCI olika egenskaper. SCI-
patienter med högre risk för AD kunde identifieras med hjälp av några kliniska markörer 
som atrofi och kardiovaskulära riskfaktorer. Efter att demensdiagnosen har ställts är 
faktorer som ålder, att vara man, lägre MMSE, annan demensdiagnos än AD, annan 
sjuklighet, lägre BMI och att bo i särskilt boende kopplat till ökad dödlighet. 
Key words: demens, subjektiva minnesstörningar, lindrig kognitiv störning, 
Alzheimers sjukdom, Lewy body demens, Parkinsons sjukdom med demens, blandad 









AD Alzheimer’s dementia 
AD-C Clinical Alzheimer’s disease 
AD-P Pathological Alzheimer’s disease 
AIDS Acquired immunodeficiency syndrome 
ApoE Apolipoprotein E 
APP Amyloid precursor protein 
BAI Body adiposity index 
BMI Body mass index 
BPSD Behavioral and psychological symptoms associated with dementia 
bvFTD Behavioral variant frontotemporal dementia 
CERAD Consortium to Establish a Registry for Alzheimer’s disease 
CSDD Cornell scale of depression in dementia 
CSF Cerebrospinal fluid 
CT Computed tomography 
DAT Dopamine active transporter 
DLB Dementia with Lewy bodies 
DSM-5 Diagnostic statistic manual, 5
th
 edition 
DSM-IV Diagnostic statistic manual, 4
th 
edition 
DXA Dual-energy X-ray absorptiometry 
FDG-PET Fluoro-deoxyglucose positron emission tomography 
FLAIR Fluid attenuation inversion recovery 
FTD Frontotemporal dementia 
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FTLD Frontotemporal lobe degeneration 
GDS Global deterioration scale 
GDP Gross domestic product 
HDL High density lipoprotein 
HIV Human immunodeficiency virus 
HR Hazard ratio 
ICD-10 International classification of diseases, 10
th
 edition 
IWG International Working Group 
LB Lewy bodies 
LBD Lewy body dementias 
LDL Low density lipoprotein 
LN Lewy neurites 
MCI Mild cognitive impairment 
MICS Malnutrition inflammation complex syndrome 
MMSE Mini-mental State Examination 
MND Motor neuron disease 
MRI 
 
Magnetic resonance imaging 
 
MTA Medial temporal atrophy 
NIA-AA National Institute of Aging-Alzheimer’s Association 
NMDA N-methyl-D-aspartate 
OR Odds ratio 
PD Parkinson’s disease 
PDD Parkinson’s disease with dementia 
PET Positron emission tomography 





REM Rapid eye movement 
SCI Subjective cognitive impairment 
SD Standard deviation 
SEN Sociedad Española de Neurología (Spanish Neurological Society) 
SMR Standardized mortality rate 
SPECT Single-photon emission computed tomography 
TDP-43 Transactive response DNA-binding protein 43 
TIA Transient ischemic attack 
US United States 
VaD Vascular dementia 
VLDL Very low density lipoprotein 
WHO World Health Organization 
WHR Waist-height ratio 
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1.1 THE EVOLVING CONCEPT AND DEFINITIONS OF DEMENTIA 
Dementia has accompanied humanity since the dawn of time and has been 
recognized as an illness associated with old age since the beginning of history.
1, 2
 
Aretaeus of Cappadocia may have been the first to draw the distinction between delirium, 
which he described as reversible, and dementia, which was permanent and progressive.
2
 
Both Hippocrates and Galen were aware that these disorders could arise either from a 
primary process to the brain or from secondary disease located in other organs of the 
body.
2
 Cicero may have been the first to distinguish dementia from normal aging and to 
propose intellectual activity as preventive of mental decline.
3
  
Alois Alzheimer’s first description of a case of Alzheimer’s disease (AD) did not 
immediately spark much subsequent research. This was possibly due to the fact that the 
author himself thought this disease to be rather uncommon. Indeed, according to 
Pubmed
®
 there were only 47 publications containing the keyword “Alzheimer” between 
1963 and 1973. The United States (US) congressional mandate which resulted in the 
creation of the National Institute of Aging in the US in 1974 changed this picture.
2, 4
 
Fourteen articles on “Alzheimer’s disease” were published in 1974, 43 in 1975, and 110 
in 1980. From there, the progression has been exponential, reaching 4 988 indexed 
publications during 2012. Other diseases, such as “dementia with Lewy bodies” and 
“frontotemporal degeneration” have joined the picture, and today dementia is widely 
understood as a collection of syndromes caused by an array of disorders of the brain.  
The World Health Organization (WHO)
5
 defines dementia as a syndrome due to 
disease of the brain, usually chronic or progressive, in which multiple cortical functions 
are disturbed with spared consciousness. A decline from previous cognitive functioning 
must be evident and delirium or major psychiatric disorder must be excluded as causes. 
The National Institute for Aging-Alzheimer’s Association (NIA-AA) workgroup further 
stipulates that cognitive impairment must be determined through a combination of 
history-taking from a knowledgeable informant and cognitive testing. Furthermore, 




judgment, visuospatial, language, or personality and behavior.
6
 This syndrome 
predominantly affects older individuals, but the disturbance goes beyond that expected 
for normal aging. 
Several diagnostic criteria, such as those of the ICD-10 (International 




 and the DSM-IV-TR and DSM-5 (Diagnostic 
statistic manual, 4
th 
edition revised and 5
th
 editions) exist for dementia (tables 1 and 2) ,
7, 8
 
and an array of guidelines and criteria exist for individual disorders.
5, 6, 9-13
 However, 
there remain areas of overlap between disorders and between the preclinical or 
predementia phases of diseases and dementia.
9
 These areas of uncertainty are the 
consequence of the limitations of all classification systems, as well as the wide range of 









Table 1. ICD-10 diagnostic criteria for dementia* 
G1. Presence 
of all of the 
following 
Impaired memory: both verbal and non-verbal.  
Mild Memory loss interferes in daily activities. Independent living 
can be maintained. 
Moderate Independent living is impaired. 
Severe 
Subject unable to retain new information, severe amnesia of old 
information, fails to recognize relatives. 
   
Impairment in other cognitive domains: judgment, 
planning, information processing, organizing… 
Subject previously had a higher level of functioning. 
Mild 
Impairment in activities of daily living, still independent. 
Requires help for complex tasks. 
Moderate Subject is unable to function without assistance. 
Severe Intelligible ideation is virtually absent. 
G2. Awareness is preserved 
  
G3.Behaviour, emotional control and motivation are affected 
G4. G1 should be present for at least six months 
 
 
ICD-10: International classification of diseases, 10th edition. 






Table 2. DSM-IV-TR diagnostic criteria for dementia* 
1. Both of the following: 
A. Objectively demonstrated memory deficit 
B. At least one other cognitive deficit: aphasia, executive dysfunction, agnosia or apraxia 
2. These deficits cause impairment of daily life activities  
3. Social and occupational impairment must be present 
4. There is a decline from a previous higher level of functioning 
5. Delirium is excluded 
 
 
DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 
*Adapted from American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 




1.2 ALZHEIMER’S DISEASE 
1.2.1 First description and current view of Alzheimer’s disease  
In 1906, Alois Alzheimer described the case of a 51 year old woman, “Auguste 
D”, who presented dementia and in whom postmortem examination revealed amyloid 
plaques and neuritic tangles. In 1911 Alzheimer published a report in which he included a 
second case, that of a 56 year-old man who was proven to have exclusively plaque 
pathology. The histological sections have been preserved to this day which has allowed 
confirmation of Alzheimer’s findings and exclusion of amyloid precursor protein (APP) 
mutations.
14, 15
 Alzheimer himself was unsure about the nature of the condition, which he 
thought could represent an early presentation of senile dementia or a different entity 
entirely. These qualms were not shared by Emil Kraepelin, Alzheimer’s supervisor and 
the world’s most prominent psychiatrist at the time, who included the condition and 
called it Alzheimer’s disease (AD) in his 1910 Textbook of Psychiatry.3 Other 
pathologists gave validity to these histological descriptions,
3
 but AD was still considered, 
for several decades, as a rare condition that only affected younger people. Regarding 
dementia presenting in older age, Kraepelin described how ““Past events gradually 
vanish from their memory, although often events of their childhood are recalled in their 
mind with surprising vividness (...)” and that “(…) particular the memory of recent events 
starts to reveal numerous and incomprehensible gaps (...)”.3 Together, Alzheimer and 
Kraepelin set the foundation stones for the concepts of young-onset and late-onset AD. 
Today, AD is understood as a complex disorder in which the neuropathological 
disease (Alzheimer’s disease pathology, AD-P) must be distinguished from its clinical 
manifestation (varying degrees of cognitive impairment and clinical syndromes caused by 
Alzheimer’s disease, AD-C).16, 17  
Two sets of research criteria are available for AD, both employing biomarkers.
18
 
The International Working Group (IWG) proposes criteria for “preclinical AD”, further 




group including presymptomatic subjects carrying autosomal dominant mutations for 
hereditary AD. Symptomatic individuals are classified as “AD” with subgroupings of 
“prodromal AD” (a mild cognitive impairment-MCI stage) and “AD dementia”. The 
second set of criteria consists of the NIA-AA recommendations. When biomarkers are 
available, individuals are classified into an asymptomatic stage called “preclinical AD”, 
an AD-MCI stage referred to “MCI due to AD” and a dementia stage “dementia due to 
AD”. When biomarkers are not available, individuals are classified according to clinical 
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AD: Alzheimer´s disease. IWG: International Working Group. MCI: mild cognitive impairment. NIA-
AA:  National Institute for Aging-Alzheimer’s Association. SCI: subjective cognitive impairment. 





1.2.2 Pathological Alzheimer’s disease (AD-P)  
AD neuropathologic change refers to the accumulation of senile β-amyloid (Aβ) 
plaques and neurofibrillary tangles (NFT) with varying degrees of intensity and 
distribution.
19
 NFT are intraneuronal fibrils primarily composed of abnormal tau and can 
be visualized with histochemical stains or immunohistochemistry directed against tau or 
phospho-tau epitopes. In early stages, they may only be present in limbic areas but 
gradually involve other brain regions including cortex, subcortical nucleii and some 
brainstem regions.
20
 The sequence of involvement starts in the entorhinal cortex, 
spreading to hippocampus and then neocortex, although there are exceptions.
20, 21
 Senile 
plaques are extracellular deposits of Aβ peptides. When they are located at the center of a 
cluster of dystrophic neurites (which often have phospho-tau immunoreactivity) they are 
called neuritic plaques. Non-neuritic structures can present as diffuse plaques, cotton 
wool plaques, amyloid lakes and subpial bands.
20
 Amyloid plaques are heterogeneous and 
it is currently believed that neuritic plaques have the greatest potential for neuronal 
injury.
20
 Aβ deposition in the brain follows a distinct sequence begining with neocortex 
(Thal phase 1), followed by allocortical brain regions (Thal phase 2), diencephalic nuclei,  
striatum and cholinergic nuclei in basal forebrain (Thal phase 3), other brainstem nuclei 
(Thal phase 4) and cerebellar deposition (Thal phase 5).
22
 It is possible for AD 
neuropathology to be present in individuals without cognitive impairment, predating 
symptom onset by years. For individuals with clinical symptoms, intermediate or high 




The cholinergic system is implicated in the genesis of AD: basal cholinergic 
neurons project to both cortex and hippocampal regions and degenerate in AD, possibly 
due to the disappearance of neurotrophic signals from these target sites. However, these 
connections might still be viable for some time after disease onset and “rescuing” them 
has become the focus of new therapeutical intervention studies.
23
 Encapsulated cell 
biodelivery of nerve growth factor (NGF) targeted towards preserving these connections 






The Braak and Braak
27
 criteria are still in effect for NFT, while the NIA-AA 
favors the Thal phases for amyloid plaques
20, 22
 and the criteria from the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) for neuritic plaque scoring.28 
Thus, the NIA-AA recommends an “ABC” score (Amyloid, Braak, CERAD) for AD 
neuropathologic changes (table 4). The NIA-AA also recommends thorough reporting on 
Lewy body (LB) and vascular pathology, as well as hippocampal sclerosis and transactive 
response DNA-binding protein 43 kDa (TDP-43) inclusions.





Table 4. NIAA-AA recommendations for classification of Alzheimer’s disease 
neuropathological change* 
A. Thal Aβ plaque score 
A0: no Aβ or amyloid plaques 
A1: Thal phase 1 or 2. 
A2: Thal phase 3 
A3: Thal phase 4 or 5 
B. NFT stage  
B0: No NFTs 
B1: Braak stage I or II 
B2: Braak stage III or IV 
B3: Braak stage V or VI 
C. CERAD neuritic plaque score 
C0: no neuritic plaques 
C1: CERAD score sparse 
C2: CERAD score moderate 
C3: CERAD score frequent 
 
 
Aβ: β-amyloid. CERAD: Consortium to Establish a Registry for Alzheimer’s Disease. NFT: neurofibrillary 
tangles. NIAA: National Institute for Aging-Alzheimer’s Association. 
*Reproduced with permission from Bradley T. Hyman et al. National Institute on Aging – Alzheimer’s 
Association guidelines on neuropathologic assessment of Alzheimer’s disease. Alzheimer’s & Dementia: 





1.2.3 Clinical Alzheimer’s disease (AD-C) 
The typical clinical picture of early AD is characterized by insidious and 
progressive cognitive decline of sufficient gravity to meet criteria for dementia with two 
or more affected cognitive domains (tables 5 and 6). The amnestic presentation is the 
most typical, with deficits in episodic memory. Nonamnestic presentations include 
language presentations (word-finding deficits), visuospatial presentations, or executive 
dysfunction. Extensive vascular cerebral damage apparent in clinical history or imaging 
may not be present.
6 
Insight may or may not be preserved and depressive symptoms are a 
common associated finding. Social graces and basic activities of daily living tend to be 
preserved until later in the course of the disease.
29
 
Two nonamnestic presentations of AD deserve special attention. One is posterior 
cortical atrophy.
6
 In this syndrome, elements of Balint’s syndrome, comprising difficulty 
integrating the perception of the entire visual field, difficulty directing eye movements 
and grasping objects presented visually can combine with apraxia, Gerstmann syndrome 
and other more typical AD symptoms.
29
 Another is logopenic-primary progressive 
aphasia. In this condition, the primary deficit is word-finding, although deficits in at least 
one other cognitive domain must be present to determine an AD diagnosis according to 
NIA-AA criteria.
6 
Primary progressive aphasia can also be associated with frontotemporal 
dementia (FTD), especially in cases of agrammatic presentations. However, although 
subtyping primary progressive aphasia can help predict whether AD or FTD is involved, 







Table 5. ICD-10 criteria for Alzheimer´s dementia* 
F00  Dementia in Alzheimer´s disease  
A. The general criteria for dementia (G1 to G4) must be met (table 1) 
B. No evidence for other causes of dementia (e.g. cerebrovascular disease, 
Parkinson’s disease, Huntington’s disease, normal pressure hydrocephalus), 
systemic disorder (e.g. hypothyroidism, vitamin B12 or folic acid deficiency, 
hypercalcemia), or alcohol- or drug-abuse. 
Comments: Neurofibrillary tangles and neuritic plaques in excess to normal aging must be 
found post-mortem in order to confirm the diagnosis. 
 
 
ICD-10: International classification of diseases, 10th edition. 
*Adapted from World Health Organization. The ICD-10 Classification of Mental and Behavioural 







Table 6. NIAA-AA clinical diagnostic criteria for dementia with Alzheimer´s disease* 
Meets criteria for dementia and, in addition, has the following characteristics: 
A. Insidious onset 
B. Clear-cut history of worsening of cognition (...); and 
C. The initial and most prominent cognitive deficits are evident on history and examination 
in one of the following categories. 
i. Amnestic presentation 
ii. Non-amnestic presentations: 
• Language presentation: word-finding deficits are most prominent. 
Deficits in other cognitive domains should be present. 
• Visuospatial presentation. Spatial cognition, object agnosia, impaired 
face recognition, simultagnosia, and alexia. Deficits in other cognitive 
domains should be present. 
• Executive dysfunction. Deficits in other cognitive domains should be 
present. 
D. The diagnosis of probable AD should not be applied when there is evidence of (a) 
substantial concomitant cerebrovascular disease (...); or (b) core features of dementia 
with Lewy bodies other than dementia itself; or (c) prominent features of behavioral 
variant frontotemporal dementia; or (d) prominent features of semantic variant primary 
progressive aphasia or non-fluent /agrammatic variant primary progressive aphasia; or 
(e) evidence of another concurrent, active neurological disease, or a non-neurological 




NIAA: National Institute for Aging-Alzheimer’s Association. 
*Adapted from McKhann et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations 
from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for 




1.2.4 The preclinical and predementia stages of Alzheimer’s disease 
1.2.4.1 Subjective cognitive impairment: a preclinical syndrome 
Subjective cognitive impairment (SCI) applies to a heterogeneous group of 
patients who present with cognitive complaints without hard evidence of 
neuropsychological decline.
31
 Neurodegeneration is expected to begin several decades 
before clinical symptoms,
32, 33
 and the MCI stage preceding dementia is calculated to last 
7-10 years.
34
 Thus, it is reasonable to search for the earliest stages of dementia among 
patients who present cognitive complaints without demonstrable impairment.
9, 35
 SCI 
affects a large percentage of patients attending memory clinics worldwide
31, 36-38
 and 
represents a relevant clinical problem. The concept has evolved since Reisberg defined 
the stage 2 of the Global Deterioration Scale (GDS),
39
 which is equivalent to SCI, and 
now many support the existence of this syndrome as an early stage in neurodegenerative 
disease, particularly AD.
40, 41
 This may be especially valid when biomarkers are available 
and suggestive.
9
 In other cases, diagnosis is more controversial.  
Nowadays AD is an established diagnosis but substantial grey areas still remain. 
MCI is even more heterogenous, with uncertainty remaining over the prognosis of many 
groups of patients. All these problems increase in SCI, by definition a diagnosis without 
demonstrable cognitive decline and with few “hard” variables, and in which research has 
historically focused on personality characteristics of patients and depression.
31
 The 
heterogeneity between patients and study methods complicates the debate: while some 
studies focus on general population and ask about cognitive complaints,
42-51 
others recruit 
patients from memory units.
52-54
 Table 7 summarizes studies which include data on 





Table 7. Studies with data on the prevalence of subjective cognitive impairment* 
















Study of the 
Elderly 
1994 Population 10.81% 8.96% 65-84 3774 
Jonker et al
36




























1995 Population 25%   ≥65 705 
Jonker et al
45
 AMSTEL 1996 Population 22.10%   65-84 2537 
Blazer et al
43





45 and Up 
Study 





















  2010 
Memory 
Unit 
- 46.23% - 92 
Andersson
37
   2005 
Memory 
Unit 





 LEILA 75+ 1999 Population 39%   >75 322 
 
 




elderly. LEILA 75+:  Leipzig Longitudinal Study of the Aged. MAS: Sydney Memory and Aging study. N: 
number of patients. PAQUID study: Personnes Agées QUID.  
*Reproduced with permission from Sociedad Española de Neurología (SEN). Garcia-Ptacek S, et al. Quejas 
cognitivas subjetivas: hacia una identificación precoz de la enfermedad de Alzheimer [Subjective cognitive 






Despite all these problems, the case is strong for including SCI as the earliest 
stage in an SCI-MCI-AD continuum. A growing body of evidence suggests that SCI 
patients are at increased risk of future cognitive decline,
51, 59-61 
although some authors 
have found no association.
62 
As can be seen in table 8, SCI is associated with future 
decline in longitudinal studies with odds ratios (OR) that range between 1.5 and 8.5 
compared to controls. White matter lesions
59 
and higher education strengthen the 
association between SCI and future decline.
60
 It may be that individuals with higher 
education are sensitive to their own cognitive decline before neuropsychological testing 
can detect it, or that the ceiling effect of cognitive testing is particularly relevant in this 
group. Highly educated individuals might also have more cognitively demanding 
occupations, which could highlight even slight decline.  
Subjects with SCI also differ from the general population in neuroimaging.
63, 64
 
Studies have demonstrated a reduction in hippocampal volume among SCI subjects 
compared to controls,
64
 as well as volumetric reductions in medial temporal and 
frontotemporal areas
63
 with the same distribution as in MCI patients, but less severe. 
Functional neuroimaging demonstrates increased activation in cognitive tasks in AD, 
MCI and apolipoprotein E (APOE) ɛ4 carriers,65, 66 indicating the presence of 
compensatory recruitment. The intensity of this hyperactivation has been correlated with 
increased subsequent decline.
65
 This pattern has been reproduced in SCI, with subjects 
presenting an increased cortical activation in prefrontal dorsolateral and left premotor 
areas during a memory coding task in one study,
67 
and an increase in thalamic, posterior 
cingulus, bilateral caudate and left hippoccampus and parahippoccampic region in 
another.
68
 Additionally, fluoro-deoxyglucose positron emission tomography (FDG-PET) 
has shown decreased metabolism in SCI subjects in parahippoccampus, parieto-temporal, 
inferior frontal, fusiform gyrus and thalamus, replicating findings in healthy subjects with 
high risk for AD (autosomic dominant familial AD, high family prevalence of AD or 
APOE ɛ4 homocygotes), and in MCI subjects.33 
SCI has also been linked to AD pathology. Two studies found a relationship 






Another found a higher frequency of AD-pattern biomarkers in cerebrospinal fluid (CSF) 
of SCI subjects compared to controls.
71
 The current theory on the evolution of biomarkers 
in AD proposes an early drop in CSF Aβ while the increase in tau occurs at later stages.54 
If SCI is part of the AD continuum, biomarkers should correspond to the earlier stages of 
this timeline. Indeed, CSF Aβ42 has been shown to correlate with performance in 
semantic and working memory tasks in SCI and controls, while tau predicts cognitive 
performance better in MCI individuals.
72
  
Amyloid load demonstrated by PET with the Pittsburgh compound B (PiB-PET) 
shows correlation with atrophy in SCI subjects, but not in controls.
73
 Chatélat et al
74
 
found that healthy subjects with high PiB deposit had larger temporal lobes than their low 
PiB comparisons, suggesting that only subjects with constitutionally large temporal lobes 
are able to remain asymptomatic with a high amyloid load, or that amyloid itself causes 
the temporal lobes to enlarge in an early stage. The inverted U relationship that has been 
found between amyloid load and cortical volume strengthens this last hypothesis.
53
 In 
Chatélat’s study, SCI subjects with high amyloid had lower temporal volumes than 
healthy subjects with high amyloid, possibly indicating the beginning of a reduction in 
temporal volume.
74
 However, these studies were cross-sectional. Without longitudinal 
studies it is impossible to know whether these findings reflect different patient 




Table 8. Studies on cognitive outcome of  subjective cognitive impairment* 
Referenc
e 


















2 years + 
OR 1.5 without 






AMSTEL 1999 2169 
MMSE, 
CAMCOG 

























KINDS 2000 543 CASI, GDS-S 3 years -   
 
 
AMSTEL: Amsterdam Study of the Elderly. AVLT: Rey Auditory Verbal Learning Test. CAMCOG: 
Cambridge Cognition Examination. CAMDEX: Cambridge Mental Disorders of the Elderly Examination. 
CASI: Cognitive Abilities Screening Instrument. CDS: Caroll Depression Scales. CES-D: Center for 
Epidemiological Studies Depression scale. DSST: Digit Symbol Substitution Test. EVA: Epidemiology of 
Vascular Aging study. FTT: Finger Tapping Test. GDS-S: Geriatric Depression Scale-Short version. GMS: 
Geriatric Mental Status interview. KINDS: Kinmen Island Neurologic Disorder Survey study.  MMSE: 
Mini-mental State Exam. N: number of patients. OR: odds ratio. SCI: subjective cognitive impairment. 
WML: white matter lesions.  
* Reproduced with permission from Sociedad Española de Neurología (SEN). Garcia-Ptacek S, et al. 
Quejas cognitivas subjetivas: hacia una identificación precoz de la enfermedad de Alzheimer [Subjective 






1.2.4.2 Mild cognitive impairment due to Alzheimer’s disease: the 
symptomatic predementia stage 
MCI describes a state of noticeable cognitive impairment in which independence 
in functional abilities is preserved.
75
 When the cause is AD, MCI can be considered a 
predementia stage in the AD disease course. The NIA-AA requires for diagnosis the 
existence of a concern regarding drop in cognition from the patient’s previous level, 
demonstrable impairment in one or more cognitive areas with preservation of 
independence despite mild problems in complex functional tasks. If social or 
occupational impairment becomes significant, the patient is diagnosed with dementia and 
the diagnosis of MCI is no longer applicable.  
1.2.5 Diagnostic tools: the role of biomarkers 
Biomarkers can be defined as anatomic, physiological or biochemical in vivo 
parameters that reflect specific features of disease-related pathophysiology. For its 2011 
criteria, the NIA-AA focused on those which were sufficiently established as being linked 
to AD and divided them into two categories based on their specificity.
17
 Thus, one 
category includes biomarkers of Aβ accumulation, as demonstrated by amyloid PET or 
low CSF Aβ42. Another category includes biomarkers of neuronal degeneration or injury, 
such as high CSF tau, decreased FDG uptake in PET in temporoparietal cortex, and 
atrophy in structural magnetic resonance imaging (MRI) in areas prone to AD pathology, 
such as medial and lateral temporal lobes, parietal and prefrontal cortex.
9, 76
 Biomarkers 
suggestive of amyloid pathology appear first in the disease process, anytime between 10 
to 20 years before clinical symptoms. Biomarkers of neuronal injury and dysfunction 
come later, maybe shortly before clinical onset, and parallel cognitive worsening.
17
 
Following the NIA-AA criteria, biomarkers are used in the preclinical phase to 
establish the presence of AD-P in asymptomatic or subtly symptomatic research subjects. 
In the MCI and AD phases, biomarkers are complementary to clinical diagnosis, which 






 In MCI, according to the NIA-AA, biomarkers remain a tool for 
research, not for routine clinical assessment.
75
 
1.3 VASCULAR DEMENTIA 
Vascular dementia (VaD) has been defined as the loss of cognitive function with 
interference with activities of daily living resulting from ischemic or hemorrhagic 
cerebrovascular disease or from cardiovascular or circulatory disturbances that affect 
brain function.
77
 Vascular causes were considered the main origin of cognitive decline 
until the 70s and 80s, when the focus shifted towards neurodegenerative causes of 
dementia.
78
 The pendulum may now be swinging back, with a renewed interest in 
vascular pathology and its interaction with AD.
79
 
VaD is often cited as the second most common type of dementia after AD,
77, 80
 
although estimates of prevalence vary depending on the definition employed.
78
 Unlike 
AD, VaD is more prevalent in men
77
 and memory disturbance is not a principal feature.
78
 
The clinical picture can be varied, ranging from post-stroke dementia to lacunar state or 
Biswanger’s disease.77 Clinical manifestations depend on the affected brain regions and 
can span from aphasia or apraxia for cortical lesions to executive dysfunction and gait 
abnormalities for subcortical pathology.
79
 Clinical course is variable, with acute or 
subacute onset, which can improve, stabilize or decline in a gradual or step-wise 
fashion.
79
 Unlike the definition of AD, which describes a specific clinical picture coupled 
with its anatomopathological correlate, VaD groups a range of clinical presentations with 
a broader cardiovascular cause. 
1.4 MIXED ALZHEIMER´S AND VASCULAR DEMENTIA 
The boundaries between VaD and AD are indistinct. Cardiovascular risk factors, 
including insulin resistance and hypertension, are linked both to AD and VaD.
78
 APOE ɛ4 
allele is a risk factor for AD but also increases the likelihood of cerebral infarcts.
81
 Most 






 which could amplify the effects of AD plaques and tangles.
77
 In the Rush 
Religious Orders Study, vascular pathology was prevalent: clinically unrecognized 
macroscopic infarcts were frequent and commonly occurred in the context of AD 
pathology.
81
 Infarcts independently added to the likelihood of dementia and almost half of 
clinical AD patients also had vascular pathology.
81
 Twenty percent of autopsy cases with 
AD pathology in CERAD did not have clinical dementia: cerebrovascular lesions may be 
the tipping point that leads to clinical symptoms in persons with AD pathology.
77
 It is 
unclear whether both disease processes have an additive effect in the progression towards 
dementia or whether they function synergistically, enhancing and accelerating cognitive 
decline.
78
 In the Religious Orders study, macroscopic infarcts increased the risk of 
dementia in an independent, non-synergistic manner.
81 
This overlap can indicate that risk 
factors for AD might act through cardiovascular, and not amyloid pathological 
pathways
81
 and expands the spectrum of possible therapeutic strategies. 
Furthermore, a proportion of patients present with both AD and VaD clinical 
features. The term mixed dementia is often used to define this group, with patients 
demonstrating varying degrees of memory and executive or other dysfunction 
accompanied by evidence of cerebrovascular disease. 
1.5 LEWY BODY DEMENTIAS: DEMENTIA WITH LEWY BODIES AND 
PARKINSON’S DISEASE WITH DEMENTIA 
Initially described as separate entities, it is now recognized that dementia with 
Lewy bodies (DLB) and Parkinson’s disease with dementia (PDD) share a common 
pathophysiology and can be understood as two expressions within a pathological 
continuum.
82
 The umbrella term Lewy body dementias (LBD) is now being proposed.
82
 
In this disease, neuronal inclusions of alfa-synuclein forming Lewy bodies (LB) and 
Lewy neurites (LN) are accompanied by neuronal loss, often with varying degrees of AD 
pathology.  The prevalence of dementia among PD patients is around 25% with a 




prevalence of DLB, which is probably underestimated.
83
 One review reported percentage 
of total dementia population ranging from 0-24%.
84
 
1.5.1 Dementia with Lewy bodies 
LB and LN are pathologic aggregations of alpha-synuclein affecting brainstem, 
limbic and cortical regions.
85
 In DLB, these neuropathological findings accompany a 
clinical LB syndrome characterized by often rapidly progressive mental impairment with 
disproportionate attention, problem solving and visuospatial difficulties, accompanied by 
fluctuations in cognitive function, visual hallucinations, parkinsonism and increased 
sensitivity to neuroleptic treatments.
86
 Rapid eye movement (REM) sleep behavior 
disorder, autonomic dysfunction, systematized delusions and hallucinations in other 
modalities can also be present. Although the first consensus criteria for the diagnosis of 
DLB accepted any intensity of LB in neuropathology as criteria for diagnosis,
86
 it is now 
recognized that up to 60% of pathologically confirmed AD cases may also have some LB 
pathology.
85
 For this reason, the new diagnostic criteria consider the intensity and 
extension of LB pathology, as well as the presence and severity of accompanying AD 
pathology to determine if a case is likely to be associated with a DLB clinical syndrome
13
 
Low striatal uptake in functional imaging of dopamine active transporter (DAT) is 
common to PD and DLB, and can help distinguish them from AD. Occipital 
hypoperfusion or hypometabolism without accompanying atrophy is another suggestive 
feature (table 9).
13 
1.5.2 Parkinson’s disease with dementia 
Dementia is a common outcome in PD, occurring 10 or more years after onset of 
motor symptoms. PD is pathologically characterized by LB and LN in the substantia 
nigra together with loss of dopamine in the nigrostriatal tract.
87 
The cognitive syndrome is 
remarkably similar to that of DLB, with the same cognitive profile and other identical 
features such as autonomic dysfunction, sleep disorders, neuroleptic sensitivity and 
neuropsychiatric symptoms.
85




parkinsonian motor symptoms and levodopa response are different. Thus, the distinction 
of both entities relies only on the temporal sequence of parkinsonian and cognitive 
symptoms. An arbitrary cut point of 1 year or more separation between appearance of 
parkinsonian and cognitive symptoms has been used to distinguish PDD from DLB
10
 
(table 9). Thus, PDD describes the appearance of the common clinical cognitive 
syndrome within well-established PD, while in DLB parkinsonian and cognitive features 
would appear simultaneously.
85
 Critics of this classification argue that the distinction is 
arbitrary, that both diseases share the LB as a pathological basis, suggesting that they are 
manifestations of the same disease.
82, 85 
Furthermore, studies on incident or early PD have 
demonstrated that a significant proportion of these patients already display some 
cognitive impairment at the time of diagnosis,
87, 88
 with 8% scoring under 24 on the Mini 
Mental State Examination (MMSE) in one cohort study, with a profile that suggested 







Table 9. Comparison between dementia with Lewy bodies and Parkinson’s disease with dementia 
current diagnostic criteria* 
Current DLB Consortium Criteria
13
 
Central feature (required for possible or probable DLB) 
a. Progressive dementia severe enough to interfere with normal social or occupational function  
b. Deficits on tests of attention, executive function, and visuospatial ability may be especially 
prominent 
Core features (2 are required for probable, 1 for possible DLB) 
a. Fluctuating cognition 
b. Recurrent visual hallucinations 
c. Spontaneous parkinsonism 
Suggestive features (if 1 or more is present with at least 1 core feature, probable DLB; in the absence of 
core features, possible DLB) 
a. REM sleep behaviour disorder  
b. Severe neuroleptic sensitivity 
c. Low dopamine transporter uptake in the basal ganglia 
Supportive features (commonly present but not proven to have diagnostic specificity) 
a. Repeated falls and syncope 
b. Transient unexplained loss of consciousness 
c. Severe autonomic dysfunction 
d. Non-visual hallucinations 
e. Systematized delusions 
f. Depression 
g. Relative preservation of medial temporal lobe structures 
h. Generalized low uptake on SPECT/PET with reduced occipital activity 
i. Abnormal MIBG myocardial scintigraphy 







A diagnosis of DLB is less likely if 
a. Cerebrovascular disease or other physical illness are sufficient to account for part or all of clinical 
picture 
b. Parkinsonism does not appear until severe dementia 
Current Criteria for PDD
10
 
Core features (both required for possible or probable PDD) 
a. Diagnosis of PD according to Queen Square Brain Bank Criteria  
b. Dementia developing in the context of established PD, with cognitive impairment in more than 1 
domain and severe enough to impair daily life 
Associated clinical features (typical profile of cognitive deficits must be present for probable, but not 
possible, diagnosis) 
a. Typical cognitive profile: Impairment in at least 2 of the following domains: a) attention (which 
may fluctuate) b) executive function, c) visuospatial function d) free recall (which usually 
improves with cueing)  
b. Presence of behavioural features supports but absence does not exclude diagnosis, and include 
apathy, depressed or anxious mood, hallucinations, delusions, and excessive daytime sleepiness 
A diagnosis of PDD cannot be made if 
a. Cognitive and behavioural symptoms appear solely in the context of other conditions such as 
systemic diseases, drug intoxication, or major depression 
b. Patient meets criteria for probable vascular dementia 
The temporal sequence of symptoms guides differential diagnosis of DLB and PDD 
a. In DLB the dementia develops before or within one year of spontaneous parkinsonism 
b. In PDD the dementia develops within the context of established PD 
 
DLB: Dementia with Lewy bodies. EEG: Electroencephalogram. MIGB: metaiodobenzylguanidine. PD: 
Parkinson´s disease. PDD: Parkinson´s disease with dementia. PET: Positron emission tomography. REM: 
rapid eye movement. SPECT: Single-photon emission computed tomography.  




1.6 FRONTOTEMPORAL LOBAR DEGENERATION 
A common cause of presenile dementia, frontotemporal lobar degeneration 
(FTLD) can present with a spectrum of clinical syndromes, from language or motor to 
behavioral dysfunction.
89, 90
 The pathology underlying this condition is unpredictable and 
heterogeneous, although neuronal loss, gliosis and spongiosis of frontotemporal 
distribution are its hallmark.
91, 92
 Neuropathological abnormalities can be represented by 
tau-positive inclusions and insoluble tau with predominance for 3 microtubule-binding 
repeats (3R), tau-positive inclusions and insoluble tau with 4 microtubule-binding repeats 
(4R), a combination of both, or ubiquitin-positive/tau negative inclusions.
92
 Around 40% 
of patients have a family history of disease, but only in some cases has the genetic cause 
been identified, usually in the genes of microtubule associated protein tau or progranulin, 
and there is considerable overlap with corticobasal degeneration.
91
 
 The most frequent syndrome in FTLD is behavioral variant frontotemporal 
dementia (bvFTD), characterized by a progressive deterioration of personality, social 
behavior and cognition due to degeneration of frontal and anterior temporal lobes.
89, 90
  
The International Consensus Criteria for bvFTD were published in 2011 and require 
progressive deterioration of behavior or cognition reported by a reliable informant and a 
combination of clinical and neuroimaging changes
89
 (table 10). Possible bvFTD may be 
diagnosed by the presence of three symptoms among a list of signs of behavioral 
disinhibition, apathy, loss of empathy, perseverative or compulsive behavior, hyperorality 
or dietary changes, or a dysexecutive neuropsychological profile. If neuroimaging shows 
frontal and/or anterior temporal atrophy in MRI or computed tomography (CT), or 
hypoperfusion or hypometabolism is demonstrated through PET or single photon 
emission computed tomography (SPECT), the patient receives a diagnosis of probable 
bvFTD. A definite diagnosis requires compatible FTDL pathology or the presence of a 
known pathogenic mutation.
89
 These criteria display high sensitivity (86%) for bvFDT,
89
 
but issues arise when seeking objective standards for behavioral symptoms, since the line 
between a jovial personality and pathological disinhibition is a thin one and might 




insidious nature of these symptoms often leads to a psychiatric misdiagnosis and the lack 
of insight typical of bvFTD patients complicates the picture.
90
 Early diagnosis in this 
condition is critical: progression is fast, behavioral abnormalities can be disturbing and 
difficult to control and survival, averaging 5.4 years after diagnosis, is among the lowest 
of the dementias.
93
 Exceptions are phenocopy cases: of unknown ethiology, these cases 
present behavioral features compatible with bvFTD without imaging abnormalities or 
functional decline.
93
 Conversely, motor neuron disease (MND) can be part of the clinical 
picture and survival of those patients is dramatically reduced.
94
 
Another form of presentation of FTLD is primary progressive aphasia in which 
speech is predominantly affected. Primary progressive aphasia can have other causes, 
among them AD, but both the non-fluent and semantic variants present FTLD pathology 








Table 10. International consensus criteria for behavioural variant frontotemporal dementia* 
I. Neurodegenerative disease  
The following symptom must be present to meet criteria for bvFTD: 
A. Shows progressive deterioration of behaviour and/or cognition by observation or history 
(…). 
II.  Possible bvFTD  
Three of the following behavioural/cognitive symptoms (A–F) must be present to meet 
criteria. Ascertainment requires that symptoms be persistent or recurrent, rather than single or 
rare events. The initial and most prominent cognitive deficits are evident on history and 
examination in one of the following categories. 
A. Early behavioural disinhibition [one of the following symptoms (A.1–A.3) must be 
present]: 
A.1  Socially inappropriate behaviour 
A.2  Loss of manners or decorum 
A.3  Impulsive, rash or careless actions 
B. Early apathy or inertia [one of the following symptoms (B.1–B.2) must be present]: 
B.1  Apathy 
B.2  Inertia 
C. Early loss of sympathy or empathy [one of the following symptoms (C.1–C.2) must be 
present]: 
C.1  Diminished response to other people’s needs and feelings 
C.2  Diminished social interest, interrelatedness or personal warmth 
D. Early perseverative, stereotyped or compulsive/ritualistic behaviour [one of the following 
symptoms (D.1–D.3) must be present]: 
D.1  Simple repetitive movements 
D.2  Complex, compulsive or ritualistic behaviours 







E. Hyperorality and dietary changes [one of the following symptoms (E.1–E.3) must be 
present]: 
E.1  Altered food preferences 
E.2  Binge eating, increased consumption of alcohol or cigarettes 
E.3  Oral exploration or consumption of inedible objects 
F. Neuropsychological profile: executive/generation deficits with relative sparing of memory 
and visuospatial functions [all of the following symptoms (F.1–F.3) must be present]: 
F.1  Deficits in executive tasks 
F.2  Relative sparing of episodic memory 
F.3  Relative sparing of visuospatial skills 
III. Probable bvFTD 
A. Meets criteria for possible bvFTD 
B. Exhibits significant functional decline (…) 
C. Imaging results consistent with bvFTD [one of the following (C.1–C.2) must be present]: 
C.1  Frontal and/or anterior temporal atrophy on MRI or CT 
C.2  Frontal and/or anterior temporal hypoperfusion or hypometabolism on PET or SPECT 
 
 
bvFTD: behavioral variant FTD. CT: Computer tomography. MRI: Magnetic resonance imaging. PET: 
positron emission tomography. SPECT: Single-photon emission computed tomography. 
*Reproduced with permission from Oxford University Press. Rascovsky K et al. Sensitivity of revised 





1.7 BODY MASS INDEX 
A number of measures of body weight and adiposity have been proposed as 
markers of nutritional status and cardiovascular risk.
95, 96
 The standardized height-weight 
tables published by the Medico-Actuarial Mortality Investigations (a life-insurance 




Galileo Galilei is credited
97
 with being the first to describe the square-cube law, 
which states that when a shape is scaled up in size, its volumetric increase is 
proportionally greater than the increase of its surface. In fact, volume increases 
proportionally to the cube of the multiplier, while area is proportional to the square of the 
multiplier.
98
 This has important implications in all areas of science, and explains why 
larger animals have thicker bones than would be expected from the scaled-up structures 
of their smaller counterparts.
99
 Hence, if the body shape is assumed to remain constant 
regardless of height, then weight (W) would be proportional to the third power of height 
(H) as is represented by Rohrer’s index (W/H3).96 Fulton’s condition factor, based on 
weight divided by the third power of length (100 x W/L
3





 as a measure of “fatness” or “well-being” in fish.97 Livi’s indice ponderale 
(ponderal index) captured the idea by employing the cube root of body weight divided by 
height, and was widely employed in pediatric populations.
96
 Cubic height-weight ratios 
are particularly suitable for organisms that display isometric scaling, in which proportions 
remain the same with changes in size. This is applicable to fish and some reptiles. 
However, mammals typically display allometric scaling, with changing proportions 




Quételet recognized these difficulties in 1842.
102
 He observed that, except for the 
first year after birth, where the square-cube law is still somewhat observed, weight 
increase was slower than predicted in children. Thus, a scaling power of 3 would 




adults. However, his final formula employed W/H
2
 and has become the most widespread 





(BMI) index massBody   
In 1972, Keys et al
96
 contended that this quadratic measure correlated best with 
skinfold and body density measurements and proposed the term body mass index (BMI). 
According to these authors, BMI had the advantage of being the least correlated with 
height, with less than 1% of the variance in their analyses accounted for by regression of 
BMI and height.
96
 Since then, BMI has become the  go-to height-weight ratio, used for 




 It is easy to 
obtain and easily reproducible,
95
 and its relationship to morbidity, particularly 
cardiovascular, has been acknowledged in medical literature since the 70s.
104, 105 
The 
World Health Organization uses BMI to classify underweight, normal weight and obesity 





Table 11. World Health Organization classification of BMI (kg/m
2
) 
Underweight Under 18.5 





Obese   
 Obese class I 30-32.5 
 Obese class II 35-39.9 
 Obese class III 40 and above 
 
 
BMI: body mass index. 
WHO classification of BMI with additional cut points. Adapted with permission from WHO, BMI 







BMI is a tool for gauging body shape, but says nothing about body composition. It 
is particularly inaccurate in athletes, who have a high lean mass, and is gender, age and 
race specific.
 106, 107
 Adiposity, particularly visceral fat, is thought to be the main driver of 
the excess cardiovascular risk found in obese individuals.
108
 Since BMI doesn’t 
distinguish between fat tissue and lean muscle mass, it could be a poor marker of the kind 
of weight excess that causes cardiovascular risk. Furthermore, fat distribution is critical. 
In 1947 Jean Vague first proposed that excess upper body fat (typical of men) carried a 
higher risk of cardiovascular complications than fat carried in the gluteal-femoral areas 
(typical of women).
109
 This finding has since been abundantly confirmed. Despite having 
higher overall percentage of body fat,
110
 only 10% of women’s fat is visceral, whereas 
this reaches 20-25% for men.
108
 Steroid hormones modulate the accumulation of visceral 
fat, which increases after menopause in women until their cardiovascular risk rises to 
match that of men. Age, stress, ethnicity, physical exercise, diet and genetic factors 
influence the accumulation of visceral fat,
108
 which has been linked to incident coronary 
heart disease, myocardial infarction and type 2 diabetes,
102,104,108, 110
 and malignancies 
such as prostate, breast and colorectal cancers.
110
 Visceral fat is thought to be a 
cornerstone in the metabolic syndrome. Characterized by an array of cardiovascular risk 
factors comprising abdominal obesity, hypertension, dyslipidemia, pro-inflammation, 
prothrombosis and insulin resistance, metabolic syndrome is associated with a 
significantly increased risk of cardiovascular disease.
111
 Current evidence suggests that 
visceral fat, more than any other marker, correlates with the presence of metabolic 
syndrome and C-reactive protein.
108
 Visceral fat tissue is hormonally active and inversely 
correlates with circulating adiponecting, a protective antiangiogenic factor.
110
 Lipolysis 
also triggers the release of free fatty acids, which reach the liver and participate in non-
alcoholic fatty liver disease. These fatty livers release very-low-density lipoproteins 
(VLDL), which carry fat to be accumulated in other organs. 
The most precise techniques for measuring body fat are often also the most 
invasive and least practical. In 1972 Keys described measuring body density by 
“weighing the subject completely under water, correcting for the air in the lungs and 
respiratory passages(...)” with a mouthpiece valve that provided 100% oxygen for 






These cantankerous methods have been surpassed by CT and MRI volume 
measurements, the current gold standards for measuring body fat.
110
 However, these 
methods are still expensive and time-intensive, and have little place outside of research 
study protocols. Dual-energy X-ray absorptiometry (DXA) might be an alternative, with a 
margin of error, when compared to MRI, under 3% for all fat modalities.
112
 Echographic 
and impedance measures of body fat are somewhat simpler, but also less accurate. For 
reasons of accessibility and convenience, biometric measures remain the most extensively 
used in clinical practice. Table 12 shows the advantages and disadvantages of different 









Table 12. Advantages and disadvantages of different methods of measuring adiposity 
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DXA intermediate moderate gold standard (-)
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Other Pletismography very low high gold standard 
   
 
 





Several measures and indexes have been proposed to capture body composition 
and fat distribution.
108
 Measuring waist circumference is perhaps the simplest; measures 
over 90 cm in men
114, 119
  and 80 cm in women
114, 119, 120
 are associated with excess risk, 
but this depends on the ethnicity of the population studied. Nonetheless, waist 
circumference does not distinguish between visceral and subcutaneous fat. Although 
abdominal fat is part of the metabolic syndrome, studies now suggest that, contrary to 
visceral fat, subcutaneous fat might be beneficial, absorbing energy surplus and 
somewhat compensating for the excess risk from visceral fat.
108
 Assuming that 
subcutaneous fat accumulation is generalized, one possible solution would be to obtain a 
hip circumference measurement and calculate a waist-hip ratio (WHR), thus accounting 
for subcutaneous fat.
110, 121
  This assumes that subcutaneous fat is distributed 
homogeneously between the two regions and that it has the same metabolic properties. A 
correlation has been described between the WHR and the ratio of visceral to 
subcutaneous fat as measured cross-sectionally in CT.
110
 The type of subcutaneous fat 
that accumulates in the glutefemoral area may be especially beneficial and has been 
associated with a favorable adiponektin profile.
121
 In practical terms, waist 
circumference, alone or relative to hip circumference, 
121
 has been proven to be related 
with cardiovascular risk and mortality. 
 Another interesting measure is the body adiposity index (BAI), which is based on 
the division of hip circumference by the 1.5 power of height.
106
 This index was originally 
developed in a Mexican American population in the context of a gestational diabetes 
mellitus study. Adiposity measured by DXA was correlated with a number of biometric 
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The BAI index was then validated on a second African American population. 




and women with the same BMI have very different proportions of fat. This is not a 
problem with BAI, where the relationship between BAI and percentage adiposity is not 
different between genders.
106
 Furthermore, by validating the index in different ethnic 
populations, BAI might avoid some of the problems encountered by BMI in describing 
adiposity across ethnicities. However, the critical question with biometric indexes is how 
they correlate to health. In one study that included several ethnic populations, BAI was 
the index with the worst correlation to lipid profile, blood pressure and glucose, while 
BMI, waist circumference, waist-hip ratio, and simple waist-to-height ratio correlated 
better.
122
  BAI may show a stronger correlation with fat percentage than BMI, but BMI 
might be more precise in older men and in persons with extremely low or high body fat 
percentages.
123
 BMI and waist circumference show a stronger association to 
cardiovascular risk markers than BAI.
124
 Yet another study compared BMI, BAI, waist, 
hip, height, weight, percentage body fat as measured by DXA and cardiovascular traits 
including systolic and diastolic blood pressure, carotid intima-media thickness, fasting 
lipid parameters and metabolic clearance of insulin.
107
 When BMI and BAI were 
compared, BMI better represented lipid profile, fasting glucose, carotid intima thickness, 
adiponectin, metabolic clearance of insulin and diastolic blood pressure. BAI was only 
superior to BMI in predicting percentage of body fat in pooled data: when data was sex 
stratified, BMI proved better.
107
  
This shows that, despite its limitations, BMI has proven to have a robust 
correlation with cardiovascular risk and all-cause mortality.
107, 122, 124, 125
 BMI, abdominal 
circumference and subcutaneous fat area are all closely correlated.
126
 BMI is moderately 
or strongly correlated with a number of cardiovascular traits and body fat percentage.
107
 It 
is difficult to determine which biometric index is best, but BMI has proved better than 
BAI in a number of measures, and could be superior to other indexes as well. In one 
study on sickness leave from work, all measures of obesity predicted paid absence from 
work, with BMI showing the strongest correlation.
127
  
Furthermore, the case can be made that BMIs popularity justifies continued use. 




can be accurately self-reported. Despite caveats on underestimation of weight and 
overestimation of height in self-reported measures, almost everyone is aware of their own 
height and weight – the same cannot be said for waist or hip circumferences. Moreover, 
many patients know their own BMI measures and understand what they represent, which 
makes it a useful tool for patient information and science popularization.  
1.8 EPIDEMIOLOGY OF DEMENTIA 
Estimates on the prevalence of dementia vary between 5 and 7% of the population 
over 60,
128
 with 45% of population over 85 affected by dementia.
129
 The ongoing 
worldwide demographic transformation translates as an increasingly aging population, 
particularly in developing nations.
128
 China, India and Latin America, in particular, could 
soon find themselves with a higher percentage of older people without sufficient 
working-age adults to support them. Prevalence of dementia increases exponentially with 
age, doubling for every 5.5-7 year increment in age.
128
 Thus, the worldwide prevalence of 
dementia was 24.3 million in 2005,
130
 35.6 million in 2010,
128
 and is expected to almost 
double by 2025.
128
 This increase in number of people with dementia will be unevenly 
distributed, varying with underlying regional demographics. Countries with a stable aged 
population, where dementia prevalence is already highest, can expect the lowest increase, 
which will still represent a 40% increase in Europe and 60% in North America. Regions 
which start with low prevalence and are experiencing demographic transformations and 
population growth, such as North Africa and the Middle East, can expect 120 to 150% 
increase in incident cases. In Latin America, different regions will experience different 
evolutions, conforming to the first or second groups. Other regions already start with a 
high prevalence, but growing populations determine a drastic increase in number of 
cases, even if incidence is less affected. This scenario is valid for China, India, the South 
East and Western Pacific with increases of 100-120% of cases. A special case is Sub-
Saharan Africa, where the crippling high mortality from human immunodeficiency virus 
(HIV) infection and infant deaths impede the demographic transition.
128
 Thus, the biggest 
increase in the burden of dementia is expected to occur in low and middle income 






These estimates assume no changes in dementia risk, so studying changes in 
trends in dementia incidence becomes paramount.
131
 Although the increase in global 
prevalence is evident, it is possible that some specific groups and locations may 
experience decreases in incidence. If so, studying these groups could be crucial to 
identifying effective preventive strategies. Studies on secular trends in dementia 
incidence are methodologically difficult because of the long intervening periods, with 
changes in diagnostic criteria
131
 and patient help-seeking behaviors. It is likely that 
diagnosis is progressively occurring earlier in the disease process and being extended to 
patients with other co-morbid conditions. Some studies have shown stable dementia 
prevalence,
132, 133
 while others propose a decline in incidence.
131 
Changes in prevalence 
estimates must be compared to trends in survival after diagnosis: if survival after 
diagnosis is increasing over time, unchanged prevalence estimates translate a decrease in 
the incidence of dementia. A recent study compared two cross-sectional surveys of the 
greater Stockholm area carried out 20 years apart with the same diagnostic criteria.
131
 
Compared to the population studied in the 80s, the more recent population proved to be 
older, with more years of formal education and a lower percentage of women. The 
persons with dementia from the recent cohort also had higher MMSE scores. Age- and 
sex-standardized prevalence for dementia was not different between the two cohorts. 
After controlling for year of birth, the more recent cohort presented with a lower OR of 
dementia diagnosis, and this reduced risk was particularly apparent among men. Both 
cohorts included follow-up: the 2001 cohort had lower mortality for all participants and 
for those diagnosed with dementia. This implies that the incidence of dementia in this 
region is decreasing.
131  
Another two-wave study was conducted in Zaragoza, Spain, and showed stable 
dementia prevalence between different cohorts examined in the 90’s and 00’s.134 The age-
adjusted prevalence of dementia among men had decreased in the more recent cohort, 
while the general population mortality in the area had gone down over time. If this were 
also true for patients with dementia, it would hint at decreased dementia incidence 
between the two cohorts.
134
 The first cohort was examined in 1994, with follow-ups in 
1997 and 1999, allowing for direct incidence calculations: according to this study, overall 




incidence increased with age, and continued to rise after age 90. Life-time risk was 
around 20%, with a trend towards increased risk with age that was only significant in 
men. In comparison, the Framingham study reported similar incidences, which were 
doubled in the Rotterdam study.
135
 Until the incidence from the second cohort is 
analyzed, the Zaragoza study can only offer indirect prevalence-based measures of 
changes in incidence. 
Secular improvements in management of cardiovascular risk factors could justify 
this possible decrease in dementia incidence. The fact that both the studies in Stockholm 
and Zaragoza find reduced risk among men is revealing.
131, 134
 Initial efforts to counter 
cardiovascular diseases in the 70s and 80s focused on men, who then bore the brunt of 
cardiovascular conditions.
136
 It is possible that cardiovascular risk factors have been 
under-diagnosed and undertreated among women for a significant proportion of the last 
three decades.
136
 More recently, increased focus on women’s cardiovascular health might 
have reversed this trend. If so, we can expect a further reduction in dementia risk in the 
future, also among women. 
Recently, an inverse correlation between risk of neoplasm and dementia has been 
described.
137
 Even relatively benign conditions such as nonmelanoma skin cancer are 
associated with decreased risk of dementia.
138
 Cancer and dementia are both associated 
with old age, and might represent different pathological mechanisms in the way bodies 
combat aging.  
Sex has a crucial effect in the prevalence of dementia. Men display 19-29% lower 
prevalence, and this gender gap increases with age, indicating an interaction between age 
and gender.
128
 All these factors need to be considered when planning resources for 





1.9 PUBLIC HEALTH PLANNING AND ECONOMICS 
The global increase in dementia prevalence places a burden on health care 
workers, families, policy-makers and societies to improve care and support for affected 
individuals. Access and quality of care is extremely uneven even within industrialized 
nations. Access to neurological care can be influenced by availability of services, public 
perception, costs, and health care policies. For example, Medicare reimbursement 
policies in the US could be to blame for low prevalence of neurological care for 
neurodegenerative conditions.
139
 In Europe, the estimated cost of dementia reached a total 
of just over 105 billion euros in 2010, constituting a major economic health challenge in 
all countries.
140
 On average, the per-patient direct health costs rose to 2 673 €, while 
indirect costs were 13 911 € or over 80% of the total expense. The per capita cost of all 
brain disorders in Spain was 1 592 €, while it was 1 882 € in Sweden.140 In dementia, 
direct non-medical costs are responsible for more than 80% of the total expenditure.
140
 
WHO data indicates that the total cost of dementia as a proportion of country gross 




1.10 MORTALITY IN DEMENTIA 
Dementia is widely recognized as a cause of reduced life-expectancy, although the 
effects of factors that contribute to this excess mortality remain under contention.
142-152
 
Age, sex, baseline cognition, residential setting, comorbidity and dementia diagnosis 
have all been identified as possible confounders or contributors to death. 
1.10.1 Age and mortality 
Higher age increases mortality after a dementia diagnoses,
143, 150, 153-155
 although 
younger subjects loose more years of life to the disease.
142
 When compared to same-age 
controls, patients with early-onset dementia presented a hazard ratio (HR) of mortality of 
43, while the HR for the older cohort was 3.4.
156 




old: as mortality rates for the non-demented population raise exponentially, the relative 
excess hazard due to dementia decreases.
148, 157, 158
 Despite this, most studies still find 




Dementia diagnosis differs between the young-onset and late-onset groups, so this 
must be taken into account when attributing death risk to age.
156
 FTD, which typically 
has earlier onset, presents with higher mortality than other dementia types,
146, 156
 
particularly when it is associated with MND.
159
 Also, comorbidites such as diabetes could 
be associated to earlier onset of dementia and are also independently responsible for 
mortality.
160
 This effect could be particularly important in younger patients, becoming 
relatively attenuated with age.
160
  
1.10.2 Sex and mortality 
Most studies have reported lower mortality rates in dementia in women than in 
men.
143, 146, 150, 152-154, 157, 161-164
 There are exceptions to this trend,
155, 165
 with some studies 
finding different effects of sex depending on dementia type
142, 158, 166, 167





 faring worse. Because of higher dementia prevalence and 
lower baseline mortality, women suffer a higher proportion of deaths due to dementia.
124, 
132-134 
As discussed above with younger patients, since women have lower baseline 
mortality risks, their mortality hazard when compared to sex matched controls is greater 




1.10.3 Cognitive performance and mortality 
The effect of baseline cognition on mortality is unclear, with some studies finding 
increased mortality with advanced but not initial cognitive impairment,
157
 others finding 
increased mortality even with mild dementia,
169, 170




difference relative to initial impairment
154




1.10.4 Neuropathology and mortality 
The association of several different pathologies upon autopsy is correlated with 
decreased survival.
151
 AD pathology in patients diagnosed with LBD or PDD decreases 
survival,
171




The location and extension of the pathology is also important. In FTD, abundant 
pathology of any sort in the basal ganglia and anterior cingulate was correlated with 
shorter survival, as did tau-positive pathology,
173
 while others have found tau-negative 
pathology associated with shorter survival.
174
 These discrepancies may be due to the 
composition of cohorts, where a large proportion of patients with tau-negative FTD with 
MND or tau-positive with Pick disease or corticobasal degeneration might skew results in 
one direction or the other.
173
 In one study, patients with 4-repeat tauopathies (4R) had 
significantly shorter disease duration that patients with 3-repeat tauopathies (3R) and, 
among the bvFTD, apathy was more common in the 4R group.
175  
1.10.5 Dementia type and mortality 
Most studies either fail to demonstrate a statistically significant difference in 
survival between dementia diagnoses
154, 161, 169, 170, 176
 or report lower mortality risk with 
AD.
142, 146, 150
 Previous research has focused on AD and VaD, where there is abundant 
information on mortality, but direct comparisons between cohorts with a range of 
diagnoses are lacking.
142
 Most have compared AD and VaD, sometimes including mixed 
dementia
150, 161, 166, 169, 177, 178
 In these, AD tends to have the more favorable prognosis
158, 
162
, with mixed dementia sometimes having intermediate risk between AD and VaD, in 
line with its presumed etiology as a combination of those two conditions.
166
 Others 
compare AD with DLB,
148, 165, 167, 179, 180






 with excess risk remaining after controlling for cognitive level.
165
 Studies 
comparing other dementia types are rarer. DLB could be more lethal than PDD,
171
 which 
itself presents higher mortality than PD or controls.
181
 Survival in FTD can range from 3 
to 9.5 years,
73,93, 159, 175
 depending on variant type,
93, 182
   presence of MND,
159
 presence 
and type of tau,
154, 159, 174
 and symptoms at onset,
93




Most previous studies have compared two,
150, 157, 171, 179, 183
 or at most three 
diagnoses.
161, 166, 170
 Two clinic-based studies
146, 156
 and one population-based study 
included more dementia types.
176
 Of these, the population-based study only included AD, 
VaD, DLB and combined dementias and did not find statistically significant differences, 
probably due to the low number of dementia cases, particularly for DLB (n=12).
176
 One 
of the clinic-based studies also did not find significant differences. The other, by 
Steenland et al,
146
 is more illuminating. The study included specialist clinic patients with 
a diagnosis of FTD, MND, AD, PD (with and without dementia), DLB, MCI and 
controls. Highest mortality was found with MND, followed by FTD, DLB, PD, AD and 
MCI, with this last group of patients still exhibiting significant excess mortality relative 
to controls. 
The origin of these disparities might lie in the particular neurodegenerative 
background of each of these conditions, but other factors need to be considered. VaD and 
mixed dementia are etiologically associated with cardiovascular risk factors. 
Cardiovascular mortality has been reported the first cause of death across dementia 
cohorts,
169
 so it stands to reason that these conditions would present with higher 
mortality. Coexisting conditions, such as MND in FTD, would naturally drive up 
mortality. The type of cognitive impairment might play a role, with behavioral problems 
present in FTD and DLB perhaps threatening survival more than mnestic decline. 
Additionally, the management of these behavioral problems might result in additional 
mortality: neuroleptics have been associated with excess mortality, as has 
institutionalization, although in both cases it is difficult to tease apart cause and effect. 




social support than others: AD patients are said to lose their “social graces” later in the 
disease process, making them relatively easier to care for at least in earlier stages. By 
contrast, FTD patients can display disturbing psychological features from onset and can 
behave unpredictably and be intractable to care. Other accompanying symptoms may be 
relevant. Autonomic dysfunction and its severity was associated to reduced survival in 
DLB and PDD,
184
 while hallucinations at disease-onset also appear to worsen 
prognosis.
171
 Language-deficits in bvFTD are associated with worse prognosis.
93
 Whether 
this is due to neurobiological reasons or heightened difficulties in communication and 
care is impossible to know. 
1.10.6 Body-mass index and mortality 
BMI is a useful biometric measure and predicts mortality in a number of 
populations.
95, 185





 and is associated with lower mortality among younger adults – the population 
among which the index was originally developed.
102
 The optimal range for older adults 
and other special populations is less clear. Cut points between 19 and 23 have been 
proposed to guide nutritional screening in older populations,
185-188
 and many studies 
propose that the optimal weight for lowest mortality might lie in the overweight range as 
defined by the WHO (25-29.9 kg/m
2





 This finding of excess weight, traditionally considered detrimental 
to health, as being protective in older adults has been termed the “obesity paradox”192 and 
mirrors findings from studies of other cardiovascular risk factors. Indeed, dislipidemia, 
high blood pressure, high body-fat,
193
 or altered homocysteine, creatinine, and 
parathyroid hormone concentrations have been associated with lower mortality in some 
populations giving rise to the “reverse epidemiology hypothesis”.194 This is a 
phenomenon that is often apparent from epidemiological studies, but it is unclear whether 
it reflects an actual biological effect or whether it is the result of biases and confounding. 
On the one hand, a survival effect needs to be considered: persons presenting 




epidemiological studies. Thus, the persons who are included are statistical oddities, 
reflecting tenacious constitutions or other factors that counter the cardiovascular risk 
factors that they present. Over-adjustment for comorbidity might also be a problem: since 
cardiovascular risk factors directly cause comorbidity, excessively controlling for said 
comorbidity might artificially reduce or eliminate the deleterious effect linked to said 
factors.
195
 Others contend that it is rather the extreme values on the low end of the 
spectrum of certain cardiovascular risk factors that might be associated with higher 
mortality: thus, it is low blood pressure below the normal range that would be associated 
with mortality and would drive the statistical findings. In one study, obese patients were 
younger, with stronger handgrip and better ability to walk, and reported less anorexia and 
feeding problems than patients from other weight categories.
196
 This reinforces the 
importance of adequately exploring the distribution of a sample throughout the widest 
possible range of values in order to detect a U or J shaped distribution. Time 
discrepancies between competitive risk factors could mediate this phenomenon.
197
 In 
cholesterol levels, blood pressure and BMI, the lowest values in the spectrum represent 
immediately life-threatening conditions, and would overwhelm the excess risk found at 
the higher end of the spectrum.
198, 199
 Finally, reverse causation might account for the 
observation, if the underlying cause and not the factor itself, were responsible for excess 
mortality. This could occur, for example, in the case of cardiac pump failure in a patient 
with low or normal blood pressure.
197
  
On the other hand, most studies include different risk groups for a given factor 
and replicate the reverse epidemiology effect. Also interesting are the populations in 
which this effect has been described, which range from older populations,
190, 200, 201
 to 
patients suffering from renal failure,
198, 202












malignancies and acquired immunodeficiency síndrome (AIDS).
203
 Although outwardly 
different, these groups share some common characteristics. First, they all present with 
shortened life-expectancies, in which the effects of traditional cardiovascular risk factors 
might not have time to materialize.
203, 206
 Second, most represent catabolic states
193
 where 
malnutrition is a frequent problem and directly linked to mortality: if the risk associated 




risk factors, patients with higher blood pressure, cholesterol and BMI would have better 
nutritional reserve and better survival, even at the expense of increased cardiovascular 
risk. However, cardiovascular mortality remains among the first causes of death in these 
populations.
169
 This may be accounted for by a third factor: inflammation. Frequently 
linked to malnutrition, inflammation is part of the malnutrition-inflammation complex 
syndrome (MICS)  described among terminal renal failure patients
198
 but could also be 
applicable to other populations, such as patients with heart failure.
197
 Chronic 
inflammation leads to decline in appetite, muscle and fat wasting, hypercatabolism, 
endothelial damage, reduced high-density lipoproteins (HDL) and increase in oxidized 
low-density lipoproteins (LDL), and atherosclerosis.195, 198 Together, these mechanisms 
explain the two main causes of death among these special populations: infectious and 
cardiovascular. Indeed, MICS has been blamed for the excess cardiovascular disease 
found among renal failure patients and much attention is being devoted to chronic 
inflammation as a cause for cardiovascular disease.
207
 The interest in periodontal disease 
and C-reactive protein,
207
 as linked to cardiovascular disease
198
 is testimony to this. 
Indeed, in a study examining the association between cholesterol level and mortality in 
dialysis patients, a reverse epidemiology phenomenon was observed only in those in 
which MISC was evident, while the normal epidemiological observation of higher 
cholesterol linked to higher mortality appeared in patients who did not have MICS.
208
  
A given factor could have competing effects: high creatinine is a marker of 
reduced renal function, but also of high muscle mass and meat intake. In patients on 
dialysis, glomerular filtration is already so low that fluctuations in creatinine can be 
accounted for by the other two factors, making it a better marker of good nutritional 
status than of renal function.
194
  
Although the impact of cardiovascular risk factors has been less studied in 
dementia, the characteristics of this syndrome make it a prime candidate for reverse 
epidemiology.
199
 Dementia presents shortened life expectancy where malnutrition is a 








Reverse epidemiology observations are in stark contrast with a large body of 
studies supporting the treatment of cardiovascular diseases even in the populations in 
which this effect is typically described. In a study on treatment of hypercholesterolemia 
with statins among diabetic patients on dialysis, no effect was found on cardiovascular 
death, but there was a reduction in cardiac events.
195
 
This may be a paradox, but only superficially. Part of the confusion may stem 
from the term “reverse epidemiology”, which seems to imply that there is something 
abnormal about these observations. As Port put it in a recent article criticizing the term: 
“Epidemiology is not reversed. There is nothing wrong with epidemiology. It is the true 
epidemiology of observational studies that led to clinically relevant findings that are 
specific to dialysis patients”.195 The term “phenomenon of altered risk factor patterns” or 
“risk factor reversal”194 has been proposed instead. Both proponents and detractors of 
reverse epidemiology agree in substance: the conclusions should not be that high blood 
pressure, high cholesterol or high adiposity are beneficial
195 
and neither should the 
treatment of cardiovascular risk factors be abandoned, although new goals might need to 
be developed in these groups.
195
 Rather, cardiovascular risk factors remain risk factors 
but identify patient subgroups which are more exposed to other, more deadly, risk factors. 
Hence, the course of action is not to stop treating obesity in all populations, but to 
identify the factors, such as malnutrition and inflammation, responsible for the higher 




1.11 SVEDEM: THE SWEDISH DEMENTIA REGISTRY  
SveDem, the Swedish Dementia Registry, www.svedem.se, was created in 2007 
following an initiative of the Swedish Brain Power network of researchers and is funded 
through the Swedish Association of Local Authorities and Regions (Sveriges Kommuner 
och Landsting) and the Swedish Brain Power.
212-216
  Its aim is to evaluate and improve 
quality and equality of care for patients with dementia throughout Sweden.
217
 Newly 
diagnosed patients with dementia are included in the web-based registry, which provides 
a framework for recording aspects of diagnostic workup,
214, 215, 218
 treatment and care.
213
 
The registry is active throughout the country.
219
 Both specialized memory clinics and 
primary care centers contribute patients to SveDem although coverage varies greatly 
between these two types of units. During 2011, the percentage of patients evaluated at 





 and 95% 2013
219
. Although the number of primary care centers 
connected to the registry rose by 45% in 2011, SveDem coverage for patients diagnosed 
in these types of units remains much lower than for specialist clinics: it was 67% of all 
primary care centers in 2012.
212
 Population-based calculations from the Swedish Board of 
health and welfare (Socialstyrelsen)  estimate around 24,000 new dementia cases in 
Sweden per year,
220
 which would imply that SveDem, with 4 941 new entries during 
2011, has a coverage of 25% of all new dementia diagnoses made nationwide. The 
coverage in 2013 with approx 8 000 entries is 35%. This gap between expected incidence 
and registration can be attributed to several factors. First, expected incidence is a 
calculation, and may be higher or lower than reality. Second, a number of incident cases 
may be missed due to late diagnosis or absence of diagnosis. According to the WHO, late 
and absent diagnosis is a world-wide problem,
221
 and there is no reason to believe 
Sweden should be an exception. Third, the uneven coverage in primary centers may be 
responsible for a substantial percentage of missing patients; enhancing coverage in all 
types of units is one of the developmental priorities of SveDem.
220
 
Patients are included in SveDem at the time of incident dementia diagnosis using 
ICD-10 criteria and are followed annually.
213




with AD, VaD, mixed AD and VaD (mixed), DLB, PDD, FTD, unspecified dementia 
(where specific dementia diagnosis is not ascertained) and other dementia types 
(grouping miscellaneous dementia disorders such as corticobasal degeneration, 
Creutzfeldt-Jakob or alcohol related dementias).
213 





 are employed for LBD, the Manchester-Lund criteria for FTD
12
 and 
Movement Disorder Society Task Force criteria for PDD.
10
 Variables recorded at the time 
of registration include age, gender, baseline MMSE, co-residency status (co-residing vs. 
living alone), residential setting, work status, driving status, weapon licence and permits, 
and biometric data (height and weight). The number of medication that the patient takes 
regularly at the beginning of diagnostic workup comprises all medications that the patient 
takes that appear in the official Swedish Drug Index
222
 and is included as a variable. This 
variable is used as a proxy for comorbidity,
213,223
 since it has been shown to be better than 
other medication-based comorbidity scores at predicting morbimortality.
223
 The presence 
of cardiovascular medication, antidepressants, antianxiety medication, neuroleptics and 
sleeping aids is recorded. Cholinesterase inhibitors and N-methyl-D-aspartate (NMDA) 
antagonists at baseline and again upon diagnosis are entered.  
After diagnosis, additional variables are included such as number of medication 
after the diagnostic process, introduction of cholinesterase inhibitors and NMDA 
medication and treatment with vascular medication, antidepressants, neuroleptics, 
sleeping aids and antianxiety medication after diagnosis.
224
 Social interventions such as 
negotiation for termination of driving with the patient and their family, removal of 
driving or weapon licenses, or referrals for social support or legal guardianship are 
noted.
213, 215, 217
 Annual follow-up includes a revision in any changes in any of the 
abovementioned variables. The proportion of patients whose diagnoses change in these 
follow-up visits is low, around 5% for the whole register.
217
 The highest percentage of 
changing diagnoses occurs in the “unspecified” diagnosis (15%) while change in 
diagnosis in the AD group occurs in only 3% of cases. SveDem is collated monthly with 
the national population registry so that deceased patients are withdrawn from the follow-





The regional ethics committee of Stockholm approved the creation and data 
management of SveDem. SveDem studies have been approved by the regional ethics 
commitees of Stockholm. At the time of work-up, patients and caregivers are informed 
orally and in writing about SveDem and can refuse to participate. There are procedures 
for withdrawal requests. Data is anonymized and analyzed off-site. The online database 
and information technology support is carried out by the Uppsala Clinical Trial Center.
213
 
A coordinator routinely selects 10% of medical records from each unit to validate the 
data. Each participating unit has access to descriptive online statistics of their 
registrations and comparisons with data from the region and from all SveDem. 
SveDem aims to integrate seamlessly into the overarching organization of 
Swedish dementia care and become a valuable tool. Clinics can directly obtain data on 
their own statistics and check them against regional and national averages. This allows 
resource planners and practitioners to compare their diagnostic times and the types of 
ancillary testing they perform against others operating in comparable or different 
settings.
225, 226
 In some instances, such statistics have revealed easily-solved problems: in 
one case, one unit realized that their diagnostic times were the longest in the country. 
They solved it by scheduling testing and the second visit directly after the first interview, 
which put their diagnostic delay on par with other units. SveDem operates within the 
highly decentralized Swedish healthcare system: elderly care and finance in each area is 




In 2010, the Swedish National Board of Health and Welfare introduced a 
framework for the management and care of persons with dementia.
228
 National indicators 
were developed for evaluation of dementia care. Seven of these indicators can be 
evaluated using SveDem. One such indicator is the proportion of patients with a basic 
diagnostic work-up as a base for the dementia diagnose. A basic diagnostic work-up is 
defined and recommended to all patients suspected of dementia. This work-up includes a 
structured clinical interview, an interview with a knowledgeable person close to the 




testing with, at minimum, MMSE and clock test, cerebral imaging and blood analyses 
including calcium, homocystein and thyroid function. SveDem´s own goal is that >90 % 
of patients diagnosed with dementia whoud have a basic dementia work-up performed.
212, 
217
 This work-up can be expanded, if necessary, depending on available testing at the 
discretion of the specialist.
228
 The guidelines further stress the importance of early 
diagnosis and attention to social aspects of the disease.  
Furthermore, primary care plays an important role in dementia care in Sweden. 
Primary care physicians diagnose a large number of cases, are capable of prescribing 
medication for dementia and independent of specialists in many cases. In certain 
instances, such as when a patient is under 65 or the diagnosis is difficult, patients can be 
referred from primary to specialist care. Conformity with these national guidelines is an 
important quality marker which SveDem is in a unique position to assess.
229
 A recent 
study on AD patients within SveDem showed that 85% of patients diagnosed in specialist 
care and 61% of those diagnosed in primary care complete this basic diagnostic work-
up.
227
 Clock-test and CT were the required examinations less-often performed in primary 
care. Table 13 shows the percentages of each diagnostic test in specialist and primary 
care.  
SveDem is a phenomenal research tool and cross-linkage possibilities with other 















Full basic examination, no. (%) 2333 (85.1%) 659 (60.7%) <0.001† 
No. of basic tests, mean (SD) 3.83 (0.43) 3.48 (0.74) <0.001‡ 
MMSE, no. (%) 2731 (96.4%) 1141 (94.9%) <0.001† 
CT, no. (%) 2593 (92.8%) 934 (80.6%) <0.001† 
MRI, no. (%) 444 (16%) 27 (2.4%) <0.001† 
Brain imaging (CT or MRI) no. (%) 2705 (97.8%) 902 (81.1%) <0.001† 
LP, no. (%) 1488 (53.3%) 50 (4.4%) <0.001† 
Isotope examination, no. (%) 322 (11.6%) 13 (1.1%) <0.001† 
EEG, no. (%) 367 (13.2%) 6 (0.5%) <0.001† 
Assessment by occupational therapist, no. 
(%)  
1160 (41.5%) 301 (26.5%) <0.001† 
Assessment by physiotherapist, no. (%) 133 (4.8%) 115 (10.2%) <0.001† 
Assessment by speech therapist, no. (%) 93 (3.3%) 102 (9%) <0.001† 
Neuropsychological test, no. (%)  796 (28.5%) 36 (3.2%) <0.001† 
Total no. of tests mean (SD) 5.55 (1.31) 3.9 (1.17) <0.001‡ 
No. of days between initial date and 
diagnosis date mean (SD, median)  88 (139, 58) 133 (239, 62) <0.001‡ 
 
CT: computed tomography. EEG: electroencephalography. LP: lumbar puncture. MMSE: Mini-mental State 
Examination. MRI: magnetic resonance imaging. no. : number of patients. SD: standard deviation.  
*Reproduced with permission from Ingrid Nilsson-Modéer Diagnosis and treatment of Alzheimer´s disease 
in specialist units compared to primary care. (Unpublished master´s thesis. Department of Neurobiology, 
Care Sciences and Society, Study program in Medicine. Karolinska University, 2013) p. 15. 
† Pearson’s Chi-square ‡Independent t-sample test. 
Abbreviations: Full basic examination refers to guidelines by the Swedish National Board of Health and 
Welfare (Socialstyrelsen) which include structured clinical interview and physical examination, cognitive 






















2.1 STUDY I 
1. To describe the baseline clinical and paraclinical characteristics of patients 
diagnosed with subjective cognitive impairment (SCI) in a memory clinic, 
and to compare them with those of patients diagnosed with mild cognitive 
impairment (MCI) and Alzheimer’s disease (AD).  
2. To determine which factors contribute to an SCI, MCI or AD diagnosis.  
2.2 STUDY II 
1. To describe the baseline characteristics of a large national cohort of 
incident dementia patients. 
2. To determine the relative mortality risks of different dementia disorders. 
3. To examine mortality risk in relation to age, sex, baseline cognitive 
performance, number of medication, institutionalization and coresidency 
status in patients with dementia. 
2.3 STUDY III 
1. To determine the body mass index (BMI) range corresponding to lowest 
mortality risk in patients with dementia. 
2. To determine whether the BMI associated with lowest mortality is 














3.1 STUDY I 
1. Individuals with subjective cognitive impairment (SCI) differ from those 
with mild cognitive impairment (MCI) or Alzheimer’s disease (AD) in 
baseline characteristics. 
2. SCI subjects are younger and have better cognition and lower frequency of 
cardiovascular risk factors than patients with MCI or AD.  
3. Psychiatric comorbidity is more prevalent among SCI individuals. 
4. SCI individuals have less cerebral atrophy than MCI or AD patients 
5. The prevalence of apolipoprotein E4 (ApoE4) is lower among SCI than 
among AD or MCI patients. 
6. AD cerebrospinal fluid (CSF) biomarker patterns are more infrequent 
within the SCI group. 
3.2 STUDY II 
1. AD type dementia is associated with lower mortality risk than other 
dementia types. 
2. Higher age is associated with increased mortality risk in both genders and 
all dementia disorders. 
3. Male sex is associated with increased mortality risk. 
4. Low cognitive level measured by the Mini Mental State Examination 
(MMSE) is associated with higher mortality risk.  
5. Higher comorbidity, measured as number of habitual medication at the 
time of diagnosis, is associated with higher mortality risk. 
6. Living in an institution is associated with higher mortality risk. 






3.3 STUDY III 
1. In patients with dementia, the distribution of body mass index (BMI) by 
mortality risk follows a U shaped curve with the point of minimum 
mortality occurring in the normal or overweight BMI range. 
2. Excess mortality risk is present in obese individuals (BMI ≥30 kg/m2). 
3. The BMI range associated with lowest mortality risk is different in women 










4.1 STUDY I 
Study I is based on the Karolinska Memory Clinic database. Methods for this 
study are described in depth in the patients and methods section of the article. What 
follows is a quick overview. 
4.1.1 The Karolinska Memory Clinic 
The Karolinska Memory Clinic is part of the Department of Geriatric Medicine at 
Karolinska University Hospital, Huddinge, and evaluates around 450 new patients each 
year referred due to cognitive problems  Diagnostic work-up is made within a clinical 
framework that includes a team of geriatricians, psychiatrists, neurologists, 
neuropsychologists, nurses, occupational therapists, speech therapists and social workers. 
Neuroimaging and CSF markers are often available to supplementary data from routine 
clinical work-up. 
All patients receive a physical examination, cognitive screening, patient interview 
and clinical assessment, with further testing when necessary. An in-depth 
neuropsychological examination is performed, with patients evaluated with MMSE and a 
combination of other tests, including items from Wechsler Adult Intelligence Scale, 
Revised (WAIS-R),
232
 different tests for memory,
233-235
 Trail making tests,
233
 and/or 
Verbal Fluency test (FAS).
236
 Diagnosis conforms to current best practice and is made by 
a multidisciplinary panel, using the diagnostic criteria valid at the time for each entity. 
The present study contains patient data from 2007 through 2009. During this period, the 
diagnosis of SCI conformed to the ICD-10 classification “Z03.3 = observation for 
possible neuro-organic disorder”  (ICD-10)  when patients described memory complaints 
that could not be objectively verified
5
. The MCI diagnosis followed the consensus criteria 
for MCI,
237
 The ICD-10/DSM-IV (Diagnostic Statistic Manual, 4
th 
edition) criteria for 







In study number I, patients diagnosed at the Karolinska Memory Clinic were 
retrospectively identified and included. From 2007 through 2009, 1 154 patients had been 
diagnosed. Diagnoses other than AD, MCI or SCI were excluded. Additionally, patients 
with severe comorbidities that put in question the diagnosis (such as cerebral tumors, 
concurrent epilepsy or metastasis) were also excluded. However, common somatic or 
psychiatric comorbidities, such as depression, anxiety and heart or kidney failure were 
not excluded. In total, 993 patients were included.  
All patients had neuroimaging and 560 had data on blinded medial temporal lobe 
atrophy rating (MTA) following the Sheltens scale
240
. In 943 patients, white matter 
lesions (WML) on axial C or fluid attenuation inversion recovery (FLAIR)-sequence 
MRI were graded following a revised Fazekas scale.
241
 Central atrophy was graded in 
980 patients (for details, please refer to the neuroimaging section in methods of article I). 
CSF was available for 744 patients, and cut-points were set at 400 ng/l or higher 
for total tau (t-tau), 80 ng/l or higher for phosphorylated tau (p-tau) and 450 ng/l and 
under for Aβ 42. ApoE genotyping was available for 325 patients. Neuropsychological 
testing is described in the corresponding section in methods of article I. Briefly, patients 
were assessed with the Mini-Mental State Examination (MMSE) together with other 
tests, selected according to the patient´s clinical picture. Behavioral and psychological 
symptoms associated with dementia (BPSD) were also noted, together with depression, 
evaluated through interview and with the Cornell Scale for Depression in Dementia 
(CSDD)
242
 with 8 as cut-point, where a score of 8 or more indicates depression. 





4.1.2 Statistical methods 
Discrete variable group differences were compared with χ2-tests. When means 
were non-normal, p-values from logistic regression were used. MCI and AD group means 
were compared to those of the SCI group. 
The second part of the article employs a statistical model to analyze the 
similarities between each patient in the database and an “AD type” as defined by the AD 
group. In order to do so, a statistical model was created in three phases. First, a number of 
variables were tested together to find which combination accurately classified the patients 
in our sample into AD/not AD (where “not AD” included MCI and SCI patients). The 
best variables proved to be age, sex, MMSE, Aβ42/t-tau quotient, and p-tau. The logistic 
regression model combining those classified 94.9% of the sample correctly. In the second 
stage, the model was applied to every patient, assigning each individual a probability of 
being more “AD-like” (henceforth refered to as “AD-likelihood”). These probabilities 
were stored as a variable and used as outcomes for the next stage. In this last third stage, 
separate models for MCI and SCI were run, using AD-likelihood as outcome. Then, each 
clinical variable was entered one by one, in order to identify which increased the 
probability of being classified as AD by the model. The statistical methods section of 
article I contains more details. 
4.2 STUDIES II AND III 
A succinct review of the methods of articles II and III follows; for more 
information, the reader is referred to the methods section of the corresponding article. 
4.2.1 The SveDem dementia registry 
Studies II and III employ data from SveDem – the Swedish Dementia Registry –





registered from 2008 through 2011 in specialist memory clinics. Primary care was 
excluded due to later and more irregular inclusion of those units into the registry, 
uncertainty over national coverage levels and differences in diagnostic processes 
compared to specialist care as has been shown in a number of studies based on SveDem 
and as is apparent in table 13.
214
 Study II and III are based on inclusion of 15 224 
patients. In study II patients were excluded if they had incomplete data on dementia 
diagnosis, age, sex and survival: 15 patients (0.1%) were missing this data, leaving 
15 209 patients available for analysis. In study III patients were excluded if they had 
incomplete data on dementia diagnosis, age, sex, survival and BMI: 11 398 remained for 
analyses. 
Variables examined in both these studies include age, sex, dementia diagnosis, 
baseline MMSE, coresidency status (living alone vs cohabiting), residential setting (at 
home, nursing home or a special institution for persons with dementia). Medication was 




), as well as presence 
or absence of cardiovascular medication, antidepressants, antianxiety, neuroleptics and 
sleeping aids was examined. Cholinesterase inhibitors and NMDA antagonists prescribed 
upon diagnosis were entered. BMI was examined as a possible confounder in study II and 
was the main focus variable in study III. 
4.2.2 Study II 
Cox proportional hazards regression models were used to identify factors 
associated with mortality risk. Results are presented as HR of death with 95% confidence 
intervals (CI). The assumption of proportionality of hazards was tested with Kaplan-
Meier survival curves and time-dependent covariates: in instances in which this 
assumption was violated, HRs were calculated at the beginning of the observation period 
and at day 1 000 of follow-up.  Means and and standard deviations (SD) were calculated 





Crude, age- and sex-adjusted, age-, sex- and medication-adjusted models were 
calculated. The fully adjusted model included age (entered as a categorical variable with 
cut-ponts at 65, 75, and 85 years), number of medication (in categories 0-1, 2-5, 6-9 and 
10 or more) and MMSE (missing, not assessable, 0-9 points, 10-19 points, 20 to 24, and 
25 and over). The model also included place of residence classified in patients living at 
home, or in an institution, sex and whether the patient lived alone. Dementia was 
included in the final model in eight categories: AD, mixed, VaD, DLB, FTD, PDD, 
unspecified and other. 
4.2.3 Study III 
Statistical methods were similar to study II and details can be found in the 
methods section of study II, so we will focus here only on the particularities of this study. 
BMI was explored in categories following WHO guidelines: underweight (BMI 
under 18.5 kg/m
2
), normal (18.5 to 24.9 kg/m
2
), overweight (25 to 29.9 kg/m
2
), and obese 
(over 30 kg/m
2
). Since previous studies showed that excess risk could be present also in 
thinner normal-weight older adults
185-187
 an additional WHO cut-point was used (“slim” 
individuals from 18.5 to 22.9). 
Piecewise linear representation variables (splines) were introduced in this article 
in order to best represent the distribution of BMI and mortality. Splines are concatenated 
variables separated by cut-points (or knots) that are chosen by the researcher. In this case, 
linear splines were used, meaning that BMI was a continuous variable, and that the 
relationship between BMI and mortality risk was considered to be linear within each 







At the time of work-up, patients and caregivers are informed orally and/or in 
writing about SveDem, and can refuse participation. Withrawal of consent is available by 
contacting SveDem and requesting removal of the patient´s data. Further information is 
available on the SveDem website at www.svedem.se. Research projects using SveDem 
data need ethical approval. Thus, study II and III were approved by the regional ethics 
commitees of Stockholm (approval number 2009/209-31). Figure 1 shows the abridged 
patient information that is displayed in units that are linked to SveDem. Additional 

















“To you who have been diagnosed with dementia:  This unit is linked to SveDem, the Swedish Dementia 
Registry, which is a national quality registry for dementia diseases. The objective of the registry is to 
support increased quality of care, so that care interventions and patient outcomes are as effective and 
favorable as possible.  
SveDem is directed by a steering commitee and receives state funds through the Swedish association of 
local authorities and regions. The register follows the law on personal data. For you who have been 
diagnosed with dementia this implies that some data from your personal history will be registered in a 
computer. Examples of data which are registered are your personal ID number, residential setting and care, 
testing methods, type of dementia, treatment. In order to obtain knowledge on long-term treatment results, 
register data can be used for research, but only after customary approval of ethical committees.  
The data in the registry is treated like your personal history, and is guarded with the same secrecy. You also 
have the right to obtain, once a year and free of cost, the data about you that is available in the registry, 
and to correct any eventual errors. This you can do by applying to the Personal Data Office in your region. 
If you do not wish to take part in the registry, you can rescind your participation at any time. If you have 




















5.1 STUDY I  
Detailed results on study I are shown in the article. A brief summary with the most 
relevant findings follows below.  
5.1.1 Descriptive statistics 
The number of included patients was 433 with SCI, 373 with mild cognitive 
impairment (MCI) and 187 with Alzheimer’s disease (AD). Descriptive statistics are 
shown in tables 1-4 of the first article. Demographic differences were evident: SCI 
patients were younger, with more years of education, better cognition (as evidenced by 
the MMSE) more likely to be female and have a family history of dementia, and less 
likely to have cardiovascular risk factors than the other groups. The mean MTA rating in 
the SCI sample was 0.98 on the right side and 1.00 on the left, significantly less than in 
the MCI or AD groups and within normal parameters. Likewise, dementia biomarkers in 
CSF was more likely to be normal in the SCI group and the percentage of patients with 
ApoE ε4 allele was lower than in the AD group. The average Cornell Scale for 
Depression in Dementia (CSDD) score for the SCI group was 7.8 (SD 5.8), near the cut-
point of 8 which was established for depression. This average was higher than in the AD 
group (table 2 of article I). 
5.1.2 Statistical prediction model 
These models calculated the predicted likelihood for the SCI and MCI patients of 
being “AD-like”. Beta-coefficients represent the percentage of difference in this 
likelihood between the two categories in dichotomous variables, while they represent the 
percentage difference per unit in continuous variables.  
Table 5 of article I shows the results from this model. Arterial hypertension was 
associated with a 7% increase in AD-likelihood in SCI patients, while results were non-





the MCI group by 26%. Mean MTA increased the AD-likelihood in the SCI group but 
decreased it among MCIs. WML were associated with reduced AD-likelihood in MCI, 
but increased in SCI. In conclusion, direct or indirect markers of cardiovascular risk 
tended to be associated with increased AD-likelihood in the SCI group and reduced AD-
likelihood in MCI. 
5.2 STUDY II 
Of 15209 patients with dementia registered in SveDem, 59 % were women. The 
average age was 78.1 years (SD 8.2) and the mean MMSE was 21.3 (SD 5.1). Few 
patients had advanced dementia as measured by MMSE (see table 1 of article II). 
Table 2 of article II shows baseline differences between dementia diagnoses. 
Thirty-seven percent of the sample were diagnosed as AD, and twenty-five percent as 
mixed dementia. The mean age of diagnosis was 77 (SD 8.3) for AD, but was lower in 
DLB and FTD and higher in VaD.  
Follow-up ranged from 0 to 1 869 days (average 2.5 years), with 37 619 PY at risk 
and 4 287 deaths (114 deaths/1 000 PY; 95% confidence interval, CI 111-117). Table 1 of 
the article shows mortality rates according to different baseline characteristics.  
Sex- and age-adjusted mortality comparisons between our cohort and the general 
Swedish population are shown in table 3 of the article. The standardized mortality ratio 
(SMR) for the cohort was 1.49 (95% CI 1.41-1.58).  The increased mortality was higher 
for younger patients (SMR 12.46; 95% CI 2.58-36.43 in persons between 45 and 54), and 
for women (SMR 1.84; 95% 1.80-1.98). 
HR for death from Cox hazard regressions are shown in table 4 of article II. Time-
dependent covariates were included for DLB, unspecified dementia and other dementias 
because they presented with non-proportional hazards (table 5; article II). In crude and 





II). There was no interaction between MMSE and sex, or sex and dementia type. This 
difference remained when stratifying by dementia disorder, although results were not 
significant in FTD or LBD (article II). 
Before adjusting, each year of age was associated with a risk increase of death of 
8%. In adjusted analyses, risk increased with each subsequent age category, was three 
times higher in 74-84 year group compared to patients under 65 and became six times 
higher in the group over 85 (table 4; article II). 
Using MMSE score 25 and over as reference group, patients scoring lower 
presented increased risk of death. Patients deemed “not assessable” by MMSE presented 
the highest risk (HR 3.72, 95% CI 3.19-4.35). 
Living in an institution and taking more medications were associated with higher 
risk (table 4; article II). There was no difference between living alone vs having a 
coresident. 
As can be observed in Kaplan-Meier survival curves included below (figure 2) 
AD had higher survival rates than other dementias. In non-adjusted Cox regression 
analyses, the highest HR for mortality appeared for VaD, when comparing to AD which 
was the reference category (see results section in article II). After adjusting for age and 
sex, Parkinson’s disease dementia (PDD) was the dementia type with highest risk. When 
medication was introduced into the model, FTD became the dementia type with highest 









Figure 2. Unadjusted Kaplan-Meier curves for the different dementia diagnoses. Y-axis: estimated survival 
percentages. X-axis: number of days. When not adjusting for age, patients with Vascular dementia (VaD) 
has the highest mortality risk.  Age-adjusted mortality risk was highest for frontotemporal dementia (FTD). 
AD: Alzheimers dementia. Mixed: mixed Alzheimer’s and vascular dementia. LBD: Lewy body dementia. 






In the final adjusted analysis, all other dementia types were significantly 
associated with higher mortality risk compared to AD (table 5; article II). FTD 
demonstrated the highest risk (HR 1.91; 95% CI 1.52-2.39). Mixed dementia presented 
intermediate risk between AD and VaD. Non-proportional hazards were present in DLB, 
unspecified dementia and other dementia, meaning that death risk diverged from AD over 
time. However, the average risk over the whole observation period for DLB was higher 
than for AD and increased over time (table 5; article II). 
Post-hoc analyses were rerun including primary care and the years 2007-2012 
which made 28 704 patients available for analyses. As can be seen in table 14 (shown 






Table 14. Comparisons of results from survival analyses between the whole cohort and only 
specialist clinic patients* 
  
All patients 2007-2012  
N= 28704 
Specialist clinics 2008-2011 
N=15209 
  
HR p HR p 





Men 1.56 <0.000 1.56 <0.000 
Age 







65-74 1.80 <0.000 1.96 <0.000 
 
75-84 2.96 <0.000 3.32 <0.000 
 
≥85 5.38 <0.000 6.17 <0.000 





20-24 1.47 <0.000 1.45 <0.000 
 
10 to 19 2.21 <0.000 2.14 <0.000 
 
0 to 9 3.11 <0.000 2.91 <0.000 
 
Not assessable 3.47 <0.000 3.72 <0.000 





Yes 1.07 0.027 1.02 0.485 





Institution 1.54 <0.000 1.42 <0.000 
      Num. 





2 to 5 1.20 <0.000 1.25 <0.000 
 
6 to 9 1.36 <0.000 1.53 <0.000 
 
≥10 2.19 <0.000 2.14 <0.000 








Dementia type AD ref ref 
 
Mixed 1.44 <0.000 1.33 <0.000 
 
VaD 1.52 <0.000 1.56 <0.000 
 
PDD 1.70 <0.000 1.47 <0.000 
 
FTD 2.12 <0.000 1.91 <0.000 
 
DLB average  1.76 <0.000 1.75 <0.000 
 
DLB at 
beginning 1.31 0.079 1.23 0.211 
 
DLB at day 
1000 2.02 <0.000 1.89 <0.000 
 
Unspecified 
average  1.02 0.598 1.42 <0.000 
 
Unspecified at 
beginning 1.21 0.002 1.75 <0.000 
 
Unspecified at 
day 1000 0.929 0.137 1.28 <0.000 
 
Other average 1.22 0.028 
  
 
Other beginning 1.56 <0.000 1.92 <0.000 
 
Other at day 
1000 1.07 0.525 1.13 0.403 
      
 
 
* Results are given as hazard ratios (HR), and p-values for parameter estimates (Cox regression) adjusted 
for all baseline factors as they appear on the table, as well as by dementia diagnosis. First category of each 
variable serves as reference (ref). 
AD: Alzheimer’s dementia. DLB: dementia with Lewy bodies. FTD: frontotemporal dementia. Mixed: 
mixed Alzheimer’s and vascular dementia. MMSE: Mini-mental state examination. Other: other dementia 
diagnoses. PDD: Parkinson’s disease with dementia. Unspecified: unspecified dementia. VaD: vascular 
dementia. 
For DLB, unspecified and other dementias the average HR over the whole observation period is given 






5.3 STUDY III 
Detailed results may be found in the corresponding section of article III. Total 
included patients numbered 11 398, with mean BMI of 24.5 (SD 4.3). Table 2 of article 
III shows mortality rates per PY in different BMI groups. The lowest weight group 
presented with the highest mortality rates. 
In Cox survival analyses, higher BMI was associated with lower mortality risk. 
The reference category employed was the 18.5 to 22.9 BMI group. Compared to these 
individuals, those with BMI under 18.5 presented significantly higher mortality, while all 
weight categories with BMI above 22.9 had lower risk. The lowest HR of death appeared 
in the BMI +30 category (HR 0.65; 0.57-0.74 p<0.001). When analyses were stratified by 
sex, the lowest risk appeared in the obese weight category for men and in the overweight 
category for women (table 3 of article III).  
When BMI splines were introduced into Cox regression analyses, each point 
increase in BMI was associated with decreased mortality risk up to the end of the 
overweight category. Results are shown in table 4 of article III. Mortality risk decreased 
11% per point increase in BMI in patients with BMI under 22, 5% for patients with BMI 
22 to 25 and 3% for patients with BMI 25 to 29.9. Results were not significant in the 
spline representing the obese patient group. When number of medication was excluded 
from analyses, each point increase in BMI was associated with higher mortality risk in 
the obese category (HR 1.04; 95% CI 1.00-1.07).  
Spline analyses confirmed the sex differences found in categorical analyses: men 
presented significant risk reduction with higher BMI in the 18.5 and 25-30 BMI groups. 
For women, risk decreased with higher BMI only up to the end of the normal category 
(HR 0.94; 95% CI 0.88 to 1.00 p= 0.05) (table 5; article III). Figure A of article III show 
plotted results for men and women.  





knots at 23 and 30 were used because of the smaller sample sizes. In all age categories, 
higher BMI was related to lower risk in the lower weight spline (BMI under 23). In the 
intermediate weight spline (BMI 23-30), a negative association between BMI and 
mortality risk was demonstrated only in the youngest age group. A trend towards 
increased risk was observed in the BMI +30 spline in the youngest and oldest age groups.  




















6.1 STUDY I 
In this sample from Karolinska Memory Clinic, SCI patients differed from mild 
MCI and AD groups. SCI patients were younger, with more years of education, fewer 
cardiovascular risk factors and higher MMSE scores. They tended to have normal scores 
in MTA rating of the medial temporal lobe The average CSF measures of dementia 
biomarkers for this group was within normal parameters: low Aß42 appeared in only 7%, 
while tau (total or phosphorylated) was high in 12% of the sample. ApoE4 was less 
prevalent than in the AD group. SCI patients were more likely to recall a family history of 
dementia and had higher depression scores.  
A number of factors might explain these differences. Clinicians had access to CSF 
and ApoE results during diagnosis, so circularity might have contributed to the results. 
Traditionally, SCI has been attributed to anxious or depressive symptoms, so the higher 
prevalence of family history and depressive symptoms among this group might match 
this conception. Our study does not distinguish between depressive symptoms and a 
diagnosis of depression, but previous studies suggest that clinically significant symptoms 
of depression might occur in 8 to 16% of elderly patients.
243
 Late-life depression is 
particularly resistant to treatment and is associated with a wide range of 
neuropsychological deficits.
244
 Processing speed and executive function appear to be 
particularly affected, which could lead to secondary memory deficits and cognitive 
complaints.
244
 However, in our study SCI subjects only differed in depressive symptoms 
from AD, and not from MCI. This might suggest that SCI and MCI patients are 
experiencing depressive symptoms as a reaction to perceived cognitive deficits, 
displaying insight that disappears in dementia. Furthermore, depressive symptoms might 
be harder to identify in patients with advanced cognitive decline. 
The interplay between depressive symptoms and dementia is exceedingly 
complex. Depression in mid-life is associated with increased risk of dementia in later 
years. Depression causes cognitive deficits and although these present a more 





difficult. To complicate matters, cognitive deficits in some patients outlast the depressive 
episode.
244
 Low mood, as a symptom, is associated with increased risk of future MCI, 
particularly of the amnestic type, and seems to interact synergistically with ApoE4.
245
 
Two recent studies shed some light on the matter.
243, 246
 Both are also based on the 
Karolinska Memory Clinic and should have comparable populations to our study. The 
first compared CSF profile in depressed elderly subjects with and without AD.
246
 This 
study did not find a relationship between an AD-type profile and depression. On the 
contrary, a negative relationship was found between depressive symptoms and p- and t-
tau in the SCI group and with t-tau in the AD group. Depressed patients were younger in 
this study than their non-depressed counterparts although they presented similar 
MMSE.
246
 Thus, in this cohort, depression could lead to earlier diagnosis through an 
increase of executive cognitive symptoms, which are harder to identify with MMSE.
247
 
This explains the lower age and lower tau values of depressed subjects. 
The other study examined temporal lobe atrophy in patients with AD, MCI or SCI, 
comparing depressed and non-depressed groups.
243
 In AD patients, depressive symptoms 
were associated with less medial temporal lobe atrophy, while patients with SCI and 
depressive symptoms had smaller hippocampal volumes. This could indicate different 
mechanisms mediating the association of cognitive and depressive symptoms in the two 
groups.
243
 One possibility is that among AD patients, depression might worsen cognitive 
symptoms, leading to earlier diagnosis and hence a group with less temporal atrophy. 
Another possibility would be that depression may require insight that is lost in AD as 
temporal atrophy progresses. In SCI, depression might be part of the neurodegenerative 
package, as part of preclinical AD. These two studies raise intriguing questions on the 
interrelationship between depression and cognition at different stages of the AD-
continuum. 
The second part of Study I is based on a statistical model created to analyze the 
likelihood of presenting an AD profile for the participants in the database. Our study 
included MTA ratings from an experienced observer who was blinded to clinical data. As 





higher MTA scores were associated with higher AD-likelihood in the SCI group. The 
opposite was observed in the MCI group: higher scores were associated with lower AD-
likelihood. Since neuroimaging (but not MTA scoring) was available to clinicians during 
clinical diagnosis, part of these results might be due to circularity: MCI patients with 
temporal atrophy probably presented clinical characteristics that were atypical for AD 
since otherwise they would simply have been classified as AD. Since SCI patients are 
clinically far from dementia, this circularity would have posed less of a problem in the 
SCI group. A similar finding was observed for central atrophy and confluent WML: 
within the statistical model, these variables showed a positive association for AD-
likelihood in the SCI group and a negative one in the MCI group.  
Our study examined a number of variables reflecting cardiovascular risk, such as 
WML, history of stroke or TIA arterial hypertension, and total number of cardiovascular 
risk factors. Within the model, the presence of these factors tended to be associated with 
increased AD-likelihood in the SCI group and decreased AD-likelihood in the MCI 
group. The interpretation of these findings is not straightforward: as can be observed in 
table I of the article, there were baseline clinical differences between groups. However, 
these findings might reflect a fundamental difference in the differential diagnosis posed in 
SCI and MCI groups. MCIs are demonstrably impaired and the differential diagnosis lies 
between AD and non-AD – probably vascular – pathology. Although vascular risk factors 
are associated with AD,
248
 they are more tightly linked with vascular causes of cognitive 
impairment: thus, in this group, vascular risk factors would mark patients who fit less into 
a pure AD profile. Within the SCI group, the question might be whether patients suffer 
from a preclinical neurodegenerative process (of any kind) or whether their complaints 
are functional in nature. Thus, cardiovascular risk factors would make patients more AD-
like. 
One of the limitations of our study is its cross-sectional design. Only longitudinal 
follow-up could address questions about progression of atrophy or declining cognition in 
SCI and MCI subjects. Furthermore, there is some indication that the association between 





thickness and CSF biomarkers is shaped like an inverted U, with cognitively preserved 
subjects with transitional CSF profile presenting thicker temporoparietal and precuneus 
regions.
53
 One explanation is that these are individuals with particularly thick cortexes 
that allow them to remain cognitively intact despite ongoing neurodegeneration, as 
evidenced by their transitional CSFs. Another possibility is that cortical thickness is 
dynamic and evolves over the course of the disease, stressing the need for longitudinal 
studies to evaluate these changing relationships over time. 
Patient selection was opportunistic and was based on consecutive memory clinic 
referrals of subjects with cognitive complaints, irrespective of origin. Thus, ours is a 
naturalistic sample which reflects the heterogeneity of ordinary clinical practice. 
Diagnosis followed routine practice and was not constrained by a particular research 
protocol. This explains why not all tests are available for all patients: some might not 
have needed, or declined certain procedures. This methodology could make our sample 
less homogeneous but more representative than selected study populations. Circularity 
occurs when there is dependency between variables used to define groups at study onset 
and result variables, and is an obvious problem with this study design. To circumvent 
this, neuroimaging ratings were evaluated blindly, although clinicians had access to the 
images while making the diagnosis. 
The lack of standardized criteria for SCI is a common problem to all studies 
dealing with this patient group
31, 61
 and hinders comparisons between studies. In keeping 
with the naturalistic design of our sample, patients were only excluded if they presented 
with severe comorbidities that made diagnosis uncertain, for example intracranial 
neoplasms. This explains the high prevalence of parkinsonism in the MCI sample (21%; 
table I of the article) and hints at these patients possibly presenting cognitive impairment 
due to Lewy body or subcortical vascular pathology. 
A growing number of publications suggest that SCI subjects differ from healthy 
populations
31, 33, 50, 51, 53, 60, 61, 63, 64, 70, 249, 250
 and some SCI subjects may represent the 
earliest detectable stage of AD.
33, 40, 251





future decline may prove to be difficult. Cognitive complaints with normal 
neuropsychological testing may be particularly predictive in highly educated subjects 
where the ceiling effect of testing is a problem.
60
 The SCI group in our sample was highly 
educated, reflecting the composition of urban Sweden in their generation. However, only 
some of these individuals will develop a neurodegenerative disease and only follow-up 
can reveal who will progress. The Dubois criteria
252
 and National Institute of Aging-
Alzheimer’s Association (NIA-AA) diagnostic guidelines9 expand diagnosis of AD into 
earlier stages. Our study attempts to be part of this effort in isolating factors that might 
help detect at risk individuals.  
6.2 STUDY II 
This second study is based on 15 209 patients diagnosed in specialist memory 
clinics from all over Sweden and included in SveDem between 2008 and 2011. Mortality 
risk for the different dementia disorders and underlying factors were calculated using HR 
obtained from Cox hazard regression analyses. Factors such as male gender, higher 
number of medication, institutionalization, worse cognition (as evaluated by MMSE), 
higher age and non-AD dementia were associated with higher mortality risk in this study. 
In this cohort men presented 56% higher mortality risk than women. This is in 
accordance with previous studies.
143, 146, 153, 154, 157, 161-164
 Some studies have suggested that 
the influence on gender in mortality risk may be different for different dementia 
disorders.
142, 150, 158, 166, 167
 We found no such association in our sample: when stratified by 
diagnosis, men presented higher mortality risk in all dementia diagnoses except FTD and 
DLB, where results were non-significant. The greatest difference between men and 
women was found for PDD) with 71% higher mortality risk for men. 
As expected from previous studies, higher age
143, 150, 153-155
 and lower MMSE
157, 
169
 increased mortality risk. There was a fourfold increase in risk for patients deemed 





Our study used number of medication as a proxy for comorbidity and found that it 
was associated with higher mortality risk. Treatment with cholinesterase inhibitors was 
associated with reduced mortality and cardiovascular events in AD patients in 
SveDem,
216
 so models with and without this variable were run to exclude confounding. In 
this cohort, cholinesterase-inhibitor treatment was indeed associated with lower mortality 
but it did not alter other results, and neither did other medication types.  
Mortality risk varied by dementia diagnosis: AD presented lower mortality than 
any other dementia type. Using AD as reference category, the highest crude HR for death 
was obtained for VaD (HR 2.27, 95% CI 2.08–2.47). This risk remained similar after 
adjusting for sex, but when adjusting for age and sex PDD became the dementia type 
with highest risk. As can be seen in table 2 of article II, PDD patients tended to be 
younger but used more medication than other dementia groups, suggesting that they had 
more comorbidity, which may explain these results. After additional adjustment for 
number of medication and when including all the variables in the final model, FTD 
became the dementia type with highest risk with a twofold increase in risk relative to AD 
(table 5 of article II). As is evident from table 2 of the article, FTD patients were younger 





 years according to previous estimates. FTD had worse 
survival than AD in most studies,
146
 although studies comparing a wide range of dementia 
types are rare.
146
 Even though FTD is a rare condition, it affects relatively young and 
healthy patients and presents disproportionally high mortality risk, highlighting the need 
for further research into this condition focusing on causes of mortality.  
According to previous literature, AD presents lower mortality than other dementia 
disorders,
142, 146, 150
 although some studies find no difference between conditions
142, 146, 
150
. However, few compare a wide range of diagnosis,
142, 146, 150
 which makes our study 
particularly novel. As expected, mixed dementia presented intermediate risk between VaD 
and AD, possibly due to the higher cardiovascular risk inherent in the “vascular” 
component. Since cardiovascular causes are the most frequent causes of death across 







 Previous literature shows that AD groups have less comorbidity 
than other dementia types,
142, 146, 150
 and this fits well with the lower number of 
medication in AD in our cohort (table 2; article II). However, models run with and 
without controlling for medication did not differ in the relationship in mortality between 
VaD and AD. 
Despite exceptions,
180
 most previous studies found worse prognosis for DLB than 
for AD.
167, 179
 In our cohort, DLB had higher mortality risk than AD. When entered as the 
reference category, DLB had significantly higher mortality risk than AD and mixed 
dementia, with no differences with PDD or VaD. DLB and PDD share many features with 
some authors proposing to include both diseases in a common Lewy body dementias 
(LBD) category,
82
 so the similar mortality risk is unsurprising. 
The absence of a control cohort with normal cognition is a weakness of this study. 
SveDem is a quality registry which includes patients diagnosed in regular clinical 
practice: as such, there is no fixed research protocol for diagnosis and different patients 
may have followed different diagnostic pathways. The Swedish National Board of Health 
and Welfare
228
 published guidelines on the requirements for a basic dementia diagnostic 
work-up: in SveDem, over 85% of patients in specialist units fulfill this criteria.
217
 In 
addition, most patients in specialist settings are also examined using an extended work-up 
according to national guidelines.  
The observational nature of this study precludes making inferences on causality. 
In Study II and III, SveDem had a coverage of over 25% of expected dementia incidence 
in all Sweden. However, in these two studies only patients from specialist setting were 
included. Since more than 90% of the specialist units are affiliated to SveDem and the 
majority of their dementia patients are registered, the coverage is much higher than 25%. 
Thus, the representativeness of incident dementia cases in Sweden from specialist 
settings is actually very good. Our study had a follow-up time of 2.5 years which may 
have been too short to evaluate changing mortality risks over time if mortality in a 





follow-up times in SveDem will be able to answer this question in the future.   
Length bias occurs when studies include prevalent cases and patients with rapidly 
progressive disease die before recruitment.
143
 The inclusion of only incident cases is a 
strength of this study, and should help control this bias. The selection of specialist 
memory clinics was meant to improve diagnostic reliability but could be a problem if 
memory clinic and primary care patients differ significantly. Indeed, previous studies on 
SveDem suggest that primary care patients are older and have more comorbidity and that 
the diagnostic process is different.
214, 227
 In order to determine whether the exclusion of 
primary care had led to bias, analyses were repeated with all patients (specialist and 
memory clinics) included in SveDem between 2007 and 2012. As was shown in table 14, 
this did not substantially alter our results.  
The wide range of diagnoses examined and the large number of patients are the 
main strengths of our study. This study is the largest prospective study of its kind to 
examine mortality in incident dementia.  
6.3 STUDY III 
Article III explores the relationship between mortality and BMI at the time of 
dementia diagnosis. The cohort includes 11 398 patients diagnosed in memory clinics 
between 2008 and 2011 and for whom complete data on BMI was available. 
Previous studies have analyzed mortality and BMI in different age groups but this 
is the first large study to evaluate this relationship in a population with newly-diagnosed 
dementia. Low BMI was associated with higher mortality risk after adjusting for sex, age, 
MMSE, dementia diagnosis and number of medication. The obese weight group 
presented the lowest mortality risk, although a significant difference was not 
demonstrated between the obese and overweight groups. When analyzed as splines, each 
point increase in BMI up to BMI 29.9 resulted in a significant decrease in mortality risk, 





SveDem has previously shown that more than a quarter of the patients at diagnosis have 




There were sex differences in the relationship between mortality risk and BMI: the 
lowest risk occurred in the overweight group in women and in the obese weight group for 
men. Furthermore, spline analyses showed that risk flattened out at lower BMIs for 
women than for men, implying that men benefited from higher BMIs (figure 1a; article 
III). 
The composition of our sample included few patients with BMI over 35 and 
precludes conclusions in this patient group. Furthermore, spline analyses repeated 
without adjusting for medication showed increased risk after BMI 30, suggesting that 
after this point, comorbidity (reflected in the number of medication) may be playing a 
part in increased risk. 
A review of literature reveals a complex association between BMI and mortality 
in special populations. The BMI associated to minimum mortality increases with age
189, 
254, 255
 and occurs in the overweight or obese weight group for older populations,
190, 191, 255, 
256
 although some have described increases in mortality in the obese old.
191, 257, 258
 A 
previous study found 17% lower mortality risk in obese adults over 75 compared to their 
normal-weight peers.
189
 In our study, the reduction in risk was 27% and 32% in the 
overweight and obese groups respectively (table 3; article III).  
The optimal BMI for minimum mortality risk could be higher in men than in 
women
190, 255
 although some studies find different associations.
191
  In one study, the 
lowest mortality appeared with BMI between 18.5 to 25 in women over 55, but between 
25 and 30 for men.
255
 This agrees with our present findings. The reasons behind this 
connection may be biological or social,
190, 259, 260
 and require further investigation.  





factor is termed “reverse epidemiology” and has been described in chronically or acutely 
ill populations such as renal failure, stroke, cardiac insufficiency, malignancies and 
acquired immunodeficiency syndrome (AIDS).
203-205
 The same concept applied to obesity 
is termed the “obesity paradox” and has also been described among the elderly.190, 200, 201 
The novelty of our study resides in describing this phenomenon among a new population; 
that of patients with dementia, but the concept itself has been known since the early 
00´s
261
. Although this effect has been evident in repeat observations, the causes behind it 
remain controversial.
195
 The explanations for this phenomenon are varied, ranging from 
bias to the presence of competing hazards or different biological mechanisms such as 
catabolic states or inflammation.
194, 195, 206, 262
 Indeed, this article motivated a letter to the 
editor by Moga et al
262
 in which issues of reverse causation and bias were raised. This 
allowed us to respond with a letter of our own, which we hope contributes to this 
fascinating subject. Moga et al had concerns about selection bias, since our original 
article included only specialist clinic patients. Indeed, primary care patients in SveDem 
present lower mortality risk (HR of 0.45; 95% CI 0.42-0.49) so these concerns are 
founded.
263
 In table I of the response letter,
263
 we show analyses on the whole database 
and primary care. Results were often not significant in primary care and less reliable due 
to missing BMI data: however, the obese group still presented significantly lower 
mortality than the reference category in primary care.
262
 
Missing data on BMI was a concern and hard to correct given the structure of 
SveDem. However, the category of missing BMI presented similar mortality risk than the 
group with BMI between 25-29.9. In order to remove the effects of persons at the 
extremes of the scale, spline analyses were repeated only for subjects with BMI 20 to 31. 
Results are shown in table II of the response letter
263
: higher BMI is still associated with 
reduced mortality risk even under these conditions.  
Another possible weakness of this study is the use of BMI as a nutritional 
measure
255
 and the lack of follow-up for BMI. However, as was argued in the 
introduction to this thesis, BMI is widely available and predicts cardiovascular health   





more sensitive to prognosis.
196, 210
 In one study, patients over 70 who either lost or gained 
weight presented higher mortality risk than their stable-weight counterparts.
254
 SveDem is 
designed with annual follow-ups and hitherto about 50% of the SveDempatients are 
followed up at least once
219
 while three and four year follow-ups comprise small sample 
sizes. However, the follow-up of BMI data in SveDem over time is one of the obvious 
future studies to do.  
Other issues presented by Moga et al
262
 have to do with the causal chain of events 
between dementia and low BMI: dementia is known to cause weight loss, which can 
precede diagnosis. Patients with dementia often forget to eat and have swallowing 
difficulties, and patients with weight loss display worse prognosis.
264
 The descriptive 
nature of SveDem precludes making inferences on causality but previous studies show 
that interventions that cause weight gain in advanced dementia are associated with 
reduced mortality.
210
 Our current methods do not allow the determination of the 
mechanisms that link lower BMI to higher mortality risk in dementia, but independent of 
its causal mechanism, this observation is valuable. For a clinician facing a patient with 
dementia the causal relationship may well be irrelevant. Rather, this study underlines the 
need for complete nutritional assessments of patients with dementia and proves the utility 
of BMI for prognosis. 
In the future, longitudinal prospective studies with cognitively-intact controls 
could determine if patients with dementia benefit from higher BMIs than healthy older 
adults. Interventional studies would be needed to determine the treatment strategies to 
























1. In the Karolinska Memory Clinic, subjective cognitive impairment (SCI) 
patients are a distinct group: younger than mild cognitive impairment (MCI) 
and Alzheimer’s disease (AD) patients, with more years of education, lower 
frequency of cardiovascular risk factors, higher Mini-Mental State 
Examination (MMSE) scores and normal dementia biomarkers in the 
cerebrospinal fluid and normal medial temporal atrophy ratings. Generalized 
central and cortical atrophy and confluent white matter lesions were less 
frequent, as was apolipoprotein E4. SCI patients presented more symptoms of 
depression as evaluated by the Cornell scale of depression in dementia than the 
AD group, but did not differ from the MCI group. 
2. The logistic regression model containing age, sex, MMSE Aβ42/t-tau 
(amyloid-beta 42 / total tau) quotient and p-tau (phosphorylated tau) accurately 
classified 94.9% of the sample. Within this model, factors directly or indirectly 
representing cardiovascular risk tended to increase the AD-likelihood in the 
SCI group but decrease it in the MCI group, possibly speaking for a 
fundamental difference in the differential diagnosis that is posed in these two 
conditions. 
3. Once dementia is diagnosed, the dementia type and other baseline factors can 
predict mortality risk. Male gender, higher age, lower MMSE, higher number 
of medication, institutionalization, and non-AD dementia are associated with 
worse prognosis. In crude analyses vascular dementia (VaD) presented the 
highest mortality risk, while in age, gender and medication adjusted analyses 
frontotemporal dementia (FTD) became the dementia with highest risk. This 
suggests that FTD is particularly deadly, considering that it affects younger and 
healthier individuals. 
4. Low body mass index (BMI) is associated with increased mortality risk. The 
BMI range associated with minimum mortality is sex dependent. Higher BMI 
is associated with lower mortality risk up to BMI 24.9 kg/m
2
 in women and up 
to 29.9kg/m
2
 in men. Our findings underscore the clinical importance of 
nutritional assessment for patients diagnosed with dementia.  
  






















8.1.1 Evolución del concepto y definición de demencia 
La demencia ha acompañado a la humanidad desde el principio de los tiempos, y 
ha sido reconocida como enfermedad desde épocas antiguas.
1, 2
 Areteo de Capadocia 
pudo ser el primero en distinguir entre el delirium como un cuadro reversible y la 
demencia, que él describió como un cuadro permanente y progresivo.
2
 Tanto Hipócrates 
como Galeno fueron conscientes de que estas enfermedades podían tener su origen en 
procesos primarios cerebrales o ser secundarios a enfermedades que afectaran a otros 
órganos.
2
 Tal vez fuera Cícero el primero en distinguir la demencia del envejecimiento 




La descripción original de Alois Alzheimer de la enfermedad que lleva su nombre 
no despertó mucho interés en un primer momento, tal vez porque el propio Alzheimer 
estaba convencido de que era una enfermedad bastante infrecuente. En la base de datos 
Pubmed
®
 sólo constan 47 publicaciones con el término “Alzheimer” entre 1963 y 1973. 
Por orden del Congreso de Estados Unidos, en 1974 se creó el National Institute of Aging 
(NIA, Instituto Nacional de Envejecimiento), y a partir de ahí se produjo un cambio.
2, 4
 
En 1974 se publicaron 14 artículos sobre enfermedad de Alzheimer (EA), 43 en 1975 y 
110 in 1980. Desde entonces la progresión fue exponencial, llegando a alcanzar un total 
de 4 988 publicaciones indexadas en 2012. Otras enfermedades como la demencia de 
cuerpos de Lewy (DLB) o la demencia frontotemporal (DFT) se han sumado al panorama 
de modo que en la actualidad la demencia se comprende como un conjunto de síndromes 
causados por una variedad de enfermedades y alteraciones anatomopatológicas. 
La Organización Mundial de la Salud (OMS)
5
 define la demencia como un 
síndrome causado por una enfermedad cerebral, generalmente crónica y progresiva, en la 
que se alteran múltiples funciones corticales, con un nivel de conciencia preservado. Para 
el diagnóstico de demencia se debe demostrar además un deterioro desde niveles 
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superiores de funcionamiento previos y se debe excluir que el deterioro ocurra en 
contexto de un delirium o de trastornos psiquiátricos mayores. El grupo de trabajo del 
National Institute for Aging-Alzheimer's Association (NIA-AA, Instituto nacional 
estadounidense para el envejecimiento – Asociación de Alzheimer) estipula que este 
deterioro cognitivo debe quedar corroborado mediante una combinación de la historia 
clínica y el examen neuropsicológico. Además, para hacer el diagnóstico de demencia el 
déficit cognitivo debe afectar al menos a dos dominios: memoria, razonamiento, 
capacidad visuoespacial, lenguaje, o personalidad y comportamiento.
6
 Aunque este 
síndrome afecte principalmente a personas mayores, el deterioro sobrepasa lo esperado 
con el envejecimiento normal. 
Existen varias clasificaciones de las demencias, entre ellas la de la Clasificación 
Internacional de Enfermedades (CIE-10)
5
 y la del Manual Diagnóstico y Estadístico de 
los Trastornos Mentales (DSM-IV y DSM-5), además de guías clínicas para tipos 
particulares de demencia.
5, 6, 9-13
 Sin embargo, existe un solapamiento entre las distintas 
enfermedades y entre las fases preclínicas (o pre-demencia) y la fase de demencia.
9
 Estas 
áreas de incertidumbre son consecuencia de las limitaciones naturales de todos los 
sistemas de clasificación y de la variedad biológica en la presentación de las 
enfermedades. 
8.1.2 La enfermedad de Alzheimer 
8.1.2.1 Primera descripción y concepto actual de la enfermedad 
En 1906 Alois Alzheimer describió el caso de “Auguste D”, una mujer de 51 años 
que presentó un cuadro de demencia y en cuya autopsia descubrió placas amiloides y 
ovillos neurofibrilares. En 1911 Alzheimer publicó un segundo caso, el de un varón de 56 
años que sólo presentó lesiones anatomopatológicas en forma de placas. Las secciones 
histológicas se han conservado hasta nuestros días, permitiendo confirmar los hallazgos 
de Alzheimer y excluir mutaciones de la proteína precursora de amiloide (PPA) en estos 
pacientes.
14, 15
 Alzheimer no estaba seguro de la naturaleza de esta enfermedad, aunque 
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pensó que podría tratarse de una presentación temprana de demencia senil o bien de otra 
entidad diferente. No obstante, Emil Kraepelin, que era supervisor de Alzheimer y el 
psiquiatra de más renombre a nivel mundial de su tiempo, la incluyó con el nombre de 
enfermedad de Alzheimer (EA) en su tratado de Psiquiatría de 1910
3
. Otros patólogos 
dieron validez a estas descripciones histológicas, pero la EA siguió considerándose como 
una enfermedad que solo afectaba a personas jóvenes hasta varias décadas después.  
Hoy en día, se entiende la EA como una enfermedad compleja en la que la 
enfermedad neuropatológica (“EA patológica”, EA-P) debe distinguirse de su 
manifestación clínica (“EA clínica”, EA-C).16, 17 Existen dos grupos de criterios para 
investigación en EA y ambos emplean biomarcadores.
18
 El International Working Group 
(IWG) propone criterios para “EA preclínica” y “EA presintomática”. En este último 
grupo se incluyen sujetos asintomáticos con mutaciones autosómicas dominantes para EA 
hereditaria. Los individuos sintomáticos se clasifican en “EA” con subgrupos: “EA 
prodrómica” (deterioro cognitivo leve, DCL) y “demencia tipo Alzheimer”. El otro grupo 
de criterios los publicó la NIA-AA. Cuando hay disponibilidad de biomarcadores, los 
individuos se clasifican en un estadio asintomático llamado “EA preclínica”, un estadio 
de DCL causado por EA y un estadio de demencia, “demencia causada por EA”. Cuando 
no existen biomarcadores, la clasificación se basa en criterios clínicos para definir la “EA 
posible o probable” y el “DCL”. La tabla 3 de la versión en inglés de esta tesis compara 
ambas clasificaciones. 
8.1.2.2  Enfermedad de Alzheimer patológica (EA-P) 
Los cambios anatomopatológicos en la EA consisten en la acumulación de placas 
seniles de β amiloide (βA) y ovillos neurofibrilares (neurofibrillary tangles, NFT) en 
grados variables de intensidad y distribución.
19
 Los NFT son depósitos intraneuronales 
compuestos principalmente por proteína tau patológica, que pueden visualizarse con 
tinciones histoquímicas o inmunohistoquímicas dirigidas contra epítopos de tau o tau 
fosforilada. En estadios tempranos su extensión puede limitarse a áreas límbicas, pero a 
medida que avanza la enfermedad se extienden a otras áreas cerebrales, incluyendo la 
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corteza cerebral, núcleos subcorticales y algunas áreas troncoencefálicas.
20
 La secuencia 
comienza en el córtex entorrinal, extendiéndose al hipocampo y neocórtex, aunque 
existen excepciones. 
20, 21
 Las placas seniles son depósitos extracelulares de péptidos  βA. 
Cuando se sitúan en el centro de un racimo de neuritas distróficas – que suelen tener 
inmunorreactividad positiva para tau fosforilada – se llaman placas neuríticas. Las placas 
no neuríticas pueden presentarse como placas difusas, “placas de lana y algodón”, lagos 
de amiloide y bandas subpiales.
20
 Las placas de amiloide son heterogéneas y actualmente 
se cree que son las placas neuríticas las que tienen mayor potencial para ocasionar daño 
neuronal.
20
 El depósito de βA en el cerebro sigue una secuencia concreta, comenzando en 
el neocórtex (fase de Thal 1), seguido de regiones alocorticales (fase 2 de Thal), núcleos 
diencefálicos, estriado, núcleos colinérgicos y prosencéfalo basal (fase 3 de Thal), otros 
núcleos troncoencefálicos (fase 4 de Thal) y cerebelo (fase 5 de Thal).
22
 Las lesiones de 
EA pueden presentarse en individuos sin deterioro cognitivo y preceden, en años, el inicio 
de los síntomas. En sujetos con síntomas, niveles intermedios o altos de patología EA se 




Los criterios de Braak y Braak
27
 todavía están en efecto para NFT, aunque la NIA-
AA prefiere las fases de Thal para describir placas de amiloide,
18, 20
 mientras que criterios 
del CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) se emplean 
para estadificación de placas neuríticas.
28
 Así, la NIA-AA recomienda una escala “ABC” 
(Amiloide, Braak, CERAD) para la clasificación de cambios patológicos de EA (tabla 4). 
La NIA-AA también recomienda que se registren la patología vascular y los cuerpos de 
Lewy (Lewy bodies, LB), así como la esclerosis hipocampal y las inclusiones de TDP-43 
(transactive response DNA-binding protein 43 kDa).
19, 20, 22
 
8.1.2.3 Enfermedad de Alzheimer clínica (EA-C) 
El cuadro típico de la EA se caracteriza por un comienzo de deterioro cognitivo 
insidioso y progresivo de suficiente gravedad como para cumplir criterios de demencia, y 
por la afectación de dos o más áreas cognitivas (tablas 5 y 6). La presentación amnésica 
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es la más típica, con déficits en memoria episódica. Las presentaciones no amnésicas 
incluyen cuadros con alteraciones del lenguaje como la anomia, de las capacidades 
visoespaciales o de las funciones ejecutivas. Además, para el diagnóstico de EA no debe 
haber evidencias de daño vascular cerebral extenso ni en la historia clínica ni en las 
pruebas de neuroimagen.
6
 La conciencia de enfermedad puede o no estar preservada y es 
frecuente la asociación de síntomas depresivos. Las habilidades sociales y las actividades 




Existen dos presentaciones no amnésicas que merecen especial atención. Una, es 
la atrofia cortical posterior.
6
 En este síndrome coexisten elementos del síndrome de 
Balint, tales como dificultad para integrar la percepción de todo el campo visual, para 
dirigir la mirada o para alcanzar objetos presentados visualmente, con apraxia, síndrome 
de Gerstmann y otros síntomas más típicos de EA.
29
 Otra es la afasia logopénica primaria 
progresiva. En este síndrome, el déficit más evidente aparece en la búsqueda de palabras, 
aunque deben coexistir déficits en al menos otro dominio cognitivo para cumplir criterios 
de EA según la NIA-AA (tabla 6).
6
 La afasia primaria progresiva también puede asociarse 
a demencia frontotemporal (DFT), especialmente en casos con presentación agramatical. 
Sin embargo, aunque el subtipo de afasia primaria progresiva pueda ayudar a predecir si 




8.1.2.4 Estadios preclínicos y predemencia de la enfermedad de Alzheimer 
El término “quejas cognitivas subjetivas” (QCS) se aplica a un grupo heterogéneo 
de pacientes que presentan quejas cognitivas sin evidencia objetiva de deterioro en el 
estudio neuropsicológico.
31
 La neurodegeneración probablemente comience décadas 
antes del inicio de los síntomas,
32, 33 
y se calcula que el estadio de deterioro cognitivo leve 
(DCL) dura 7 a 10 años.
34
 Así, es natural buscar los estadios más tempranos de esta 
enfermedad entre pacientes que presenten síntomas cognitivos sin evidencia demostrable 
de deterioro.
9, 35
 Las QCS afecta a un alto porcentaje de los pacientes que acuden a 
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clínicas de memoria a nivel mundial
36, 37
 y, por lo tanto, representa un problema clínico 
relevante. El concepto ha evolucionado desde que Reisberg definió el estadio 2 de la 
escala Global Deterioration Scale (GDS),
39
 que es equivalente a QCS, y en la actualidad 
son muchos los autores que apoyan la existencia de este síndrome como un estadio 
temprano de enfermedad neurodegenerativa, en particular de la EA.
40, 41 
Este concepto 
puede ser especialmente válido cuando hay acceso a biomarcadores y estos son 
sugerentes de EA.
9
 En otros casos, el diagnóstico es más controvertido.  
Hoy en día la EA es un diagnóstico establecido, aunque persisten áreas de 
incertidumbre. El DCL es más heterogéneo y existen dudas en cuanto al pronóstico de 
muchos pacientes. Todos estos problemas se acrecientan en los pacientes con QCS, por 
definición un diagnóstico sin variables “duras” y en el que la investigación se ha centrado 
sobre todo en aspectos de depresión y personalidad de los pacientes.
31
 La diversidad de 
los pacientes con QCS y de los métodos de estudio contribuye a esta confusión: mientras 
que algunos trabajos se centran en la población general,
42-51
 otros reclutan pacientes 
desde unidades de memoria.
52-54
 La tabla 7 resume los estudios sobre prevalencia de 
QCS.  
Pese a estos problemas, existen evidencias para considerar las QCS como el 
estadio más temprano de un continuo QCS-DCL-EA. Los resultados de algunos estudios 
parecen indicar que los sujetos con QCS tienen un riesgo aumentado de deterioro 
cognitivo en el futuro,
51, 59-61
 aunque no todos los autores encuentran esta asociación.
62
 
Como puede verse en la tabla 8, las QCS se asocian a una razón de probabilidades (odds 
ratio, OR) para deterioro cognitivo posterior entre 1,5 a 8,5 en comparación con los 
controles. La presencia de determinados factores, como las lesiones de sustancia blanca 
cerebral o el alto nivel educativo, aumentan la fuerza de esta asociación.
59, 60
 Es posible 
que los individuos con mayor nivel educativo sean más sensibles para su propio deterioro 
que los tests neuropsicológicos, o que el efecto techo de estos tests sea particularmente 
relevante en este grupo. Además, los individuos con alto nivel académico suelen tener 
ocupaciones con mayores requerimientos cognitivos, que podrían poner de manifiesto la 
existencia de déficits más sutiles.  
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Los sujetos con QCS también difieren de la población general en las pruebas de 
neuroimagen.
63, 64
 Se ha demostrado que los pacientes con QCS tienen menor volumen 
del hipocampo que los controles,
64
 así como una reducción del volumen de regiones 
temporomediales y frontotemporales,
63
 con una distribución similar a la que se ha 
encontrado en pacientes con DCL. La neuroimagen funcional demuestra aumento de 
activación para ciertas tareas cognitivas en la EA, el DCL y en sujetos portadores del 
alelo ɛ4 de la apolipoproteina ɛ (APO ɛ4),65, 66 indicando la presencia de reclutamiento 
compensatorio. La intensidad de esta hiperactivación se ha correlacionado con el 
deterioro cognitivo subsiguiente del paciente.
65
 Este patrón se ha reproducido en el estado 
de QCS, con un aumento de activación en la corteza prefrontal dorsolateral y premotora 
izquierda,
67
 el tálamo, el cíngulo posterior, ambos caudados, el hipocampo izquierdo y la 
región parahipocampal
68
 en distintas tareas. Además, mediante tomografía de emisión de 
positrones con fluorodesoxiglucosa (FDG-PET) se ha demostrado reducción del 
metabolismo en regiones parahipocampales, parietotemporales, frontales inferiores, giro 
fusiforme y tálamo, replicando los hallazgos de sujetos sanos con alto riesgo de EA 
(formas familiares autosómico-dominantes de EA, familias con altas prevalencias de EA 
u homocigotos APO ɛ4) y de pacientes con DCL.33 
Las QCS se asocian a lesiones de EA en la autopsia,
69, 70
 y marcadores de EA en el 
líquido cefalorraquídeo (LCR)
71
. La teoría actual sobre la evolución de los marcadores de 
EA propone una caída precoz del βA seguida de un aumento de tau en estadios 
posteriores.
54
 Si el estado QCS es parte de la historia natural de la EA, los biomarcadores 
deberían corresponderse con las fases más tempranas de esta evolución. Esto encaja con 
la correlación demostrada entre los niveles de βA de 42 aminoácidos (βA42) y el 
rendimiento en tareas semánticas y de memoria de trabajo en individuos con QCS y 
controles, mientras que los niveles de tau predicen mejor la cognición de los pacientes 
con DCL.
72
   
Los sujetos con QCS y los controles también difieren en marcadores de atrofia y 
depósito amiloide visualizados con tomografía de emisión de positrones (PET) con 
compuesto B de Pittsburgh (PiB-PET).
73
 En algunos trabajos los sujetos sanos con 
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depósito alto de PiB tenían lóbulos temporales de mayor tamaño que los sujetos sanos 
con depósito de PiB bajo.
74
 Esto sugiere que sólo los sujetos que constitutivamente 
tengan lóbulos temporales de gran tamaño pueden mantenerse asintomáticos con altas 
cargas de amiloide, o bien que el amiloide en sí mismo aumenta el volumen de los 
lóbulos temporales en fases tempranas. La relación entre volumen cortical y amiloide 
parece describir una curva en U.
53
 Sin embargo estos estudios son transversales y se 
necesitan estudios longitudinales para determinar si sus hallazgos corresponden a grupos 
de pacientes distintos o a pacientes en distintas fases de la misma enfermedad. 
El DCL describe un estadio de deterioro cognitivo apreciable en el cual aún se 
conserva la independencia funcional.
75
 Cuando la causa es la EA, el DCL se considera un 
estadio predemencia en el curso de la EA. La NIA-AA requiere la existencia de una caída 
respecto al nivel de funcionamiento previo, que el deterioro sea demostrable en una o más 
áreas cognitivas, y que el paciente mantenga su independencia para las actividades de la 
vida diaria. Si aparece una afectación social u ocupacional se considera que el paciente ya 
tiene una demencia y el término DCL deja de ser aplicable.  
8.1.2.5 Instumentos diagnósticos: el papel de los biomarcadores 
Los biomarcadores se definen como parámetros anatómicos, fisiológicos o 
bioquímicos que se detectan “in vivo” y que reflejan aspectos específicos de la 
fisiopatología de una enfermedad particular. En los criterios de 2011, la NIA-AA clasificó 
los biomarcadores de EA en dos categorías basándose en su especificidad.
17
 Así, una 
categoría incluye los biomarcadores de acumulación de βA, tales como demostración de 
amiloide en PET o el descenso de βA42 en LCR. Otra categoría incluye biomarcadores 
de degeneración o daño neuronal, tales como tau alta en LCR, descenso de captación de 
FDG en PET en corteza temporoparietal o atrofia en áreas típicas de EA en pruebas de 
neuroimagen estructural.
9, 76
  Los biomarcadores que reflejan patología amiloide aparecen 
entre 10 y 20 años antes de los primeros síntomas. Los biomarcadores de daño neuronal y 
alteración funcional llegan más tarde, en paralelo con el empeoramiento cognitivo.
17
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Siguiendo los criterios de la NIA-AA, los biomarcadores se emplean en fases 
preclínicas para establecer la presencia de EA-P en sujetos de investigación asintomáticos 
o sutilmente sintomáticos. En las fases DCL y DTA los biomarcadores son 
complementarios al diagnóstico clínico, que puede hacerse exclusivamente con criterios 
clínicos si no se dispone de biomarcadores.
17, 75
 En el DCL, de acuerdo con la NIA-AA, 




8.1.3 Demencia vascular 
La demencia vascular (DV) se define como una pérdida de capacidad cognitiva 
con repercusión en las actividades de la vida diaria resultante de enfermedad 
cerebrovascular isquémica o hemorrágica, o de alteraciones cardiovasculares o 
circulatorias que afectan a la función cerebral.
77
 Las causas vasculares se suponían las 
principales responsables del deterioro cognitivo hasta los años 70 y 80, cuando el enfoque 
se desvió hacia causas neurodegenerativas de demencia.
78
 En la actualidad, existe un 
renovado interés en la patología vascular y en su interacción con la EA.
79
 
La DV se considera la segunda causa de demencia, después de la EA,
77, 80
 aunque 
las estimaciones de prevalencia varían dependiendo de la definición empleada.
78
 A 
diferencia de lo que ocurre en la EA, la DV es más frecuente en varones
77
 y los déficits 
mnésicos no son la alteración principal.
78
 El cuadro clínico puede ser variado, desde 
demencias post-infarto al estado lacunar o enfermedad de Biswanger.
77
 La clínica 
depende de las regiones cerebrales afectadas y varían desde afasia o apraxia como 
síntomas más propios de afectación cortical, hasta síntomas disejecutivos y trastornos de 
la marcha como marca de patología subcortical.
79
 La evolución de los síntomas es 
variable, con curso agudo o subagudo que puede mejorar, estabilizarse o progresar de 
forma gradual o escalonada.
79 
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8.1.4 Demencia mixta: entre la demencia tipo Alzheimer y demencia 
vascular 
En realidad no existe un límite claro entre la EA y la DV. Los factores de riesgo 
vascular, entre ellos la hipertensión arterial y la resistencia a la insulina, se han 
relacionado tanto con la EA como con la DV.
78
  El alelo APOE ɛ4 aumenta el riesgo de 
EA pero también de infartos cerebrales,
81
 y la mayoría de los pacientes de edad avanzada 
que presentan EA también tienen algún grado de patología vascular
77, 81
 que podría 
potenciar el efecto de la patología tipo Alzheimer. 
77
 No está claro si ambos procesos 
tienen un efecto aditivo o sinérgico en la progresión hacia la demencia.
78
 En el estudio de 
las órdenes religiosas Rush, los infartos macroscópicos aumentaban el riesgo de 
demencia de una forma independiente y no sinergística.
81
 Este solapamiento entre 
entidades podría indicar que algunos factores de riesgo de la EA actuarían a través de 
mecanismos vasculares, y no sobre la patología amiloide.
81
 
Una proporción importante de pacientes presenta características tanto de EA como 
de DV. El término demencia mixta se aplica a este grupo, que expresa grados variables de 
afectación de funciones mnésicas o ejecutivas, o de otras áreas cognitivas, unida a 
evidencia de enfermedad cerebrovascular. 
8.1.5 Demencias causadas por cuerpos de Lewy: demencia con cuerpos de 
Lewy y enfermedad de Parkinson con demencia 
Aunque inicialmente se describieran por separado, en la actualidad se acepta que 
la demencia con cuerpos de Lewy (Dementia with Lewy Bodies, DLB) y la enfermedad 
de Parkinson con demencia (EPD) comparten un sustrato fisiopatológico común y que 
pueden considerase como dos entidades dentro de un mismo continuum.
82
 Se ha 
propuesto el término de “demencias con cuerpos de Lewy” para englobar ambas 
entidades. En estas enfermedades aparecen inclusiones intraneurales de alfa-sinucleína 
formando cuerpos de Lewy (Lewy bodies, LB) y neuritas de Lewy, con pérdida neuronal, 
a menudo acompañadas de algún grado de patología de EA. La prevalencia de esta 
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entidad se estima en torno al 25% de los pacientes con enfermedad de Parkinson (EP), y 
aumenta con la duración de la enfermedad. Existe menos información sobre la 
prevalencia de DLB, que probablemente se encuentre subestimada.
83
 Se ha calculado que 
la DLB podría representar entre el 0 y el 24% de las demencias.
84
 
8.1.5.1 Demencia con cuerpos de Lewy  
En la DLB los aspectos patológicos arriba descritos se acompañan de un síndrome 
clínico caracterizado por un cuadro de deterioro cognitivo de rápida progresión dominado 
por dificultades en la capacidad de atención, la solución de problemas y las capacidades 
visoespaciales y unido a fluctuaciones en el funcionamiento cognitivo, alucinaciones 
visuales, parkinsonismo e hipersensibilidad al tratamiento con neurolépticos.
86
 Los 
pacientes con DLB también pueden presentar trastorno de conducta en sueño REM, 
disautonomía, delirios y alucinaciones en otras modalidades. En la actualidad, se acepta 
que el 60% de los casos de EA confirmados patológicamente pueden presentar grados 
variables de patología con LB.
85
 Por este motivo, los nuevos criterios diagnósticos no 
sólo consideran el cuadro clínico, la intensidad y la extensión de la patología con LB, 
sino también las lesiones de EA.
13
 Tanto en la EP como en la DLB se demuestra 
hipocaptación del transportador activo de dopamina (DAT, dopamine active transporter) 
en el estriado en la neuroimagen funcional, y este hallazgo puede ayudar a distinguir 
ambas entidades de la EA. La hipoperfusión o hipometabolismo occipital sin atrofia es 
otra marca distintiva (tabla 9).
13, 85
 
8.1.5.2 Enfermedad de Parkinson con demencia 
El cuadro de demencia asociado a la EP normalmente se inicia unos 10 años o 
más después de los primeros síntomas motores. Desde el punto de vista 
anatomopatológico y neuroquímico, la EP se caracteriza por la presencia de neuritas y LB 
en la sustancia negra y la pérdida de dopamina en el tracto nigroestriatal.
87
 El síndrome 
cognitivo es muy similar al de la DLB.
85
 Sin embargo, ambas entidades difieren en la 
edad al inicio de los síntomas, la secuencia de aparición de síntomas motores y cognitivos 
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y la respuesta a la levodopa. Para diferenciar ambas entidades, se ha establecido 
arbitrariamente el punto de corte de un año entre el comienzo de los síntomas motores y 
el de los síntomas cognitivos (tabla 9).
10
 Así, si el parkinsonismo precede a los déficits 
cognitivos en un año, o más, el paciente recibe el diagnóstico de EPD.
85
 
8.1.6 Degeneración lobular frontotemporal 
La degeneración lobular frontotemporal (DLFT) es una causa frecuente de 
demencia presenil. Se puede presentar como diversos síndromes clínicos, que incluyen 
trastornos motores o del lenguaje y alteraciones de conducta. La patología subyacente es 
impredecible y heterogénea, pero lo más característico es la pérdida de neuronas asociada 
a gliosis y espongiosis de distribución frontotemporal.
91, 92
 Pueden aparecer inclusiones 
positivas para tau con predominio de tres o cuatro repeticiones (3R y/o 4R), o inclusiones 
negativas para tau y positivas para ubiquitina.
92
 Cerca del 40% de los pacientes tienen 




La forma más frecuente de la demencia frontotemporal es la variante conductual 
(vcDFT). Esta forma de DLFT se caracteriza por un deterioro progresivo de la 
personalidad, el comportamiento social y la cognición y se relaciona con una 
degeneración de las regiones anteriores de los lóbulos frontales y temporales.
89, 90
 La 
tabla 10 resume los criterios internacionales publicados en 2011.
89
 Estos criterios tienen 
una sensibilidad alta (86%) para vcDFT
89
, aunque la naturaleza insidiosa de la 
enfermedad junto con la proliferación de síntomas psiquiátricos lleva con frecuencia a 
errores diagnósticos.
90
 La progresión es rápida y los pacientes fallecen unos 5,4 años 
después del diagnóstico, en promedio,
93
 con menor supervivencia si existe una 
enfermedad de motoneurona asociada.
94
 La excepción a este mal pronóstico son los casos 
de “fenocopia”, que no muestran alteraciones en neuroimagen ni deterioro progresivo.93 
Otra forma de presentación es la afasia primaria progresiva, en la que el déficit de 
lenguaje domina el cuadro. La afasia primaria progresiva puede tener otras causas, entre 
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ellas la EA, pero tanto la variante no fluente como la variante semántica se asocian a 
DLFT en el 70% de los casos.
90
 
8.1.7 Índice de masa corporal 
A lo largo del tiempo se han propuesto diversas medidas de peso corporal y 
adiposidad como marcadores del estado nutricional y del riesgo cardiovascular.
95, 96
 
Galileo Galilei fue el primero en describir la ley cuadrático-cúbica
97
, que establece que 
cuando una forma crece en tamaño, su volumen aumenta en mayor medida que su 
superficie. De hecho, el nuevo volumen es proporcional al cubo del multiplicador, y la 
nueva superficie es proporcional al cuadrado del mismo.
98
 Esto tiene implicaciones 
importantes en todas las áreas de la ciencia, y explica por qué los animales de mayor 
tamaño tienen huesos más gruesos de lo que se esperaría simplemente al aumentar el 
tamaño de sus parientes de menor envergadura.
99
 Siguiendo esta ley, y si la forma del 
cuerpo no cambiase, al modificarse el tamaño el peso sería proporcional a la estatura 
elevada a la tercera potencia, tal como se representa en el índice de Rohrer  (W/H3, 
donde W=peso y H=altura).
96
 El índice ponderal de Livi aplicó este concepto a 
poblaciones pediátricas, y se calcula como la raíz cúbica del peso dividida por la 
estatura.
96
 Las ratios cúbicas entre peso y estatura son válidas para organismos con 
escalas isométricas, en las que las proporciones del cuerpo no varían al cambiar de 
tamaño. Sin embargo, los mamíferos presentan proporciones alométricas: las 




Quételet comprendió estos problemas en 1842.
102
 Observó que la ley cuadrático-
cúbica se mantiene sólo en el primer año de vida y que el incremento ulterior de peso en 
la infancia es menor al esperado. Comprobó que un exponente de 3 representa el 
crecimiento de los recién nacidos y lactantes, un exponente de 2 el de los niños, y un 
exponente de 2,5 el de los adultos. Sin embargo, finalmente propuso una ratio 
homogénea con el peso en el numerador y la estatura al cuadrado en el denominador, que 
se ha convertido en el índice peso-estatura de mayor difusión. 







(IMC) corporal masa de Índice   
En 1972, Keys et al
96
 sugirieron que esta era la fórmula que mejor se 
correlacionaba con medidas de pliegue adiposo y densidad corporal, y la llamaron índice 
de masa corporal (IMC). Desde entonces, el IMC se ha convertido en una medida básica 
para evaluar el estatus nutricional,
103, 185
 y para emitir recomendaciones de salud.
95
 Es 
fácil de obtener y fácilmente reproducible.
95
 Además su asociación con la morbilidad de 
la población, especialmente la morbilidad cardiovascular, es bien conocida desde los años 
70.
104, 105
 La OMS usa el IMC para clasificar a los adultos en bajo peso, peso normal y 
obesidad. Los puntos de corte para estas categorías se pueden ver en la tabla 11. 
En realidad el IMC no aporta información sobre la composición del cuerpo. Esta 
limitación es de particular trascendencia en los atletas, cuya ratio músculo-grasa es 
especialmente alta, pero la composición corporal también cambia entre sexos, edades y 
grupos étnicos.
106, 107
 El IMC no distingue entre grasa y masa muscular, y aporta aún 
menos información sobre la distribución de dicha grasa. Dado que la grasa de 
distribución central es la más importante para el riesgo cardiovascular, el IMC podría no 
ser una medida óptima del riesgo asociado al aumento ponderal.
108, 109, 111
 
Las técnicas más precisas para medir la composición grasa del cuerpo son también 
las más sofisticadas.
96
 En la actualidad, la tomografía computarizada (TC) y la resonancia 
magnética (RM) son las más precisas.
110
 Sin embargo, son técnicas costosas, que no 
tienen gran cabida fuera de protocolos de investigación. La imagen por energía dual de 
absorción de rayos X (dual-energy X-ray absorptiometry, DXA) es una alternativa válida, 
con un margen de error, en comparación con la RM, de un 3%.112 La tabla 12 resume las 
ventajas e inconvenientes de distintos métodos para medir adiposidad, entre las que se 





No obstante, el aspecto fundamental de un índice de adiposidad es su grado de 
asociación con la morbimortalidad de la población. Sin ser perfecto, el IMC ha 
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demostrado una correlación robusta con el riesgo cardiovascular y la mortalidad en 
general.
107, 122, 124, 125, 255
 El IMC muestra una correlación muy alta con la circunferencia 
abdominal y la grasa subcutánea.
126
 También se correlaciona con un gran número de 
parámetros cardiovasculares y el porcentaje de grasa corporal.
107
 
Más allá de estas asociaciones, la popularidad del IMC justifica también su uso. 
Las medidas de peso y estatura son fácilmente accesibles y, posiblemente, las únicas que 
pueden ser autoadministradas con precisión. Además, la mayoría de las personas conocen 
y comprenden su IMC, y esta circunstancia hace del IMC en una herramienta muy útil en 
la educación sanitaria. 
8.1.8 Epidemiología de la demencia 
Se estima que la demencia afecta entre el 5 y el 7% de la población por encima de 
los 60 años,
128
 y que la prevalencia asciende hasta el 45% en la población de más de 85 
años.
129
 La población mundial está experimentando un aumento progresivo del número 
total de ancianos y del porcentaje de población envejecida, especialmente en naciones en 
vías de desarrollo.
128
 China, India y Latinoamérica, en particular, pueden experimentar 
transformaciones demográficas drásticas en los próximos años. La prevalencia de la 
demencia aumenta con la edad, multiplicándose por 2 cada 5,5 a 7 años. Así, el número 
de personas afectadas por demencia se estimó en 24,3 millones en 2005,
130
 35,6 millones 
en 2010,
128
 y se calcula que se duplicará para el 2025.
128
  
Estos cálculos asumen que no habrá cambios en la incidencia de la demencia.
131
 
Aunque la prevalencia global esté en aumento, es posible que ciertos grupos y zonas 
experimenten reducciones en la incidencia. En ese caso, estudiar estas poblaciones 
aportaría claves críticas en la lucha contra esta dolencia. La investigación sobre cambios 
seculares en la incidencia de demencia es muy compleja desde el punto de vista 
metodológico, dados los largos periodos de tiempo que separan distintas cohortes y los 
cambios que se han producido en los criterios diagnósticos.
131
  Es probable que la 
detección de demencia cada vez sea más precoz, y que se esté extendiendo a pacientes 
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con otras comorbilidades. Algunos estudios describen estabilidad en la prevalencia de 
demencia,
132, 133
 mientras que otros proponen que hay un descenso en la incidencia.
131
   
Los cambios en estimaciones de prevalencia deben relacionarse con los cambios 
en supervivencia tras el diagnóstico: así, si la supervivencia aumenta pero la prevalencia 
se mantiene estaremos ante un descenso de incidencia. Un estudio reciente comparó dos 
cohortes transversales en el área de Estocolmo, Suecia, separadas por intervalos de 20 
años, pero diagnosticadas con los mismos criterios.
131
 En comparación con la población 
estudiada en los años 80, la cohorte más reciente tenía una edad media más alta, más años 
de escolaridad y menor proporción de mujeres. Además, presentaban puntuaciones más 
altas en la escala MMSE. La prevalencia estandarizada por edad y sexo no varió entre 
cohortes. Después de controlar por año de nacimiento, la cohorte más reciente presentó 
un OR menor de diagnóstico de demencia, y este riesgo se vio particularmente reducido 
entre los varones. Ambas cohortes tuvieron seguimiento: la cohorte del 2001 presentó 
menor mortalidad para todos los participantes y también para el subgrupo de demencia. 
Esto implica que la incidencia de demencia está disminuyendo en la región
131
. 
Otro estudio en dos fases que se llevó a cabo en Zaragoza describió una 
prevalencia estable en dos cohortes examinadas en los años 90 y 00.
134
 La prevalencia 
ajustada por edad entre los hombres había bajado en la cohorte más reciente, mientras que 
la mortalidad general de la región se había reducido. Si se asume que la mortalidad 
también se redujo entre las personas con demencia, esto sugeriría que hubo un descenso 
de incidencia entre las dos cohortes.
134
 La primera cohorte tuvo seguimiento y se 
disponen de cálculos de incidencia, que fueron 8,6/1 000 personas-año, de las cuales  
5,4/1 000 personas-año sufrieron EA. Hasta que se publiquen los seguimientos de la 
segunda cohorte, estos estudios solo pueden ofrecer medidas indirectas en cambios de 
incidencia. 
Esta disminución aparente en la incidencia podría responder a mejoras en el 
manejo del riesgo cardiovascular. Es importante señalar que tanto el estudio de 
Estocolmo como el de Zaragoza encontraron reducción de riesgo entre los varones.
131, 134
 
VERSIÓN REDUCIDA EN CASTELLANO 
111 
 
Los esfuerzos iniciales en el tratamiento del riesgo cardiovascular en los años 70 y 80 se 
centraron en los hombres, que entonces presentaban las incidencias más altas de estas 
enfermedades.
136
 Es posible que los factores de riesgo cardiovascular hayan estado 
infradiagnosticados e infratratados en las mujeres durante una parte importante de las tres 
últimas décadas.
136
 El interés reciente por la salud cardiovascular de las mujeres quizás 
haya contribuido a cambiar esta tendencia. Una mejor atención hacia la salud 
cardiovascular podría acompañarse de una reducción en la incidencia de demencia, 
también entre las mujeres. 
Recientemente se ha descrito una asociación inversa entre demencia y riesgo de 
neoplasia.
137
 Incluso tumores relativamente benignos como los carcinomas de piel no 
melanocíticos se asocian a una reducción del riesgo de demencia.
138
 Tanto el cáncer como 
la demencia se asocian a la edad avanzada, y podrían representar distintos caminos 
patológicos en la forma en la que el cuerpo combate el envejecimiento.  
8.1.9 Mortalidad en la demencia 
Se sabe que las personas con demencia tienen ven reducida su supervivencia, pero 
existe controversia sobre los factores que pueden influir en su pronóstico.
142-150
 La edad, 
el sexo, el nivel cognitivo en el momento del diagnóstico, la comorbilidad, el tipo de 
demencia y el lugar de residencia han sido señalados como factores que pudieran 
contribuir a ese pronóstico.  
8.1.9.1 Edad y mortalidad 
La edad avanzada aumenta la mortalidad tras un diagnóstico de demencia,
143, 150, 
153-155
  aunque los años de vida perdidos son lógicamente superiores en sujetos jóvenes.
142
 
Las enfermedades que causan demencia no son las mismas en edades tempranas y tardías, 
lo que debe tenerse en cuenta cuando se atribuye la mortalidad a la edad.
156
 La DFT, que 
aparece típicamente en edades más tempranas,
146, 156
 también es una de las que presenta 
mayor mortalidad, especialmente si se asocia a enfermedad de motoneurona.
159
 Las 
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comorbilidades como la diabetes pueden asociarse a un inicio más temprano, y también 
ser causas independientes de mortalidad.
160
  
8.1.9.2 Género y mortalidad 
La mayoría de los estudios publicados encuentran una menor mortalidad de la 
demencia en mujeres.
143, 146, 150, 153, 154, 157, 161-164
 Existen excepciones a esta tendencia,
155, 
165
 y algunos autores encuentran que el efecto del sexo depende del tipo de demencia.
142, 
158, 166, 167




 tendrían peor pronóstico que 
los hombres. En todo caso, dado que tienen un mayor riesgo de demencia y una mayor 
supervivencia global, las mujeres presentan una mayor proporción de muertes por 
demencia que los hombres.
150, 153, 157
  Al tener menor mortalidad basal, el OR de 
mortalidad de las mujeres con demencia comparadas con controles sin demencia será más 
alto que en los hombres, aunque presenten menores tasas de mortalidad cruda.
158
  
8.1.9.3 Funcionamiento cognitivo y mortalidad.  
El efecto del funcionamiento cognitivo basal está poco aclarado, con unos 
estudios que encuentran incremento de mortalidad con déficit cognitivo avanzado,
157
 pero 
no moderado, otros detectan una relación con el grado de deterioro cognitivo incluso en 
estadios leves,
169, 170
 y aún otros que no encuentran ninguna asociación con el nivel 
cognitivo basal
154
 ni con la velocidad de deterioro tras el diagnóstico.
163
  
8.1.9.4 Tipo de demencia y mortalidad 
La mayoría de los estudios describen menor mortalidad en la EA,
142, 146, 150
 o no 
encuentran diferencias con otras demencias
151, 159, 167, 168, 174
. Los estudios previos se han 
centrado en EA y DV, 
150, 161, 166, 169, 177, 178
 pero hay pocas comparaciones directas con un 
espectro más amplio de diagnósticos.
142
 Cuando los estudios examinan EA, DV y 
demencia mixta, en ocasiones encuentran que esta última presenta un riesgo intermedio 
entre las dos primeras.
166
 Los estudios que comparan EA y DLB suelen encontrar mayor 





 incluso después de controlar por nivel cognitivo.
165
 Para otras 
comparaciones existen menos evidencias. La DLB podría ser más letal que la EPD,
171
 que 
a su vez presenta mayor mortalidad que la EP o la población sana.
181
 La DFT parece tener 
peor pronóstico que otras demencias.
146, 183
 
8.1.9.5 Índice de masa corporal y mortalidad 
El índice de masa corporal predice mortalidad.
 95, 185
 La OMS define como normal 




 que se asocia a menor mortalidad en adultos jóvenes.
95
 
El rango óptimo para personas mayores está menos claro, y se han propuesto puntos de 
corte de 19 y 23 como guías de screening nutricional en estas poblaciones.
185-188
 Muchos 
estudios proponen que el IMC óptimo para una menor mortalidad en edades avanzadas 





o incluso en los primeros tramos de la obesidad (por encima de 30 kg/m
2
). Este hallazgo 
del sobrepeso como factor protector en personas mayores se ha denominado “paradoja de 
la obesidad”192 y es el equivalente de la “hipótesis de epidemiología inversa” descrita 





8.1.10 SveDem: Registro Nacional Sueco de Demencia  
El registro SveDem se creó en 2007 a partir de una iniciativa de investigadores del 
Swedish Brain Power, con el apoyo de la asociación de autoridades locales y regiones 
(Sveriges Kommuner och Landsting).
212-216
 Su objetivo principal es evaluar y mejorar la 
calidad del cuidado de los pacientes con demencia en toda Suecia, y garantizar su 
equidad.
217
 Los diagnósticos de novo se incluyen en un registro informático, junto con 
datos sobre el proceso diagnóstico,
214, 215, 218
 el tratamiento y el cuidado de cada 
paciente.
213
 Los pacientes y los datos incluidos proceden tanto de centros de atención 
primaria como de unidades especializadas.
212
 
Los pacientes se incluyen en el momento en que se establece un diagnóstico de 
demencia, según los criterios de la ICD-10, y a partir de ahí se programa un seguimiento 





 La demencia se clasifica en EA, DV, mixta, DLB, EPD, DFT, demencia no 
especificada y otras demencias (incluyendo cualquier otra causa conocida de demencia no 
incluida en las categorías previas).
213
 Además se recogen edad, sexo, MMSE basal, si el 
paciente vive solo o acompañado, lugar de residencia (en casa o en una institución), si el 
paciente trabaja, conduce o tiene permiso de armas, y datos biométricos como estatura y 
peso. También se incluye el número de fármacos que el paciente consume de forma 
regular.
222
 Esta variable se usa como un indicador de comorbilidad porque ha demostrado 
ser mejor que otros indicadores farmacológicos en predecir morbimortalidad.
223
 Se 
anotan los tratamientos con antidepresivos, ansiolíticos, hipnóticos, neurolépticos, 
fármacos de acción cardiovascular, y fármacos específicos para la demencia como los 
inhibidores de la acetilcolina y antagonistas de  N-metil-D-aspartato (NMDA).
213, 215, 217
 
El Comité Regional de Ética de Estocolmo aprobó la creación y gestión de 
SveDem. En el momento del diagnóstico se informa a pacientes y allegados de la 
existencia del registro, y de que pueden denegar su consentimiento a participar. Existen 
procedimientos para retirar pacientes del registro. Los datos se archivan de forma 
anónima y se procesan en el Uppsala Clinical Trial Center.
213
 Un coordinador examina 
de forma aleatoria un 10% de las historias clínicas, y valida los datos incluidos en 
SveDem. Cada unidad que participa en el registro puede acceder con facilidad a 
estadísticas on-line y comparar sus procesos diagnósticos con los de otras unidades.  
En 2010, el Ministerio de Sanidad sueco publicó recomendaciones para el 
diagnóstico y atención a personas con demencia.
228
 El proceso diagnóstico básico 
recomendado en todos los casos incluye una historia clínica estructurada, una entrevista 
con un informador válido, una evaluación física y psicológica, un estudio cognitivo que 
como mínimo incluya MMSE y test del reloj, una prueba de neuroimagen y un análisis de 
sangre que incluya calcio, homocisteína y función tiroidea.
228
 Además, estas 
recomendaciones enfatizan la importancia del diagnóstico temprano y de ofrecer una 
atención integral a los pacientes con demencia. En Suecia, muchos pacientes son 
diagnosticados y tratados en centros de atención primaria. En el registro SveDem se han 
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detectado algunas diferencias entre los procesos diagnósticos de las cohortes de atención 




8.2.1 Estudio I 
1. Describir y comparar las características basales de los sujetos con quejas 
cognitivas subjetivas (QCS), deterioro cognitivo leve (DCL) y demencia 
tipo Alzheimer (EA) diagnosticados en una unidad de memoria.  
2. Determinar qué factores contribuyen a los diagnósticos de QCS, DCL y 
EA. 
8.2.2 Estudio II 
1. Describir las características basales de una gran cohorte nacional de 
pacientes registrados en Suecia con diagnóstico de novo de demencia.  
2. Determinar el riesgo de mortalidad relativo de los distintos tipos de 
demencia.  
3. Analizar el riesgo de mortalidad en relación con la edad, el sexo, el 
funcionamiento cognitivo basal, la institucionalización, vivir solo o  
acompañado y el número de fármacos consumidos en los pacientes con 
demencia.  
8.2.3 Estudio III 
1. Encontrar el rango de índice de masa corporal (IMC) que se corresponde 
con menor riesgo de mortalidad en pacientes con demencia. 
2. Determinar si el rango de IMC asociado a menor mortalidad difiere en 
hombres y mujeres y en función de la edad.  




8.3.1 Estudio I 
1. Los individuos con quejas cognitivas subjetivas (QCS) difieren en varios 
aspectos de aquellos con deterioro cognitivo leve (DCL) o enfermedad de 
Alzheimer (EA).  
2. Los sujetos con QCS son más jóvenes y tienen mejor rendimiento 
cognitivo y menos factores de riesgo cardiovascular que los pacientes con 
DCL o EA.  
3. La prevalencia de enfermedades psiquiátricas es mayor en los sujetos con 
QCS. 
4. Los sujetos con QCS tienen menos atrofia temporal medial que los 
pacientes con DCL o EA. 
5. La prevalencia de apolipoproteína E4 (ApoE4) es menor en los individuos 
con QCS que en los pacientes con DCL o EA. 
6. El patrón de biomarcadores típico de EA en el líquido cefalorraquídeo es 
menos frecuente en el grupo con QCS. 
8.3.2 Estudio II 
1. La EA tiene menor riesgo de mortalidad que otros tipos de demencia. 
2. La edad avanzada aumenta el riesgo de mortalidad en ambos sexos y en 
todos los tipos de demencia.  
3. El sexo masculino se asocia a un incremento de mortalidad.  
4. Los niveles cognitivos más bajos, según la puntuación del Mini Mental 
State Examination (MMSE), se asocian a un riesgo de mortalidad más 
elevado.  
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5. La mayor comorbilidad, medida a través del número habitual de fármacos 
consumidos por el paciente en el momento del diagnóstico, se asocia a 
mayor riesgo de mortalidad.  
6. La institucionalización se asocia a mayor riesgo de mortalidad. 
7. Vivir solo se asocia a mayor riesgo de mortalidad.  
8.3.3 Estudio III  
1. La relación entre el índice de masa corporal (IMC) y el riesgo de 
mortalidad en pacientes con demencia sigue una distribución en U, con el 
punto de menor riesgo situado en el IMC correspondiente a la categoría 
normal o de sobrepeso. 
2. Con IMC superiores a ≥30 kg/m2, aparecerá un exceso de riesgo de 
mortalidad. 
3. El IMC asociado con menor riesgo de mortalidad es distinto en hombres y 
en mujeres.  
8.4 MÉTODOS 
8.4.1 Estudio I 
El primer estudio I utilizó los registros de la base de datos del Karolinska Memory 
Clinic. Los métodos empleados se describen con detalle en la sección correspondiente del 
artículo. Lo que aquí se recoge es un breve resumen.  
8.4.1.1 Karolinska Memory Clinic 
La Karolinska Memory Clinic forma parte del Departamento de Geriatría del 
Hospital Universitario Karolinska, Huddinge, y atiende unos 450 pacientes nuevos al año. 
La valoración de los trastornos cognitivos se lleva a cabo dentro de un marco clínico que 
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incluye geriatras, psiquiatras, neurólogos, neuropsicólogos, enfermeras, terapeutas 
ocupacionales y logopedas. Con frecuencia el proceso diagnóstico se completa con 
distintas pruebas de neuroimagen y análisis del LCR.  
Todos los pacientes son evaluados mediante una entrevista, una exploración física 
y un examen cognitivo con pruebas de screening y con otros tests en caso de ser 
necesarios, incluyendo partes de la Wechsler Adult Intelligence Scale, Revised (WAIS-
R),
232




 y/o fluencia verbal (Verbal 
Fluency test, FAS).
236
 El diagnóstico sigue los estándares de buena práctica clínica, y lo 
realiza un equipo multidisciplinario haciendo uso de los criterios diagnósticos vigentes 
para cada entidad clínica. El estudio que nos ocupa recoge datos de pacientes evaluados 
entre 2007 y 2009. Durante este periodo, el diagnóstico de QCS siguió la clasificación de 
la ICD-10 (“Z03.3 = observación para un posible trastorno neuro-orgánico”)  en los casos 
en los que los pacientes describieron quejas cognitivas que no pudieron objetivarse en los 
tests.
5
 El diagnóstico de DCL siguió los criterios de consenso sobre DCL.
237
 Por su parte, 
el diagnóstico de EA se basó en los criterios de la ICD-10/DSM-IV para demencia y en 
los criterios de la NINCDS-ADRDA.
5, 238, 239
  
En el estudio I se analizaron de forma retrospectiva los 1 154 pacientes evaluados 
en la Karolinska Memory Clinic entre 2007 y 2009. Se excluyeron pacientes con 
diagnósticos distintos de EA, DCL o QCS. También fueron excluidos del estudio los 
pacientes con comorbilidades graves que ponían en entredicho el diagnóstico (tales como 
tumores cerebrales, epilepsia concurrente o metástasis). No se excluyeron pacientes con 
afecciones comunes, como depresión, ansiedad, insuficiencia cardiaca o insuficiencia 
renal. Finalmente, se incluyeron un total de 993 pacientes. El comité ético de Estocolmo 
aprobó este estudio. 
Todos los pacientes habían sido estudiados con pruebas de neuroimagen y en 560 
casos se había cuantificado la atrofia del lóbulo temporal de forma ciega, mediante la 
escala Scheltens.
240
 En 943 pacientes se analizó la presencia de lesiones de sustancia 
blanca en tomografía axial computarizada (TC) o en secuencias FLAIR de resonancia 





 La presencia de atrofia central se evaluó en 980 pacientes (para más 
detalles, ver la sección de neuroimagen en el apartado de métodos del artículo I). 
Los marcadores de EA del LCR se determinaron en 744 pacientes, y los puntos de 
corte se fijaron en 400 ng/l, o más, para tau total (t-tau), 80 ng/l, o más, para tau 
fosforilada (p-tau) y 450 ng/l, o menos, para beta amiloide de 42 residuos (Aβ 42). El 
genotipo de la apolipoproteina E (ApoE) se analizó en 325 pacientes. La exploración 
neuropsicológica se describe en la sección de métodos del artículo I. En resumen, se 
empleó la escala Mini-Mental State Examination (MMSE), además de otros tests 
seleccionados según el perfil clínico del paciente.
233-235
 Se registraron asimismo los 
síntomas psicológicos y conductuales asociados a demencia (BPSD, behavioral and 
psychological symptoms associated with dementia). La presencia de depresión se 
estableció mediante los datos recogidos en la entrevista clínica y la escala Cornell de 
depresión en demencia, con un punto de corte de 8.
242
  
8.4.1.2 Métodos estadísticos 
Las diferencias entre grupos para variables discretas se analizaron con el test de 
χ2. Para variables cuantitativas se presentan las medias en cada grupo (EA, DCL y QSC). 
Las medias de los grupos EA y DCL se compararon con los QSC. En los casos en los que 
las variables no siguieron una distribución normal, se usaron valores p obtenidos de 
regresión logística binaria.  
A continuación se analizaron las similitudes entre cada paciente de la base de 
datos y un “tipo EA” definido por el grupo EA de la muestra. Para ello se creó un modelo 
estadístico en tres pasos. En primer lugar, se probó un gran número de variables, para 
determinar qué combinación clasificaba mejor a los pacientes de la muestra en EA/no EA 
(donde “no EA” incluyó pacientes con QCS y DCL). Las mejores variables fueron la 
edad, el sexo, la puntuación en el MMSE, el cociente Aβ42/t-tau y el valor de p-tau, de 
modo que el modelo de regresión logística con esa combinación de variables clasificó 
correctamente al 94,9% de la muestra. En la segunda fase, el modelo se aplicó a cada 
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paciente, asignando en cada instancia una probabilidad de ser más “similar a EA” 
(llamada “probabilidad EA” de aquí en adelante). Estas probabilidades se almacenaron 
como una variable y se usaron como variable resultado en la tercera fase. En este tercer 
paso, se analizaron modelos independientes para DCL y QCS usando la probabilidad EA 
como resultado. Así, se fueron introduciendo las variables clínicas una a una en los 
modelos, en un intento de identificar cuáles de ellas aumentaban la probabilidad de los 
pacientes de ser clasificados como EA por el modelo. La sección de métodos del artículo 
I contiene más detalles.  
8.4.2 Estudios II y III 
Lo que sigue es un breve resumen de los métodos empleados en los estudios II y 
III. Para más información, se remite al lector a las secciones de métodos de los artículos 
correspondientes.  
8.4.2.1 El registro SveDem de demencia 
Los estudios II y III emplean datos de SveDem – el registro sueco de demencia –  
que recoge pacientes con diagnósticos de demencia de novo a nivel nacional. Estos dos 
estudios incluyen pacientes registrados entre 2008 y 2011 en unidades de memoria. Se 
excluyeron los pacientes registrados desde los centros de atención primaria, dado que 
estos centros se unieron más tarde y de forma más dispersa, y que además muestran 
diferencias en los procedimientos diagnósticos con respecto a los centros de atención 
especializada (tabla 13).
214
 De un total de 15 224 pacientes atendidos en centros 
especializados, en el estudio II se excluyeron 15 pacientes que tenían datos incompletos 
en los campos de diagnóstico, edad, sexo o supervivencia (0.1%), de forma que quedaron 
15 209 pacientes para los análisis. En el estudio III se requirieron, además, datos 
completos para el índice de masa corporal (IMC), quedando 11 398 pacientes para el 
análisis. 
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En ambos estudios, se incluyeron como variables el tipo de demencia, el sexo, la 
puntuación basal en el MMSE, la situación de corresidencia (vivir solo o acompañado), el 
lugar de residencia (en casa, en una institución, o en una institución para personas con 





). Además se incluyeron de forma específica los 
fármacos de acción cardiovascular, antidepresivos, ansiolíticos, neurolépticos, hipnóticos, 
inhibidores de la acetilcolinesterasa y antagonistas de NMDA. El IMC se analizó como 
posible factor de confusión en el estudio II y como variable principal en el estudio III.  
8.4.2.2 Estudio II 
Se usaron regresiones de Cox para identificar los factores asociados a aumento de 
riesgo de mortalidad. Los resultados se presentan como cocientes de riesgo (hazard 
ratios—HR) e intervalos de confianza del 95%. La suposición de proporcionalidad de 
riesgos se comprobó con curvas de Kaplan-Meier y variables tiempo-dependientes. En 
los casos en los que este supuesto no se cumplía, se calcularon los HR al principio del 
periodo de observación y al cabo de 1 000 días. Se calcularon las medias y desviaciones 
estándar (DE) para la estadística descriptiva.  
Se crearon modelos crudos (sin ajustar), ajustados por edad y sexo, y ajustados 
por edad, sexo y medicación. El modelo final se ajustó por sexo, edad (incluida como 
variable categórica con puntos de corte en 65, 75 y 85), número de fármacos (en 
categorías 0-1, 2-5, 6-9 y 10 o más) y MMSE (categorías según “falta”, “paciente no 
valorable”, MMSE 0-9, 10-19, 20 a 24, y 25 o más). Además, el modelo incluyó lugar de 
residencia (vivir en casa o en una institución), y si el paciente vivía o no solo. El 
diagnóstico de demencia se incluyó en el modelo final siguiendo ocho categorías: EA, 
mixta, DV, DLB, DFT, EPD, otras causas de demencia, y demencia no especificada.  
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8.4.2.3 Estudio III 
Los métodos estadísticos fueron similares a los del estudio II. Para más detalles se 
remite al lector a la sección de métodos del artículo III. Aquí sigue un resumen de las 
particularidades de este estudio.  
El IMC se exploró usando las categorías de la OMS: bajo peso (IMC debajo de 
18,5 kg/m
2
), normal (18.5 a 24,9 kg/m
2
), sobrepeso (25 a 29,9 kg/m
2
), y obesidad (por 
encima de 30 kg/m
2
). Dado que en estudios previos se había encontrado un exceso de 
mortalidad con IMC en rango normal en personas mayores,
185-187
 se incluyó otra 
categoría siguiendo las guías de la OMS (tabla 11) para definir un grupo de individuos 
con peso normal pero “delgados” (desde 18,5 a 22,9). 
Se emplearon variables de representación lineal por tramos (splines) para ajustar 
mejor la relación entre IMC y mortalidad. Los splines son variables concatenadas 
separadas por puntos de corte (nudos) que el investigador elige. En este caso, se 
emplearon splines lineares, lo que implica que se trató el IMC como una variable 
continua y que la relación entre IMC y mortalidad se consideró lineal dentro de cada 
segmento. Se probaron distintos nudos y también se realizó estratificación por grupos de 
edad y sexo. 
8.4.2.4 Consideraciones éticas 
El Comité Ético Regional de Estocolmo aprobó la creación y gestión de datos de 
SveDem. Los estudios basados en SveDem se aprobaron por los comités regionales de 
Estocolmo (número de permiso 2009/209-31). En el momento del diagnóstico, los 
pacientes y familiares reciben información oral y/o por escrito sobre SveDem y pueden 
negarse a participar. Es posible solicitar la retirada de un paciente de SveDem. Para más 
información sobre SveDem, se puede consultar la página web www.svedem.se. En la 
figura 1 de la versión en inglés se muestra la nota informativa que se exhibe en las 
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unidades que registran pacientes en SveDem. Los datos se archivan de forma anónima y 
se analizan de manera remota.  
8.5 RESULTADOS 
8.5.1 Estudio I  
Los resultados aparecen detallados en al artículo I. Lo que sigue a continuación es 
un breve resumen.  
8.5.1.1 Estadística descriptiva 
En este estudio se incluyeron 433 sujetos con quejas cognitiva subjetiva (QCS), 
373 con deterioro cognitiva leve (DCL), y 187 con demencia tipo Alzheimer (EA). Las 
características de estos grupos se muestran en las tablas 1 a 4 del artículo I. Se 
encontraron diferencias demográficas y clínicas evidentes. En el grupo de QCS los 
sujetos incluidos fueron más jóvenes, tenían más años de escolaridad y mejor nivel 
cognitivo (según las puntuaciones del Mini-Mental State Examination, MMSE). Además 
entre los pacientes con QCS hubo mayor proporción de mujeres y  más antecedentes 
familiares de demencia. A cambio, los factores de riesgo cardiovascular fueron menos 
frecuentes en este grupo. La puntuación media en la escala de atrofia temporal en el 
grupo de QCS fue 0,98 en el lado derecho y 1,00 en el izquierdo, menor que en los 
grupos de DCL o EA. Los marcadores de líquido cefalorraquídeo con patrón de EA no 
fueron tan frecuentes en el grupo de QCS, y el porcentaje de pacientes con uno o más 
alelos  ApoE ε4 fue menor que en el grupo de EA, pero sin diferencias significativas con 
el grupo DCL. En los pacientes con QCS la puntuación media en la escala de Cornell de 
depresión en demencia fue 7,8 (desviación estándar 5,8), próxima al punto de corte de 8 
que se estableció como límite para depresión y por encima de la puntuación media del 
grupo con EA pero sin diferencias significativas con el grupo DCL (tabla 2 del artículo I)  
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8.5.1.2 Modelo de predicción estadístico 
Se desarrollaron dos modelos estadísticos para predecir qué características hacían 
a los pacientes DCL y QCS más parecidos al grupo DA en esta muestra (“probabilidad-
DA”). En la tabla 5 del artículo I se observan los resultados de estos modelos. La 
hipertensión arterial aumentaba en 7% el “probabilidad-DA”, mientras que no resultó 
significativo entre los DCL. El antecedente de ictus reducía el probabilidad-DA en el 
grupo DCL en un 26%. La puntuación de atrofia temporal aumentaba el probabilidad-DA 
en el grupo QCS pero lo reducía en el grupo DCL. Las lesiones de sustancia blanca 
(LSB) se asociaron a una reducción en DCL, pero a un aumento en SCI. 
8.5.2 Estudio II 
Los resultados detallados de este trabajo pueden verse en la sección 
correspondiente del artículo III. Se analizaron en total 15 209 pacientes, 59% fueron 
mujeres. La edad media fue 78,1 años (DE 8,2) y el MMSE medio 21,3 (DE 5,1). Pocos 
pacientes tenían demencia avanzada según MMSE (tabla 1; artículo II). 
La tabla 2 del artículo II muestra diferencias basales entre los distintos tipos de 
demencia. Un 37% de la muestra había sido diagnosticado de EA, y un 25% de demencia 
mixta. El seguimiento medio fue de 2,5 años con un total de 4 287 muertes observadas 
(114 muertes/1 000 persona-año; 95% CI 111 -117). En la tabla 1 se aprecian las tasas de 
mortalidad en función de las características basales. 
Las razones de riesgo (hazard ratio, HR) de mortalidad obtenidos de regresiones 
de Cox se muestran en la tabla 4 del artículo II. Se incluyeron variables tiempo-
dependientes para DCL, demencia no especificada y otras demencias dado que 
presentaban HR no proporcionales.  En análisis crudos y ajustados, los hombres 
presentaron mayor riesgo de mortalidad que las mujeres (tabla 4; artículo II). No hubo 
interacción entre MMSE y género, o entre género y tipo de demencia. Las diferencias 
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entre hombres y mujeres permanecieron al estratificar por tipo de demencia, aunque los 
resultados fueron no significativos para la DFT y la DLB (artículo II).  
En los análisis crudos, cada año de edad se asociaba a un exceso de riesgo del 8%. 
Tras ajustar el análisis, el riesgo aumentaba en cada categoría de edad: en comparación 
con los pacientes menores de 65, aquellos entre 75 y 84 años tenían un riesgo de 
mortalidad tres veces mayor, que se hacía seis veces mayor por encima de los 85 años 
(tabla 4; artículo II). 
Empleando al grupo de MMSE igual o superior a 25 como referencia, los 
pacientes con menor puntuación presentaron aumento de riesgo de muerte. Los pacientes 
que se consideraron “no evaluables” para MMSE presentaron el riesgo más alto (HR 
3,72, 95% CI 3,19-4,35). 
Vivir en una institución y tomar más medicación se asociaron a un aumento de 
riesgo. En cambio, vivir solo no se asoció a un aumento de riesgo estadísticamente 
significativo (tabla 4; artículo II). 
Tal como se puede observar en la figura 2 de la versión inglesa de esta tesis, las 
curvas Kaplan-Meier de supervivencia muestran que la EA tiene tasas de supervivencia 
mayores que otras demencias. En análisis Cox no ajustados, el HR más alto se asoció a 
DV (ver sección de resultados del artículo II). Después de ajustar por edad y sexo, la EPD 
fue la que presentó mayor riesgo. Cuando se introdujo el número de medicación en el 
modelo, la DFT pasó a ser la de mayor riesgo (ver figura y resultados del artículo II). 
En el modelo ajustado final, todos los otros tipos de demencia presentaron mayor 
riesgo que la DA, siendo la DFT la de mayor riesgo (HR 1,91; 95% CI 1,52-2,39). La 
demencia mixta presentó un riesgo intermedio entre la EA y la DV. 
En un análisis post-hoc se reanalizó toda la cohorte, incluyendo los pacientes 
registrados en centros de atención primaria entre los años 2007 y 2012, con un total de 
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28 704 pacientes. Como se puede comprobar en la tabla 14 (versión en inglés de esta 
tesis), los HR fueron muy similares a los obtenidos en la cohorte de unidades 
especializadas.  
8.5.3 Estudio III  
Los resultados detallados pueden verse en la sección correspondiente del artículo 
III. Aquí se incluye un breve resumen. El total de pacientes ascendió a 11 398, con un 
valor medio de IMC de 24,5 (DE 4,3). La tabla 2 del artículo III muestra las tasas de 
mortalidad de los distintos grupos de IMC.  
En los análisis de supervivencia de Cox, los IMC más altos se asociaron a menor 
riesgo de mortalidad. El grupo de IMC entre 18,5 y 22,9 se tomó como referencia. En 
comparación con este grupo, el grupo de IMC menor de 18,5 presentó mayor riesgo, 
mientras que los pacientes de más IMC presentaron un riesgo menor. El riesgo de 
mortalidad más bajo se observó en el grupo con IMC superior a 30 (HR 0,65; 0,57-0,74 
p<0.001). Al estratificar los análisis por sexos, el grupo de menor mortalidad 
correspondió a la categoría con obesidad en los hombres, y a la categoría con sobrepeso 
en las mujeres (tabla 3;  artículo III).  
Cuando se usaron splines de IMC, cada punto de aumento en la escala de IMC se 
asoció a un descenso en el riesgo de mortalidad hasta el valor de IMC de 29,9. Los 
resultados se muestran en la tabla 4 del artículo III. El riesgo de mortalidad descendió un 
11% por cada punto incrementado en el IMC para pacientes con IMC por debajo de 22, 
un 5% por punto para pacientes con IMC entre 22 y 25 y un 3% para pacientes entre 25 y 
29,9. Los resultados no fueron significativos en el tramo de IMC mayor de 30. Cuando se 
retiró el número de fármacos consumidos del modelo, apareció un aumento significativo 
del riesgo en el tramo de IMC mayor de 30 (HR 1,04; 95% CI 1,00-1,07).  
Los análisis con splines confirmaron diferencias entre los sexos: los varones 
presentaron reducciones significativas del riesgo con el aumento del IMC en los grupos 
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de menos de 18.5 y entre 25 y 30 kg/m
2
. En las mujeres, este menor riesgo fue 
significativo solo hasta el final del rango de la categoría normal (HR 0,94; CI 0,88 to 1,00 
tabla 5 y figura A; artículo III). 
8.6 DISCUSIÓN 
8.6.1 Estudio I 
En esta cohorte de la Karolinska Memory Clinic, los pacientes con QCS se 
diferenciaron de aquellos con DCL o EA. Los individuos con QCS eran más jóvenes,  
tenían menos factores de riesgo cardiovascular y sus puntuaciones del MMSE fueron más 
altas. Los biomarcadores en el LCR en este grupo presentaron, de media, niveles 
normales, y el alelo ApoE4 fue menos frecuente que en los pacientes con EA. Los 
pacientes con QCS refirieron con mayor frecuencia historia familiar de demencia y sus 
puntuaciones en la escala Cornell de depresión en demencia fueron más altas. 
Estas diferencias se podrían justificar por distintos factores. Los clínicos que 
diagnosticaron a estos pacientes tuvieron acceso a los resultados en LCR y ApoE durante 
el proceso diagnóstico, de modo que la circularidad del proceso podría haber influido en 
los diagnósticos. Tradicionalmente, se han atribuido las QCS a cuadros de ansiedad o 
depresión, así que la mayor prevalencia de historia familiar y mayor puntuación en la 
escala Cornell podrían encajar en una teoría psicosomática de las QCS. Nuestro estudio 
no distingue entre síntomas depresivos y un diagnóstico formal de depresión, pero 
algunos estudios han detectado estos síntomas en el 8 y el 16% de los pacientes 
mayores.
243
 La depresión en edades avanzadas es particularmente resistente al 
tratamiento, y se asocia a déficits en tests neuropsicológicos. La velocidad de 
procesamiento y la función ejecutiva parecen particularmente afectadas, lo que conlleva 
déficits mnésicos secundarios y quejas cognitivas. 
244
  En nuestro estudio, los pacientes 
con QCS se diferenciaron en cuanto a la presencia de síntomas depresivos solo de los 
pacientes con EA y no del grupo con DCL. Esto podría indicar que los pacientes con QCS 
y DCL experimentan depresión como síntoma reactivo ante la pérdida cognitiva,  
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demostrando que tienen conciencia de enfermedad que podría en la fase de demencia de 
la EA. Otra posible explicación es que los síntomas de depresión fueran más difíciles de 
identificar en pacientes con un deterioro más avanzado.  
La interrelación entre la depresión y la demencia es compleja. La depresión en las 
edades medias de la vida se asocia a un incremento del riesgo de demencia en años 
posteriores. Por otra parte, la depresión causa déficits cognitivos y, aunque estos 
presentan un patrón más “subcortical” que la EA, el diagnóstico diferencial puede ser 
difícil. Para complicar más aún las cosas, los déficits cognitivos asociados a depresión a 
veces persisten una vez resuelto el episodio depresivo.
244
 El ánimo bajo, como síntoma, 
se asocia a riesgo futuro de DCL de tipo amnésico, y parece interaccionar de forma 
sinérgica con la presencia de ApoE4.
245
 Dos estudios recientes contribuyen a aclarar 
algunas cuestiones.
246
 Ambos se llevaron a cabo en la  Karolinska Memory Clinic y 
presentan cohortes similares a la nuestra. El primero comparó el perfil del LCR entre 
sujetos mayores deprimidos con o sin EA.
243, 246
 Este estudio no encontró relación entre 
biomarcadores de EA y depresión. Sin embargo, apareció una correlación negativa entre 
síntomas depresivos y los niveles de t-tau) y p-tau. Los pacientes deprimidos eran más 
jóvenes en este estudio, aunque presentaron puntuaciones análogas en el MMSE.
246
 Tal 
vez en esa cohorte la depresión podría llevar a un diagnóstico más temprano de demencia 
a través de un aumento de síntomas disejecutivos que el MMSE tendría difícil 
identificar.
247
 Este supuesto podría explicar la edad media más baja y los menores niveles 
de tau en los sujetos deprimidos. 
El otro estudio analizó el grado de atrofia del lóbulo temporal medial en pacientes 
con QCS, DCL y EA, comparando grupos de pacientes deprimidos y no deprimidos.
243
 
En la EA los síntomas depresivos se asociaron a menor atrofia temporal, mientras que en 
pacientes con QCS se asociaron a menores volúmenes del hipocampo. Estos hallazgos 
podrían indicar que los dos grupos se diferencian en los mecanismos que median la 
asociación entre el funcionamiento cognitivo y la depresión.
243
  Una posibilidad es que, 
entre los pacientes con EA, la depresión empeore los síntomas cognitivos ocasionando un 
diagnóstico más temprano. Otra posibilidad es que la depresión requiera conciencia de 
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enfermedad, que desaparece en pacientes con EA cuando progresa la atrofia temporal. En 
las QCS, la depresión podría ser una manifestación del proceso neurodegenerativo que 
tiene lugar en la EA preclínica. Sin duda, estos dos estudios plantean cuestiones 
intrigantes sobre la interrelación entre depresión y cognición en los distintos estadios del 
continuum de la EA.   
La segunda parte de nuestro estudio se basó en un modelo estadístico creado para 
analizar la probabilidad de presentar un perfil clínico de EA en los participantes de 
nuestra base de datos. Este modelo se creó en tres pasos: primero, se generó un modelo 
de regresión logística, que clasificó correctamente a los pacientes en EA/no EA según se 
definió por su diagnóstico clínico. El mejor modelo para esta clasificación resultó ser 
aquel que contenía edad, sexo, MMSE, cociente Aβ42/t-tau y p-tau. En el segundo paso 
se aplicó este modelo a cada individuo de la muestra, asignando a cada uno una 
probabilidad de tener EA. Esta probabilidad se denominó “probabilidad de EA” y se usó 
como variable resultado en el último paso. En este tercer paso, todas las variables se 
introdujeron una a una para determinar cuáles se asociaban a un aumento de la 
“probabilidad de EA” dentro de este modelo.  
Nuestro estudio incluyó una cuantificación de la atrofia temporal medial por parte 
de un observador experimentado que no tuvo acceso a datos clínicos. Como cabía 
esperar, los pacientes con QCS tendían a presentar valores normales. Dentro del modelo 
estadístico, las puntuaciones altas en la escala de atrofia temporal se asociaron a un 
aumento de la probabilidad de EA en el grupo con QCS. En el grupo con DCL se observó 
una relación opuesta: cuanto mayor fue el grado de atrofia, menor fue la probabilidad de 
EA. Dado que los clínicos tuvieron acceso a la neuroimagen (aunque no a las 
puntuaciones) este resultado se puede, en parte, achacar a la circularidad ya mencionada. 
Los pacientes del grupo de DCL que presentaban atrofia temporal probablemente 
presentaron otras características atípicas para EA; de otro modo, habrían sido 
diagnosticados de EA. Dado que los pacientes con QCS clínicamente estaban más lejos 
de la demencia, este problema podría ser menos relevante en ese grupo. Los hallazgos en 
cuanto a la atrofia central y las lesiones de sustancia blanca confluentes fueron similares: 
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dentro del modelo estadístico, estas variables se asociaron positivamente a “probabilidad 
de EA” en el grupo con QCS y negativamente en el grupo con DCL. 
En este trabajo se examinaron una serie de variables que reflejan riesgo vascular, 
incluyendo las lesiones de sustancia blanca, los antecedentes de ictus, la hipertensión 
arterial, o el número total de factores de riesgo cardiovascular. Dentro del modelo, estos 
factores tendían a asociarse a un incremento de la probabilidad de EA en el grupo con 
QCS y a un descenso de la misma en el grupo con DCL. Es complicado interpretar estos 
resultados, puesto que estos grupos difieren en las características basales, tal y como 
puede observarse en la tabla I del artículo. En todo caso, estos resultados podrían estar 
reflejando diferencias fundamentales en el diagnóstico diferencial que se establece en 
cada categoría. Los pacientes con DCL tienen un deterioro demostrado, y su diagnóstico 
diferencial se plantea entre la EA y otra patología no EA – posiblemente vascular. Aunque 
los factores de riesgo vascular se asocian con la EA,
248
 lo hacen en mayor medida con la 
patología vascular, y su presencia empujaría el diagnóstico de este grupo en sentido 
opuesto de la EA.  En el grupo de QCS el diagnóstico diferencial se establece 
fundamentalmente entre una patología neurodegenerativa de cualquier tipo o quejas de 
origen funcional. Así, en estos pacientes los factores de riesgo cardiovascular hacen al 
paciente más similar al de EA.  
Una de las limitaciones del estudio es su diseño transversal. Solamente un 
seguimiento longitudinal podría aportar respuestas acerca de la progresión de la atrofia o 
el deterioro cognitivo en sujetos con QCS y DCL. Existen algunas pruebas de que la 
relación entre el grosor cortical y la cognición pudiera ser variable. La relación entre 
biomarcadores en LCR y grosor cortical sigue una relación en U invertida, y los sujetos 
con cognición normal que presentan valores transicionales en el LCR tienen también 
mayor grosor de la corteza en regiones temporoparietales y en el precuneus.
53
 Una 
explicación es que solo los individuos con cortezas cerebrales constitucionalmente más 
gruesas pueden permanecer intactos desde el punto de vista cognitivo, aún con indicios 
de neurodegeración. Otra posibilidad es que el espesor cortical sea dinámico y que 
evolucione a lo largo del curso de la enfermedad. Estas cuestiones sólo pueden aclararse 
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con estudios prospectivos.  
La selección de los pacientes para este estudio fue oportunista, basándose en los 
pacientes remitidos a una unidad de memoria. Se trata, por tanto, de una muestra 
naturalística, que refleja la heterogeneidad de la práctica clínica habitual. Esto explica por 
qué no se aplicaron todos los tests a todos los pacientes: algunos no los necesitaron, o se 
negaron a someterse a alguna prueba. La circularidad ocurre cuando hay una dependencia 
entre variables empleadas para definir grupos al comienzo del estudio y variables 
analizadas, y es un problema evidente en estudios de este diseño. Para evitarla en lo 
posible, las valoraciones de las pruebas de neuroimagen se realizaron de forma ciega, 
aunque los clínicos tuvieron acceso a las imágenes a la hora de hacer el diagnóstico.  
La falta de un criterio estandarizado para definir el estado de QCS es un problema 
en todos los estudios que tratan esta entidad.
31, 61
 Siguiendo nuestro diseño naturalístico, 
solo se excluyeron los pacientes que presentaban comorbilidades graves que ponían en 
duda el diagnóstico (tales como tumores intracraneales o metástasis). Esta heterogeneidad 
explica el alto porcentaje de parkinsonismo en el grupo de DCL (21%) y apunta a posible 
presencia de patología de Lewy o vascular subcortical.  
En diversos estudios se han encontrado múltiples diferencias entre los individuos 
con QCS y la población sana.
31, 33, 50, 51, 53, 60, 61, 63, 64, 70, 249, 250
 De hecho, algunos autores 
sugieren que las QCS pueden ser el primer estadio detectable en la EA.
33, 40, 251
 Sin 
embargo, es difícil identificar qué sujetos presentarán deterioro en el futuro. Las quejas 
cognitivas con tests neuropsicológicos normales podrían ser particularmente reveladoras 
en personas con alto nivel educativo, puesto que en ellas el efecto techo de los tests les 
resta sensibilidad.
60
 El grupo con QCS de nuestra muestra tenía un nivel educativo alto, 
reflejando la composición de la Suecia urbana de su generación. Sin embargo, solo 
algunos de ellos desarrollarán una enfermedad neurodegerativa y solo el seguimiento 
puede indicar cuáles serán. Nuestro estudio sigue la línea de los criterios de Dubois 
252
 y 
las guías de la NIA, 
9
 que buscan expandir el diagnóstico de la EA a estadios más 
tempranos. 
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8.6.2 Estudio II 
El segundo estudio se basa en una cohorte de 15 209 pacientes diagnosticados en 
unidades de memoria e incluidos en SveDem entre 2008 y 2011. El riesgo de mortalidad 
para diferentes tipos de demencia y factores de base se calculó empleando razones de 
riesgo (hazard ratios, HR) obtenidas a partir de regresiones de Cox. Los factores 
asociados con mayor riesgo de mortalidad fueron el sexo masculino, la edad más 
avanzada, el consumo de una mayor cantidad de de fármacos, la institucionalización, el 
peor nivel cognitivo (medido por el MMSE) y los diagnósticos de demencia distintos de 
la EA.   
En esta cohorte, los hombres presentaron un riesgo de mortalidad un 56% superior 
a las mujeres. Este hallazgo está en la línea de estudios previos.
143, 146, 150, 153, 154, 157, 161-164
. 
Al estratificar por diagnóstico, los hombres continuaron presentando mayor riesgo de 
mortalidad en todos los tipos de demencia excepto en en la DFT y la DLB, en las cuales 
las diferencias no fueron significativas. La mayor diferencia entre hombres y mujeres 
apareció en la EPD, con un 71% de aumento de riesgo en los varones. 
Como cabía esperar de estudios previos, la edad más avanzada 
143, 150, 153-155
 y el 
menor rendimiento en el MMSE
157, 169
 se asociaron a aumento de riesgo de mortalidad. 
Los pacientes “no evaluables” por MMSE presentaron un riesgo cuatro veces mayor que 
aquellos con MMSE igual o superior a 25,  lo cual revela un efecto suelo de este test.  
Nuestro estudio empleó el número de fármacos consumidos de forma habitual 
como una medida indirecta de la comorbilidad, y su aumento se asoció a un mayor riesgo 
de mortalidad. El riesgo de mortalidad dependió asimismo del diagnóstico de modo que 
la EA presentó menor riesgo que cualquier otro tipo de demencia. En análisis crudos, el 
riesgo más alto se asoció a la DV, y en análisis ajustados la demencia de mayor riesgo fue 
la DFT (tabla 5; artículo II). Como puede observarse en la tabla 2 del artículo, los 
pacientes con DFT eran más jóvenes y tomaban menos medicación. La supervivencia en 




 años según estudios previos. La DFT presenta peor 
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supervivencia que la EA en la mayoría de los estudios.
146
 Aunque es una enfermedad rara, 
afecta a individuos jóvenes y relativamente sanos y se asocia a un riesgo de mortalidad 
desproporcionado, lo que subraya la necesidad de redoblar esfuerzos en esta enfermedad. 
De acuerdo con la literatura previa, la EA presenta menor mortalidad que otros 
tipos de demencia,
142, 146, 150
 aunque algunos estudios no encuentran diferencias.
142, 146, 150
 
Pocos estudios comparan un espectro amplio de diagnósticos,
142, 146, 150
 y esa es una de las 
aportaciones fundamentales de nuestro estudio. Como era esperable, la enfermedad mixta 
entre EA y DV presentó un riesgo intermedio entre estas dos entidades. Dado que las 
enfermedades cardiovasculares constituyen las primeras causas de mortalidad en los 
pacientes con demencia (independientemente del diagnóstico), el aumento de riesgo 
observado en la DV no es sorprendente.
142, 146, 150
 En estudios previos se ha encontrado 
que la EA tiene menor morbilidad asociada que otros tipos de demencia
142, 146, 150
, lo que 
encaja con la menor cantidad de medicación que tomaban los pacientes con EA de 
nuestra muestra (tabla 2; artículo II). 
Salvo excepciones,
180
 la mayoría de los estudios publicados describen peor 
pronóstico para la DLB que para la EA.
167, 179
. En nuestra cohorte, los pacientes con DLB 
tenían mayor riesgo de mortalidad que la EA. Cuando se introdujo la DLB como 
categoría de referencia, el riesgo en la EA fue más bajo y no se detectaron diferencias con 
la EPD o la DV. Las similitudes entre EDP y DCL
82
 podrían explicar, en parte, este 
hallazgo.  
La ausencia de un grupo de control cognitivamente intacto es una limitación de 
este estudio. SveDem es un registro nacional que incluye pacientes diagnosticados de 
demencia en la práctica clínica habitual, sin un protocolo de estudio para el diagnóstico. 
Las guías del Socialstyrelsen
228
 – el ministerio de Sanidad sueco – establecen unos 
requerimientos básicos para el diagnóstico de demencia. En SveDem, más del 85% de los 
pacientes cumplen estos criterios.
217
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La naturaleza observacional de este estudio impide hacer inferencias de 
causalidad. SveDem tiene una cobertura superior al 25% de la incidencia esperada de 
demencia, pero esta proporción resulta insuficiente para hacer cálculos de incidencia. Sin 
embargo, ambos estudios incluyeron únicamente pacientes de atención especializada. 
Dado que la cobertura de SveDem en unidades especializadas es superior al 90%, y dado 
que éstas registran a la mayoría de sus pacientes, la cobertura para atención especializada 
sería muy superior al 25%. Nuestro estudio tuvo un seguimiento de 2,5 años de media, 
quizás insuficiente para detectar cambios en el riesgo de mortalidad a lo largo del tiempo 
y saber si el riesgo aumenta o disminuye en alguna fase concreta de la enfermedad. 
El sesgo de duración aparece en estudios que mezclan casos de novo y casos 
prevalentes, en los que pacientes con enfermedades rápidamente progresivas mueren 
antes del reclutamiento.
143
 La inclusión exclusiva de casos de novo en nuestro estudio es 
uno de sus puntos fuertes, y debería ayudar a controlar este sesgo. La selección de casos 
atendidos en unidades de memoria tuvo como objetivo aumentar la fiabilidad del 
diagnóstico, pero podría suponer una limitación si este grupo no fuese comparable al de 
los pacientes valorados en atención primaria. Cuando se han analizado las diferencias 
entre ambas cohortes, dentro de SveDem, se ha encontrado que los pacientes de atención 
primaria son de más edad, tienen más comorbilidad y son evaluados con protocolos 
diferentes.
214, 227
 Para determinar si la exclusión de los centros de primaria podía tener un 
impacto relevante en los resultados, se procedió a repetir los análisis con todos los 
pacientes incluidos en SveDem, tanto los de niveles de atención primaria como los de la 
atención especializada, entre los años 2007 y 2012. Tal y como se muestra en la tabla 14, 
esta inclusión no alteró los resultados de un modo sustancial. El rango de categorías 
diagnósticas y el gran número de pacientes son los puntos más fuertes de este estudio. Se 
trata del mayor estudio prospectivo de su categoría que explora mortalidad en demencia 
de reciente diagnóstico.  
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8.6.3 Estudio III 
En el artículo III se analiza la relación entre el IMC en el momento del 
diagnóstico y el riesgo de mortalidad. La cohorte incluyó 11 398 pacientes diagnosticados 
de demencia entre 2008 y 2011 y que tenían datos sobre IMC basal en los registros de 
SveDem.   
En estudios previos se ha analizado la relación entre IMC y mortalidad en 
distintos grupos de edad, pero este es el primero que lo que hace en un grupo grande de 
pacientes con diagnóstico reciente de demencia. El IMC bajo se asoció con un 
incremento del riesgo de mortalidad en los análisis ajustados. El grupo con obesidad 
presentó el riesgo de mortalidad más bajo, aunque no se encontraron diferencias 
significativas entre los grupos con obesidad y sobrepeso. Cuando se analizaron como 
splines, cada punto de aumento en la escala de IMC hasta 29,9 se asoció a una reducción 
del riesgo de mortalidad (figura 1; artículo III). 
Hubo diferencias entre ambos sexos: en mujeres, el punto de menor riesgo se 
encontró en el grupo con sobrepeso, mientras que los hombres tenían el riesgo más bajo 
en el rango de obesidad. Además, el análisis con splines mostró que el riesgo descendía a 
medida que ascendía el IMC hasta un IMC de 24,9 en mujeres y 29,9 en hombres.  
La composición de la muestra, con pocos pacientes de IMC mayor de 35, hace 
difícil sacar conclusiones en este grupo. Cuando los análisis por splines se repitieron sin 
ajustar por medicación, apareció un aumento del riesgo para IMC de más de 30, 
indicando que a partir de este punto podría aparecer comorbilidad – reflejada en la 
cantidad de medicación – que elevaría el riesgo de mortalidad. 
La revisión de la literatura parece indicar que existe una relación compleja entre el 
IMC y la mortalidad en poblaciones especiales. El IMC asociado a menor mortalidad 
aumenta con la edad
189, 254, 255
 y se sitúa en el rango del sobrepeso en poblaciones 
ancianas,
190, 191, 255, 256
 aunque algunos autores describen una mayor mortalidad en 
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personas mayores con obesidad.
191, 257, 258
 Un estudio encontró que el riesgo era un 17% 
menor en sujetos con obesidad de más de 75 años comparados con el grupo de peso 
normal. 
189
 En nuestro estudio, la reducción del riesgo fue de un 27 y en un 32% en los 
grupos con sobrepeso y obesidad, respectivamente (tabla 3; artículo III). 
Aparentemente, el IMC óptimo para una menor mortalidad es más alto en 
hombres que en mujeres,
190, 255
 aunque no todos los estudios apoyan estas diferencias 
191
. 
Uno de los trabajos sobre la relación entre IMC y mortalidad en la población situaba el 
punto de menor mortalidad entre 18,5 y 25 para las mujeres de más de 55 años, y entre 25 
y 30 para los hombres.
255
 Estos datos encajan con los resultados de nuestro estudio. Las 
causas de estas diferencias entre sexos podrían ser biológicas o sociales,
187, 259, 260
 y 
requieren más investigación.  
El hallazgo de una menor mortalidad en presencia de factores tradicionales de 
riesgo cardiovascular se ha denominado “epidemiología inversa” y se ha descrito en 
poblaciones con enfermedades crónicas y agudas como el fallo renal, ictus, insuficiencia 
cardiaca, cáncer o SIDA.
203-205
 El mismo concepto aplicado a la obesidad se llama 
“paradoja de la obesidad” y se ha descrito en poblaciones ancianas. 254, 262, 263. La novedad 
de nuestro estudio consiste en describir este fenómeno en pacientes con demencia, pero el 
efecto en sí se conoce desde principios de la década pasada.
261
 Aunque este efecto esté 
validado por observaciones reiteradas, sus causas siguen generando controversia.
195
 Las 
explicaciones son variadas, desde efectos de sesgo, competición entre distintas causas de 
mortalidad o diferentes mecanismos biológicos.
194, 262
 De hecho, nuestro artículo motivó 
una carta al editor de Moga et al
262
 en la que propuso que los resultados podrían 
corresponder a sesgo o causalidad inversa. Esto nos permitió contestar con otra carta al 
editor y continuar este fascinante debate. Moga et al expresaron dudas sobre un posible 
sesgo de selección, dado que en nuestro artículo original solo se incluyeron pacientes de 
centros especializados. Como estos autores señalan, el riesgo de mortalidad difiere entre 
centros: en SveDem, el riesgo de mortalidad es más bajo en la atención primaria que en la 
especializada (HR 0,45; CI 0,42-0,49) 
263
. En la tabla I de nuestra carta al editor 
263
, 
pueden verse análisis repetidos en toda la base de datos y en atención primaria, donde el 
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grupo de pacientes con obesidad presentó menor mortalidad que la categoría de 
referencia. 
Por otra parte, la falta de cumplimentación de datos biométricos en algunas 
entradas de SveDem supone una limitación para los análisis aunque son difíciles de 
solventar. No obstante, la categoría de pacientes que carecían de datos de IMC presentó 
un riesgo de mortalidad muy similar a los de IMC entre 25 y 29,9. Para eliminar el efecto 
de pacientes en extremos de la escala, se repitieron los análisis de splines con los 
pacientes que tenían valores de IMC entre 20 y 31. Los resultados se muestran en la tabla 
II de la carta al de respuesta
263
: el mayor IMC siguió asociándose a un menor riesgo de 
mortalidad.  
Otras posibles limitaciones del estudio serían el uso de IMC como marcador 
nutricional
255
 y la falta de seguimiento del IMC. Tal y como se argumentó en la 
introducción de esta tesis, el IMC está ampliamente disponible y es un parámetro bastante 
fiable para estimar riesgo cardiovascular y mortalidad
196, 210
 Sin embargo, los cambios en 
el IMC sí que podrían ser más sensibles al pronóstico que una medida estática. En un 
estudio longitudinal realizado en personas de más de 70 años, tanto aquellos que 
perdieron como los que ganaron peso experimentaron mayor riesgo de mortalidad que 
aquellos que mantenían un peso estable.
254
  
Otras cuestiones planteadas por Moga et al 
262
 tienen que ver con la cadena causal 
entre demencia e IMC: la demencia causa pérdida de peso, y esta pérdida de peso puede 
preceder al diagnóstico.
264
  La naturaleza descriptiva de SveDem impide hacer 
inferencias de causalidad, pero algunos trabajos aseguran que las intervenciones que 
logran incrementos de peso en pacientes con demencia se asocian con reducciones en su 
mortalidad.
210
 Los métodos de nuestro estudio no permiten determinar qué mecanismos 
unen el menor IMC con un mayor riesgo de mortalidad en la demencia, pero esta 
observación tiene valor independientemente del mecanismo causal. Para un clínico que se 
enfrenta a un paciente con demencia, la relación causal quizás sea poco relevante: lo que 
importa es recalcar la importancia de la evaluación nutricional completa en pacientes con 
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demencia, y subraya la utilidad del IMC como marcador pronóstico. 
En un futuro, la realización de estudios longitudinales prospectivos podría 
determinar si los pacientes con demencia se benefician de IMC más altos que los adultos 
mayores sin demencia. Se necesitarían, además, estudios de intervención para poder 
precisar las estrategias a aplicar en este caso. Por el momento, el IMC bajo identifica a un 
grupo de pacientes con demencia con alto riesgo de mortalidad.  
8.7 CONCLUSIONES 
1. En la Karolinska Memory Clinic, los pacientes con quejas cognitivas subjetivas 
(QCS) constituyeron un grupo distintivo, con edades más jóvenes que los 
pacientes con deterioro cognitivo leve (DCL) y demencia tipo Alzheimer (EA),  
más años de escolaridad, menos factores de riesgo cardiovascular, 
puntuaciones más altas en el Mini Mental State Examination (MMSE), 
patrones normales en el análisis de los biomarcadores de EA del líquido 
cefalorraquídeo y volúmenes normales de los lóbulos temporales en las pruebas 
de neuroimagen. Además la atrofia central generalizada, la atrofia cortical y las 
lesiones de sustancia blanca fueron menos frecuentes en estos pacientes que en 
los otros grupos, al igual que el genotipo con alelo ApoE4. Los pacientes con 
QCS presentaron más síntomas de depresión evaluada por la escala Cornell que 
los pacientes con EA, aunque no se distinguieron en este aspecto del grupo con 
DCL.   
2. El modelo de regresión logística que incluyó edad, sexo, puntuación en el 
MMSE, coeficiente Aβ42/t-tau y p-tau clasificó correctamente al 94,9% de la 
muestra en las categorías correspondientes de QCS, DCL o EA. Dentro de 
dicho modelo, los factores que directa o indirectamente representaban riesgo 
cardiovascular tendían a aumentar la probabilidad de EA en el grupo con QCS 
y a disminuirla en el grupo con DCL, traduciendo quizás diferencias 
fundamentales en el diagnóstico diferencial que se plantea en cada una de estas 
dos entidades.  
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3. Una vez diagnosticada la demencia, el tipo de demencia y otras características 
basales pueden predecir el riesgo de mortalidad. Los factores asociados con 
mayor riesgo de mortalidad fueron el sexo masculino, la edad más avanzada, el 
consumo de una mayor cantidad de fármacos, la institucionalización, el peor 
nivel cognitivo (medido por el MMSE) y los diagnósticos de demencia 
distintos de la EA. En los análisis crudos la demencia vascular (DV) presentó 
el riesgo más alto, mientras que la demencia frontotemporal (DFT) se convirtió 
en la demencia de mayor riesgo tras ajustar por edad, sexo y medicación. Esto 
sugiere que la DFT es una enfermedad particularmente letal, teniendo en 
cuenta que afecta a sujetos jóvenes y relativamente sanos.  
4. En los pacientes con demencia, los valores más bajos del índice de masa 
corporal (IMC) se asociaron a riesgos de mortalidad más elevados. El rango de 
IMC asociado a menor mortalidad fue dependiente del sexo. El riesgo 
descendía a medida que se incrementaba el IMC hasta los niveles de 24,9 
kg/m
2
 en las mujeres y 29,9 kg/m
2
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Background: Body-Mass Index (BMI) is used worldwide as an indirect measure of nutritional 36 
status and has been shown to be associated with mortality. Controversy exists over the cut-points 37 
associated with lowest mortality, particularly in older populations. In patients suffering from dementia, 38 
information on BMI and mortality could improve decisions about patient care.  39 
Objectives: To explore the association between BMI and mortality risk in an incident dementia 40 
cohort. 41 
Design: Cohort study based on SveDem, the Swedish quality dementia registry; 2008-2011. 42 
Setting: specialist memory clinics; Sweden. 43 
Participants: 11.398 incident dementia patients with data on BMI (28.190 person-years at risk 44 
for death).  45 
Main outcome measures: Hazard ratios (HR) and 95% confidence intervals (CI) for mortality 46 
associated with BMI were calculated controlling for age, sex, dementia type, results from Mini-Mental 47 
State Examination, and number of medication. BMI categories and linear splines were employed. 48 
Results: Higher BMI was associated with decreased mortality risk, with all higher BMI 49 
categories showing reduced risk relative to patients with BMI 18.5 to 22.9 kg/m2, while underweight 50 
patients (BMI under 18.5kg/m2) displayed excess risk. When explored as splines, increasing BMI was 51 
associated with decreased mortality risk up to BMI 30 kg/m2. Each point increase in BMI resulted in 52 
an 11% mortality risk reduction in patients with BMI under 22 kg/m2, 5% reduction when BMI was 53 
22-24.9 kg/m2, and 3% risk reduction among overweight patients. Results were not significant in the 54 
obese weight range. Separate examination by sex revealed a reduction in mortality with increased BMI 55 
up to BMI 29.9 kg/m2 for men and 24.9 kg/m2 for women. 56 
Conclusion: Higher BMI at the time of dementia diagnosis was associated with a reduction in 57 
mortality risk up to and including the overweight category for the whole cohort and for men, and up to 58 
the normal weight category for women.  59 
1. Introduction: 60 
Body-mass index (BMI) is a useful biometric measure and predicts mortality in a number of 61 
populations
1,2
. The World Health Organization (WHO) defines normal BMI as 18.5-24.9 kg/m2
2
 which 62 
correlates with lower morbidity among young adults.
3
 However, there is some indication that older 63 
adults might benefit from higher BMIs,
4-8
 and BMI cut-points between 19 and 23 have been used to 64 
guide nutritional screening in this population. 
1,7,9,10
 Controversy exists over the BMI associated with 65 
lowest mortality among older individuals, which could lie in the overweight range of BMI as defined 66 
by the WHO (25-29.9 kg/m2).
4,6,8
 This finding of excess weight, traditionally considered detrimental 67 
to health, being protective in older populations has been termed the "obesity paradox".
11
 68 
The relationship between body weight and cognition is complex. Overweight and obese 69 
patients have demonstrated better cognitive performance than normal weight individuals in some 70 
instances
12







 A reduction in BMI can predict dementia
14
 and predates onset by at least a 72 
decade.
15,16
 However, higher BMI at middle-age has been shown to increase the risk of dementia in 73 
later decades,
11,17
 indicating that there is a positive relationship between BMI and dementia that is 74 
reversed in old age. The intermediate prodromic stages of the disease are the most difficult to analyze. 75 
Among women, being overweight correlates with development of Alzheimer's dementia (AD) even at 76 
older ages.
18
 Methodological differences between studies in follow-up and design might contribute to 77 
these apparent contradictions. Also important is the difficult distinction between BMI as a possible 78 
causal factor for dementia and changes in BMI linked to preclinical disease. The overlap between 79 
these two factors is especially important in neurodegenerative processes such as AD in which 80 
pathological changes begin decades before diagnosis while uncertainty remains about the early course 81 
of the disease. 82 
In patients already suffering from dementia, lower BMI has been correlated with increased 83 
mortality
19
 and severity of cognitive impairment.
13
 Since malnutrition is a contributing factor in death 84 
by dementia,
19,20
 baseline BMI at diagnosis could contribute to predicting mortality and influence 85 
decisions on patient care. 86 
The SveDem national incident dementia registry was created in 2007 to improve quality and 87 
equality of care for dementia patients throughout Sweden. To date, it includes more than 90% of all 88 
new dementia diagnoses made in specialist memory clinics nationwide
21
. The aim of this study is to 89 
describe mortality risk relative to BMI, to examine whether lower BMI is associated with higher 90 
mortality and determine the BMI corresponding with lowest mortality risk in our dementia population. 91 
2. Patients and methods: 92 
SveDem is a nationwide Swedish quality registry that includes more than 28.000 incident 93 
dementia patients to date. Patients meeting ICD-10 
22
 criteria for dementia, diagnosed at either 94 
memory clinics or primary care are included in the database together with data on height and weight, 95 
age, gender, medication and results from diagnostic work-up
23,24
  including baseline Mini-Mental State 96 
Examination (MMSE). Number of medication at diagnostic work-up, ie approximately at the time of 97 
diagnosis, is used as a proxy for comorbidity, since it has been shown to be better than other 98 
medication-based comorbidity scores at predicting morbi-mortality 
24,25
. Dementia diagnoses are coded 99 
as Alzheimer's Disease (AD), Vascular Dementia (VaD), mixed AD and VD (mixed), Lewy Body 100 
Disease (LBD--McKeith criteria
26
), Parkinson's-Disease Dementia (PDD--Movement Disorder Society 101 
Task Force criteria 
27
), Fronto-temporal dementia (FTD--Lund-Manchester criteria
28
), unspecified 102 
dementia (where diagnosis is not ascertained) and other dementia types (grouping alcohol related 103 
dementias and rare dementia disorders). The national guidelines published by the Swedish National 104 
Board of Health and Welfare
29
 recommend an established basal dementia work-up for patients with 105 
suspicion of dementia: in SveDem, this basic work-up is completed in over 85% of cases
30





testing expanded if necessary. Quality control is performed by random cross-checks of histories and 107 
entries
30
.  Changing diagnoses within the first year of follow-up are about 5%. Based on estimates of 108 
dementia incidence in Sweden, SveDem captured around 25% of all new diagnoses in 2011, with a 109 
coverage for specialist memory clinics of 93%
30
. SveDem is collated with the national population 110 
registry to record deaths. 111 
For this study, we selected patients included in SveDem who had received a dementia 112 
diagnosis from a specialist memory clinic between 2008 through 2011 and for whom complete data on 113 
BMI, dementia diagnosis, age and sex was available. Primary care was excluded because of more 114 
irregular inclusion in the registry and differences in diagnostic process compared to specialist care. 115 
Patients were followed up until death, as entered in the national population registry, or end of follow-116 
up in February 2013. Of a total of 15.224 patients registered in this period, 11.413 patients had data on 117 
BMI. Of these, 15 (0.1%) patients were excluded because of incomplete information on diagnosis, 118 
age, gender or time of death. This left 11.398 patients included in analysis. 119 
2.1. Statistical analyses: 120 
Prospective analyses to identify the relationship between BMI and mortality risk were 121 
calculated using Cox proportional hazards regression models and are shown as hazard ratios (HR) of 122 
death with 95% confidence intervals (CI). Kaplan-Meier survival curves were employed for a visual 123 
confirmation that the assumption of proportional hazards was met. Person-time at risk was calculated 124 
individually for all patients from dementia diagnosis to date of death or end of follow-up, on February 125 
2013. Means and standard deviations are provided when appropriate. SPSS version 21 was used for 126 
computations. 127 
BMI was explored in categories according to WHO guidelines defining underweight as BMIs 128 
under 18.5 kg/m2, normal between 18.5 to 24.9 kg/m2 , overweight from 25 to 29.9 kg/m2 and obese 129 
over 30 kg/m2. Because of the previous literature supporting excess risk even in moderately thin older 130 
adults
1,9,10,31
 and in order to better represent the distribution of our cohort, we also employed the 131 
additional WHO cut-off point within the normal range, creating a group for "slim" individuals from 132 
18.5 to 22.9 BMI and another "normal" group, from 23 to 24.9. In order to determine the BMI 133 
corresponding to lowest mortality and to better represent the correlation in case of a J or U shaped 134 
distribution, piecewise linear representation variables (splines) were used. Linear splines are a series 135 
of concatenated variables separated by pre-defined cut points (knots) and designed so that within each 136 
interval BMI is explored as a continuous variable. In this way, linearity is only assumed within each 137 
interval within the scale while at the same time retaining some of the statistical power of the original 138 
continuous variable. Different cut points were explored to capture the shape of the distribution. 139 
Because the BMI of lowest mortality was suspected to be different for women and men, stratified 140 





cohort was divided into age tertiles (cut points at age 76 and 83) and analyses repeated in these 142 
separate groups. 143 
All estimates were adjusted for age, gender, MMSE, dementia diagnosis and number of 144 
medication at diagnostic work-up. A quadratic term was entered for age, since it fitted the mortality 145 
distribution best. Gender was treated as a dichotomous variable. MMSE score was classified as not 146 
assessable, severe (0-9), moderate (10-19), mild (20-24), and slight impairment (25 and over). 147 
Dementia diagnosis was entered as eight diagnostic categories (AD, VaD, mixed, LBD, PDD, FTD, 148 
unspecified and other). Number of medication was categorized as 0-1, 2-5, 6-9, and 10 or more 149 
habitual drugs at time of diagnostic workup.  150 
Standard protocol approvals and patient consent: The data collection and analysis 151 
procedures were approved by the regional ethics committee in Stockholm (approval number 2009/209-152 
31). Patients and caretakers were informed orally and in writing about SveDem, and could decline 153 
participation and withdraw consent at any time. Data was collected locally and entered into the web-154 
based database, and coded and anonymized before statistical analysis.  155 
3. Results:   156 
A total of 11398 patients were included and followed-up for an average of 2.5 years (28190 157 
person-years at risk [PYAR]). 3162 deaths were observed (112 deaths per 1000 PYAR). Characteristics 158 
of study subjects and mortality are presented in table 1. Mortality for different BMI groups are 159 
presented in table 2.  160 
BMI presented a normal distribution with a mean of 24.5 (SD 4.3). The highest mortality rate 161 
was observed in the group with BMI under 18.5 (199 deaths PYAR) while the lowest rate occurred in 162 
the BMI +30 group (86 deaths PYAR; table 2).  163 
Higher BMI was associated with decreased mortality risk. The slim category (18.5-164 
22.9kg/m2) was used as reference for comparisons, since it was the group with highest number of 165 
individuals. In crude analysis, compared to this reference, all other groups except the underweight 166 
presented significantly decreased mortality risk. Results remained significant after adjusting and are 167 
shown in table 3. The lowest hazard ratio corresponded to the obese BMI +30 group (HR 0.68; 0.59-168 
0.78 p<0.001) followed by the overweight 25-29.9 group (HR 0.73; 95% CI 0.66-0.85) and normal 23-169 
24.9 (HR 0.81; 95% CI 0.73-0.89). The underweight BMI under 18.5 group presented excess risk 170 
compared to the slim group (HR 1.60; 95% CI 1.39-1.84 p<0.001). The lowest mortality risk occurred 171 
in the BMI + 30 category for the whole database and for men, while it occurred in the overweight 172 
category for women. The analyses were repeated with and without adjusting for number of medication 173 
(used as a proxy for comorbidity), without substantial changes in the results. When compared with the 174 
obese category, there was significant excess risk in the underweight, slim and normal 23-24.9 175 





sample was split into age tertiles, the BMI +30 category continued to present the lowest HR for 177 
mortality, except in the oldest age group in which the obese and overweight categories had similar HR 178 
(table 3). 179 
A number of splines were created, joined by cut points or knots. Between each knot, BMI is 180 
represented as a continuous variable. When explored as splines, each point increase in BMI was 181 
associated with reduced mortality risk up to, and including, the overweight category. Several knots 182 
were examined, following WHO guidelines or the Swedish National Board of Health and Welfare. A 183 
number of very small splines (spanning only 0.5 points, 1 point or 2 points in BMI) were also tested: 184 
due to smaller sample sizes, these were most often non-significant, but they did provide a guideline of 185 
how the distribution behaved. Finally, cut points at 18.5, 22, 25 and 30 kg/m2 were chosen: these 186 
correspond to the WHO cut-points for underweight, normal weight and obesity
32
, with an additional 187 
cut-point at BMI 22 which is suggested by the Swedish National Board of Health and Welfare for 188 
screening for malnutrition in population over 70
9
. Adjusted results are given in table 4, but were not 189 
substantially different from crude results. For patients with BMI under 22, each point increase in BMI 190 
was associated with 11% less mortality risk, while it was associated with 5% decreased risk in the 22-191 
25 category, and 3% in the overweight 25-30 category. No significant results were obtained in the 192 
obese category. Analyses were rerun controlling for all variables except medication: in this case, 193 
growing mortality risk was demonstrated with each point increase in BMI in the obese category (HR 194 
1.04; 95% CI 1.00-1.07). 195 
Stratified by sex, men presented a significant reduction in risk with increasing BMI in the 25-196 
30 group, while for women, decreased risk was present and significant up to, and including, the 197 
normal BMI range but not in the overweight or obese categories (table 4). Figure 1a shows results for 198 
men and women. 199 
To examine whether the relationship between mortality and BMI was influenced by age, 200 
spline analyses were repeated separately on the different age tertiles. Adjusted results are represented 201 
in figure 1b. Because of the smaller sample sizes, only splines with knots set at 23 and 30 were used. 202 
Probably due to this smaller sample size, results were often not significant in individual splines and 203 
categories. Increased BMI was associated with decreased mortality risk in all age categories in the 204 
lowest BMI spline (BMI under 23). In the intermediate weight spline (BMI 23-30) a significant, 205 
protective effect was detected only in the youngest age group (p=0.003). In the BMI +30 spline, a 206 
trend towards increased risk with higher BMI was detected in the youngest and oldest age groups (HR 207 
1.05; 95%CI 0.99-1.10 p=0.071 and HR 1.05; 95% CI 0.98-1.12 p=0.145, respectively). The 208 
interaction between the linear splines and age were tested. The difference between the youngest and 209 
oldest age groups was significant (p=0.010). This indicates that, compared to the youngest age group, 210 





4. Discussion: 212 
In our large national incident dementia cohort, low BMI was associated with increased 213 
mortality after adjusting for age, gender, MMSE, dementia diagnosis and medication at the beginning 214 
of the diagnostic workup. The lowest mortality risk was observed in the obese group, with no 215 
significant differences in mortality risk between the obese and overweight categories. In spline 216 
analysis, each point increase in BMI resulted in decreased mortality risk up to the end of the 217 
overweight category (BMI 29.9). Results were not significant in the BMI +30 spline, possibly due to 218 
an absence of covariation between BMI and mortality within this group (the lower horizontal section 219 
of a J-shaped curve). Furthermore, our sample contained less obese patients (N=1168) and few with 220 
BMI over 35 (n=233). Since it is precisely these patients who could present higher mortality from 221 
adiposity-related conditions
2,33
, the composition of our sample might not have been ideal to 222 
demonstrate excess mortality at the higher end of the obesity spectrum. The lowest mortality was 223 
observed in the obese weight range in men, while it occurred in the overweight weight range for 224 
women. As is shown in figure 1a, when men and women are considered separately, the point of lowest 225 
risk for both genders seems to lie around BMI 30 kg/m2 but the risk for women flattens out at lower 226 
BMIs than it does for men.  This suggests that men benefit from the reduction of mortality risk 227 
associated with higher BMI well into the overweight range.  228 
Previous literature suggests that optimal BMI might be lower for women
5,6
, although some 229 
studies contradict this finding
8
. One publication reported lowest mortality between BMI 18.5-25 230 
among healthy women over 55, and between 25-30 among men
5
. In SveDem, the lowest mortality was 231 
observed at lower BMIs in women than in men. Social and biological reasons might motivate this 232 
finding. Obesity is linked to sedentary habits, which have a greater negative impact on women than on 233 
men
6
. The relationship between BMI, body fat and sarcopenia is different for men and women
34
. 234 
Higher BMIs have been correlated with enhanced risk of functional impairment, but increased risk is 235 
apparent at lower BMIs in women than in men
35
. On average, muscle mass percentage is greater in 236 
men, so body composition, for the same BMI, differs between genders
34
. Sarcopenia predicts frailty in 237 
older individuals and increases the risk of death
36
, but relative sarcopenia, calculated by dividing 238 
muscle mass by weight, could be more relevant in women
34,37
, placing obese women with low muscle 239 
mass at particular risk. 240 
The appropriateness of BMI as a measure of adiposity in the elderly has been questioned.
5
 241 
BMI does not distinguish between fat and lean mass and biometric indexes including waist girth have 242 
also been proposed
38
. However, BMI remains widely available and easy to assess: even if other 243 
measures of nutritional status prove to be more precise, BMI still remains a valuable option in many 244 
settings. Fluctuations in BMI, rather than a single static measure, might predict prognosis better
19,39
. 245 
Increased risk was demonstrated for patients over 70 who either lost or gained weight
40
. Others have 246 





with a reduction in mortality.
19
 Supplementation might increase survival in older adults
1,7
 and it is 248 
reasonable to suppose that maintaining a good nutritional status could reduce mortality, particularly in 249 
dementia.  250 
The optimal BMI for lowest mortality remains contentious
33
 but appears to increase with 251 
age
4,5,40
, with previous studies indicating that it lies in the overweight range in older populations
4-6,8,40
. 252 
Some even suggest that obese older individuals either do not have excess mortality risk compared to 253 
those who are normal-weight
40
, or even display lower mortality
4,41
. However, others find a mortality 254 
increase among the obese
8,42,43
. In a study among people over 55, the optimal BMI for lowest mortality 255 
was 18.5-30
5
. In another population sample over 65, compared to those with normal BMI mortality 256 
risk was 11% lower in overweight patients and 13% lower in the obese category
4
. This protective 257 
effect was accentuated in the +75 subgroup, where mortality risk was 27% lower in the obese group
4
. 258 
This compares to our finding of 27% and 32% lower mortality risk for the whole cohort in the 259 
overweight and obese groups respectively (table 3). Other studies have found the lowest mortality in 260 
the overweight range of BMI for population over 65,
8
 and 70 to 75 years of age
6
. In our cohort, the 261 
BMI for minimum mortality was comparable across age groups but the whole cohort was older than in 262 
previous studies, with an average age of 79. Thus, the finding of lowest mortality in the obese category 263 
fits well within previous literature.  264 
It is difficult to disentangle the role of comorbidities, which could be responsible for some of 265 
the excess mortality detected in lower weight groups.
5,7
 Overweight and obesity
4
 have been linked to 266 
comorbidity, so controlling for said comorbidity may artificially reduce the risk associated with higher 267 
BMIs. However, one study showed that overweight elderly presented lower mortality, without 268 
increased risk for most stroke, cancer or myocardial infarction, although diabetes risk did increase.
4
 In 269 
our study, the number of medication at the beginning of diagnostic work-up was used as a proxy for 270 
comorbidity. Models run without controlling for number of medication continued to show the obese 271 
category presenting lowest mortality, but spline analyses demonstrated significant excess risk for each 272 
point increase in BMI after BMI 30. No substantial changes were evident in other splines or BMI 273 
categories in models with and without number of medication. This suggests that the protective effect 274 
seen at lower weights is not altered by controlling for medication, but that a proportion of the 275 
increasing risk after BMI 30 might be mediated by comorbidity. With our current data, it is impossible 276 
to determine if this comorbidity could be obesity related. 277 
Numerous studies indicate that cardiovascular risk factors such as high blood pressure and 278 
BMI are protective in some populations.
6,39,44-46
 This phenomenon has been termed the "reverse 279 
epidemiology hypothesis",
6,39,44-46
 or the "obesity paradox" when concerning BMI
47
, and has been 280 
observed in the elderly,
6,44,46







, malignancies and AIDS.
45
 The explanations for this phenomenon are varied, ranging from 282 
bias to the presence of competing hazards or different biological mechanisms
49





examined the influence of BMI and mortality after dementia diagnosis
19
 and population studies with 284 
older cohorts can be expected to contain a significant percentage of persons with dementia and other 285 
conditions in which reverse epidemiology applies.  286 
With our current data, it is impossible to know what mechanisms link lower BMIs to higher 287 
mortality risk in our incident dementia cohort, but examining the characteristics of populations in 288 
which reverse epidemiology has been described might provide some insight. These populations all 289 
present low life-expectancies in which the deleterious effect of conventional cardiovascular risk 290 
factors may not have time to materialize.
40,45
 In essence, low BMI might identify patients with strong 291 
competing hazards that would supersede cardiovascular risk
49
. Additionally, these populations display 292 
high prevalence of malnutrition which is thought to be an important contributor to death.
45,49,50
 293 
Malnutrition is linked to inflammation (malnutrition-inflammation syndrome complex-MISC) and 294 
through it to atherosclerosis and congestive heart failure,
51
 and has been blamed for the 295 
disproportionally high mortality rates (mostly cardiovascular) observed among renal failure 296 
patients.
45,51
 Indeed, in a study examining the association between cholesterol level and mortality in 297 
dialysis patients, a reverse epidemiology phenomenon was observed only in those in which MICS was 298 
evident, while the normal epidemiological observation of higher cholesterol linked to higher mortality 299 
appeared in patients who did not have MISC
52
. Another study among institutionalized elderly found 300 
that those with BMI under 21 presented higher cardiovascular, as well as all-cause, mortality.
7
 301 
Coincidentally, all of the above are also causes for sarcopenia
53
, and low grade inflammation has been 302 
independently associated with Alzheimer's disease and with involuntary weight loss in the elderly
54
. 303 
Furthermore, since malnutrition is a contributing factor for death in dementia,
20
 and since dementia 304 
causes weight loss
13
, the ideal weight range may be higher in subjects with dementia than among the 305 
general old population. Further research is needed to determine the causes of the association between 306 
lower BMI and higher mortality in populations with dementia. A longitudinal prospective study 307 
comparing cohorts with dementia and controls would be needed to confirm whether patients with 308 
dementia benefit from higher BMIs than their cognitively-intact peers, and markers of inflammation 309 
would be important to explore. Further research is needed to optimize nutritional strategies for persons 310 
with dementia. For now, low BMI serves as a clinical marker that identifies patients with dementia at 311 
higher mortality risk. 312 
2. Conclusion: 313 
In our large nationwide incident dementia cohort, increased BMI was associated with reduced 314 
mortality risk. This remained true up to BMIs 25 to 29.9 kg/m2 for men and up to 24.9 kg/m2 for 315 
women and confirms existing literature suggesting that older populations might fare better with higher 316 
body weight. The reduction in mortality risk may be accentuated in dementia, where malnutrition is a 317 
common contributor to death. In the future, studies evaluating fluctuations in BMI and nutritional 318 





this population. 320 
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Figure 1.Title: Hazard of mortality per point change in BMI as obtained by Cox regression 
using linear splines. 
Legend: BMI spline variables entered into Cox hazard regression. Results are adjusted by age 
(entered as a quadratic term), sex, Mini-Mental State Examination (MMSE), dementia diagnosis, and 
number of medication at the beginning of diagnostic work-up (all entered as categorical variables). 1a: 
split by gender. 1b: by age tertiles. Vertical axis on a logarithmic scale; represents HRs relative to the 








Table 1. Characteristics of study subjects       





All   
11398 
(100.0) 3162 (27.7) 28190 112 
            
Sex Women 6734 (59.1) 1698 (25.2) 17080 99 
  Men 4664 (40.9) 1464 (31.4) 11110 132 
            
Age <76 3630 (31.8) 556 (15.3) 9625 58 
  76-83 396 (134.8) 1035 (26.1) 10042 103 
  >83 3807 (33.4) 1571 (41.3) 8523 184 
Mean (SD) 78.5 (7.9) 
            
Dementia diagnosis AD 4092 (35.9) 793 (19.4) 10795 73 
  Mixed 3076 (27.0) 940 (30.6) 7400 127 
  VD 2124 (18.6) 771 (36.3) 4904 157 
  LBD 331 (2.9) 111 (33.5) 807 138 
  FTD 259 (2.3) 65 (25.1) 622 105 
  PDD 173 (1.5) 47 (27.2) 413 114 
  Unspecified 1103 (9.7) 367 (33.3) 2639 139 
  Other 240 (2.1) 68 (28.3) 609 112 
            
MMSE ≥25 3396 (29.8) 596 (17.6) 8916 67 
  20-24 4193 (36.8) 1089 (26.0) 10476 104 
  10-19 3080 (27.0) 1126 (36.6) 7245 155 
  <10 269 (2.4) 115 (42.8) 580 198 
  
Not 
assessable 227 (2.0) 127 (55.9) 516 246 
  Missing 233 (2.0) 109 (46.8) 448 243 
Mean (SD) 21.4 (5.1) 
Number of medication 
before diagnosis           
            
  <2 1859 (16.3) 328 (17.6) 4945 66 
  2-5 5153 (45.2) 1299 (25.2) 13079 99 
  6-9 3157 (27.7) 996 (31.5) 7526 132 
  >10 987 (8.7) 436 (44.2) 2063 211 
  Missing 262 (2.3) 103 (39.3) 577 179 
Mean (SD) 4.8 (3.3) 





Table 1: characteristics of study subjects. Number of patients (N) and percentages, or means 
and standard deviations (SD) are given as appropriate. PYAR: person-years at risk. Age categories 
correspond to the tertile distribution of age in the sample. MMSE categories result from the tertile 
distribution of MMSE in the sample (cut points at 19 and 25) with a further subdivision of the lowest 
MMSE category so as not to group patients with very different cognitive performance, plus another 
category for those in which MMSE was not assessable. Number of medication corresponds to the sum 
of all pharmacological treatments, as defined by the official Swedish Drug Index
55
, that the patient was 























N (%) PYAR 
Deaths 
/PYAR 
         
Global 
11398 
(100) 6734 (59.1) 78.5 (7.9) 21.4 (5.1) 4.8 (3.3) 3162 (27.7) 28190 112 
 
BMI mean 
(SD) 24.5 (4.3) 
   
BMI <18.5 631 (5.5) 517 (81.9) 79.9 (8.1) 19.8 (5.4) 4.5 (3.4) 270 (42.8) 1358 199 
BMI 18.5-
22.9 3740 (32.8) 2405 (64.2) 79.4 (7.9) 21.1 (5.0) 4.4 (3.2) 1182 (31.6) 9025 131 
BMI 23-24.9 2367 (20.8) 1284 (54.2) 78.5 (7.9) 21.8 (4.9) 4.6 (3.1) 604 (25.5) 5927 102 
BMI 25-29.9 3492 (30.6) 1839 (52.7) 77.9 (7.9) 21.6 (5.1) 4.9 (3.2) 846 (24.2) 8859 96 
BMI≥30 1168 (10.3) 689 (59.0) 76.3 (7.9) 21.7 (5.0) 5.8 (3.5) 260 (22.3) 3021 86 
          
     
Table 2: characteristics of subjects in each body-mass index (BMI) category. N: number of 
patients; SD: standard deviation; MMSE: Mini-Mental State Examination; PYAR: person-years at risk. 
No: number. Number of medication corresponds to the sum of all pharmacological treatments, as 
defined by the official Swedish Drug Index
55









          




22.9 BMI 23-24.9 BMI 25-29.9 BMI over 30 
           
 




HR 95% CI HR 95% CI HR 95% CI 
All 1.60 1.39-1.84 0.81 0.73-0.89 0.73 0.66-0.85 0.68 0.59-0.78 
Grouped by sex 
      Women 1.62 1.38-1.89 0.81 0.70-0.93 0.75 0.61-0.79 0.77 0.65-0.93 
Men 1.62 1.23-2.14 0.80 0.69-0.93 0.69 0.61-0.79 0.58 0.47-0.72 
Grouped by age 
      Under 
76 1.42 1.00-1.99 0.73 0.57-0.93 0.62 0.50-0.77 0.59 0.44-0.78 
76 to 83 1.58 1.23-2.03 0.75 0.63-0.89 0.71 0.61-0.83 0.62 0.49-0.78 
Over 83 1.66 1.38-2.00 0.89 0.77-1.02 0.78 0.69-0.89 0.79 0.63-0.98 




Table 3. Hazard ratios (HR) for death by BMI group, adjusted for results from Mini-Mental 
State Examination (MMSE), dementia diagnosis and number of medication before diagnosis. MMSE 
score was classified as not assessable, severe (0-9), moderate (10-19), mild (20-24), and slight 
impairment (25 and over). Dementia diagnosis was entered as eight diagnostic categories (Alzheimer's 
dementia [AD], Vascular dementia [VaD], mixed  AD and VaD, Lewy Body dementia,  Frontotemporal 
dementia, Parkinson's disease with dementia, unspecified dementia and other dementia diagnoses). 
Number of medication corresponds to the sum of all pharmacological treatments, as defined by the 
official Swedish Drug Index
55
, that the patient was regularly taking at the time of diagnosis, and was 
categorized as 0-1, 2-5, 6-9, and 10 or more habitual drugs at time of diagnostic workup. Results for 
all patients, women and men are additionally adjusted with a quadratic term for age. Results for age 
categories are additionally adjusted for sex.  
The slim group (BMI 18.5-22.9) serves as reference category. 95% confidence intervals (CI) 











Table 4. Adjusted HR obtained from BMI spline analyses. 
 
All Women Men 
 
HR 95% CI p value HR 95% CI p value HR 95% CI p value 
BMI<18.5 0.89 0.82-0.96 0.003 0.83 0.76-0.91 <0.001 1.08 0.89-1.29 0.426 
BMI 18.5-22 0.89 0.85-0.93 <0.001 0.92 0.87-0.97 0.004 0.82 0.76-0.89 <0.001 
BMI 22-24.9 0.95 0.91-0.99 0.027 0.94 0.88-1.00 0.050 0.97 0.91-1.03 0.357 
BMI 25-29.9 0.97 0.94-0.99 0.037 0.99 0.95-1.04 0.667 0.94 0.90-0.99 0.014 
BMI ≥30 1.03 0.99-1.06 0.144 1.03 0.99-1.07 0.205 1.01 0.95-1.07 0.804 




Table 4. Spline variables entered into Cox hazard regression for the whole database, women 
and men. Hazard ratios (HR) correspond to mortality risk per point increase in BMI within the 
specified BMI range. 95% confidence intervals (CI) and p values are given. Results are adjusted by 
age (entered as a quadratic term), sex, Mini-Mental State Examination (MMSE), dementia diagnosis, 
and number of medication at the beginning of diagnostic work-up (all entered as categorical 
variables). 
 
